US6399296B1
(en)
*
|
1994-07-20 |
2002-06-04 |
The General Hospital Corporation |
Interaction trap systems for detecting protein interactions
|
US5731168A
(en)
*
|
1995-03-01 |
1998-03-24 |
Genentech, Inc. |
Method for making heteromultimeric polypeptides
|
US6066617A
(en)
*
|
1996-04-03 |
2000-05-23 |
Human Genome Sciences, Inc. |
Human cystatin F
|
US6136311A
(en)
|
1996-05-06 |
2000-10-24 |
Cornell Research Foundation, Inc. |
Treatment and diagnosis of cancer
|
IL127892A0
(en)
*
|
1996-07-12 |
1999-10-28 |
Genentech Inc |
Gamma-heregulin
|
IL127891A0
(en)
*
|
1996-07-12 |
1999-10-28 |
Genentech Inc |
Chimeric heteromultimeter adhesins
|
SI1897890T1
(sl)
|
1996-11-27 |
2010-03-31 |
Genentech Inc |
Afinitetno čiščenje polipeptida na proteinskemA matriksu
|
US20040038894A1
(en)
*
|
1996-12-31 |
2004-02-26 |
Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) |
Compounds for modulating cell negative regulations and biological applications thereof
|
US6045774A
(en)
*
|
1997-01-10 |
2000-04-04 |
Epicyte Pharmaceutical Inc. |
J chain polypeptide targeting molecule linked to an imaging agent
|
KR100794454B1
(ko)
|
1997-04-07 |
2008-01-16 |
제넨테크, 인크. |
항-vegf 항체
|
ES2236634T3
(es)
|
1997-04-07 |
2005-07-16 |
Genentech, Inc. |
Anticuerpos anti-vegf.
|
IL132560A0
(en)
*
|
1997-05-02 |
2001-03-19 |
Genentech Inc |
A method for making multispecific antibodies having heteromultimeric and common components
|
US7951917B1
(en)
|
1997-05-02 |
2011-05-31 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20020062010A1
(en)
*
|
1997-05-02 |
2002-05-23 |
Genentech, Inc. |
Method for making multispecific antibodies having heteromultimeric and common components
|
US20030207346A1
(en)
*
|
1997-05-02 |
2003-11-06 |
William R. Arathoon |
Method for making multispecific antibodies having heteromultimeric and common components
|
PT998486E
(pt)
*
|
1997-06-13 |
2007-08-21 |
Genentech Inc |
''recuperação de proteínas por cromatografia seguida de filtração numa camada carregada''
|
EP0896825B1
(en)
|
1997-08-14 |
2002-07-17 |
Sulzer Innotec Ag |
Composition and device for in vivo cartilage repair comprising nanocapsules with osteoinductive and/or chondroinductive factors
|
US8088386B2
(en)
|
1998-03-20 |
2012-01-03 |
Genentech, Inc. |
Treatment of complement-associated disorders
|
CA2313028A1
(en)
*
|
1997-12-01 |
1999-06-10 |
Cfy Biomedicals, Inc. |
Multivalent recombinant antibodies for treating hrv infections
|
US6451977B1
(en)
*
|
1998-02-26 |
2002-09-17 |
Genentech, Inc. |
Fused polypeptides
|
EP1941905A1
(en)
|
1998-03-27 |
2008-07-09 |
Genentech, Inc. |
APO-2 Ligand-anti-her-2 antibody synergism
|
US6528624B1
(en)
*
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
US6194551B1
(en)
*
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
EP2333069A3
(en)
|
1998-05-15 |
2011-09-14 |
Genentech, Inc. |
Therapeutic uses of IL-17 homologous polypeptides
|
EP3112468A1
(en)
|
1998-05-15 |
2017-01-04 |
Genentech, Inc. |
Il-17 homologous polypeptides and therapeutic uses thereof
|
EP1865061A3
(en)
|
1998-05-15 |
2007-12-19 |
Genentech, Inc. |
IL-17 homologous polypeptides and therapeutic uses thereof
|
ES2395693T3
(es)
|
1998-06-12 |
2013-02-14 |
Genentech, Inc. |
Anticuerpos monoclonales, anticuerpos que reaccionan de forma cruzada y procedimiento para la fabricación de los mismos
|
US20020172678A1
(en)
|
2000-06-23 |
2002-11-21 |
Napoleone Ferrara |
EG-VEGF nucleic acids and polypeptides and methods of use
|
AU1727500A
(en)
*
|
1998-11-17 |
2000-06-05 |
Tanox, Inc. |
Bispecific molecules cross-linking itim and itam for therapy
|
SI1135498T1
(sl)
|
1998-11-18 |
2008-06-30 |
Genentech Inc |
Variante protitelesa z višjo vezavno afiniteto vprimerjavi z izvirnimi protitelesi
|
US20030035798A1
(en)
*
|
2000-08-16 |
2003-02-20 |
Fang Fang |
Humanized antibodies
|
EP2075335A3
(en)
|
1998-12-22 |
2009-09-30 |
Genentech, Inc. |
Methods and compositions for inhibiting neoplastic cell growth
|
US7833529B1
(en)
|
1999-01-07 |
2010-11-16 |
Zymogenetics, Inc. |
Methods for inhibiting B lymphocyte proliferation with soluble ztnf4 receptor
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
EP2364997A3
(en)
|
1999-01-15 |
2012-07-04 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
WO2000064327A2
(en)
*
|
1999-04-26 |
2000-11-02 |
Duke University |
Inhibition of complement action
|
AU5152700A
(en)
|
1999-06-15 |
2001-01-02 |
Genentech Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
AU784157B2
(en)
|
1999-06-25 |
2006-02-16 |
Genentech Inc. |
Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
|
HU226742B1
(en)
|
1999-06-25 |
2009-08-28 |
Genentech Inc |
Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
|
SK782002A3
(en)
|
1999-07-21 |
2003-08-05 |
Lexigen Pharm Corp |
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
|
GB9919597D0
(en)
*
|
1999-08-18 |
1999-10-20 |
Oxford Glycosciences Uk Ltd |
Methods and compositions for diagnosis of hepatoma
|
NZ517150A
(en)
|
1999-08-27 |
2005-01-28 |
Genentech Inc |
Dosages for treatment with anti-ErbB2 antibodies
|
CA2490853A1
(en)
|
1999-12-01 |
2001-06-07 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
DK1897945T3
(da)
|
1999-12-23 |
2012-05-07 |
Genentech Inc |
IL-17 homologe polypeptider og terapeutiske anvendelser deraf.
|
ATE424457T1
(de)
|
2000-01-13 |
2009-03-15 |
Genentech Inc |
Menschliche stra6 polypeptide
|
AU3458401A
(en)
|
2000-01-25 |
2001-08-07 |
Genentech Inc. |
Compositions and methods for treatment of cancer
|
US6740520B2
(en)
|
2000-03-21 |
2004-05-25 |
Genentech, Inc. |
Cytokine receptor and nucleic acids encoding the same
|
LT2857516T
(lt)
|
2000-04-11 |
2017-09-11 |
Genentech, Inc. |
Multivalentiniai antikūnai ir jų panaudojimas
|
US7030219B2
(en)
|
2000-04-28 |
2006-04-18 |
Johns Hopkins University |
B7-DC, Dendritic cell co-stimulatory molecules
|
US6696620B2
(en)
*
|
2000-05-02 |
2004-02-24 |
Epicyte Pharmaceutical, Inc. |
Immunoglobulin binding protein arrays in eukaryotic cells
|
EP1299128A2
(en)
|
2000-06-20 |
2003-04-09 |
Idec Pharmaceuticals Corporation |
Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination
|
DK1303293T3
(da)
|
2000-07-27 |
2009-03-30 |
Genentech Inc |
Sekventiel indgivelse af CPT-11 og APO-2L-polypeptid
|
US6984522B2
(en)
*
|
2000-08-03 |
2006-01-10 |
Regents Of The University Of Michigan |
Isolation and use of solid tumor stem cells
|
US6902734B2
(en)
|
2000-08-07 |
2005-06-07 |
Centocor, Inc. |
Anti-IL-12 antibodies and compositions thereof
|
UA81743C2
(uk)
|
2000-08-07 |
2008-02-11 |
Центокор, Инк. |
МОНОКЛОНАЛЬНЕ АНТИТІЛО ЛЮДИНИ, ЩО СПЕЦИФІЧНО ЗВ'ЯЗУЄТЬСЯ З ФАКТОРОМ НЕКРОЗУ ПУХЛИН АЛЬФА (ФНПα), ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, ЩО ЙОГО МІСТИТЬ, ТА СПОСІБ ЛІКУВАННЯ РЕВМАТОЇДНОГО АРТРИТУ
|
US7288390B2
(en)
|
2000-08-07 |
2007-10-30 |
Centocor, Inc. |
Anti-dual integrin antibodies, compositions, methods and uses
|
DE60136281D1
(de)
|
2000-08-24 |
2008-12-04 |
Genentech Inc |
Methode zur inhibierung von il-22 induziertem pap1
|
EP1944317A3
(en)
|
2000-09-01 |
2008-09-17 |
Genentech, Inc. |
Secreted and transmembrane polypeptides and nucleic acids encoding the same
|
CA2420475A1
(en)
|
2000-09-26 |
2002-04-04 |
Genentech, Inc. |
Ige receptor antagonists
|
US8178304B2
(en)
*
|
2000-10-06 |
2012-05-15 |
Smith Terry J |
Diagnostic methods relating to Graves' disease and other autoimmune disorders
|
US8153121B2
(en)
|
2000-10-06 |
2012-04-10 |
Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center |
Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders
|
DE60139944D1
(de)
|
2000-10-12 |
2009-10-29 |
Genentech Inc |
Niederviskose konzentrierte proteinformulierungen
|
US7408041B2
(en)
|
2000-12-08 |
2008-08-05 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US9249229B2
(en)
|
2000-12-08 |
2016-02-02 |
Alexion Pharmaceuticals, Inc. |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
US20060057651A1
(en)
|
2000-12-08 |
2006-03-16 |
Bowdish Katherine S |
Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
|
AU2002246632B2
(en)
|
2000-12-08 |
2007-04-05 |
Alexion Pharmaceuticals, Inc. |
Chronic lymphocytic leukemia cell line and its use for producing an antibody
|
US6492327B2
(en)
*
|
2000-12-19 |
2002-12-10 |
Sulzer Biologics Inc. |
Isolation of purified TGF- β1 and TGF -β2 from bone tissue
|
US20020159996A1
(en)
|
2001-01-31 |
2002-10-31 |
Kandasamy Hariharan |
Use of CD23 antagonists for the treatment of neoplastic disorders
|
EP2301971A1
(en)
*
|
2001-02-20 |
2011-03-30 |
ZymoGenetics, L.L.C. |
Antibodies that bind both BCMA and TACI
|
US20020155109A1
(en)
*
|
2001-04-20 |
2002-10-24 |
Lynch David H. |
Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2
|
EP1436003B3
(en)
|
2001-05-24 |
2012-03-14 |
ZymoGenetics, Inc. |
Taci-immunoglobulin fusion proteins
|
US20070160576A1
(en)
|
2001-06-05 |
2007-07-12 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
US20060270003A1
(en)
|
2003-07-08 |
2006-11-30 |
Genentech, Inc. |
IL-17A/F heterologous polypeptides and therapeutic uses thereof
|
CA2633171C
(en)
|
2001-06-20 |
2012-11-20 |
Genentech, Inc. |
Antibodies against tumor-associated antigenic target (tat) polypeptides
|
AR034749A1
(es)
*
|
2001-07-09 |
2004-03-17 |
Schering Ag |
Formulaciones de interferon beta humano
|
EP1578917A4
(en)
|
2001-07-19 |
2008-01-23 |
Perlan Therapeutics Inc |
MULTIMEDIA PROTEINS AND METHODS FOR THE PRODUCTION AND USE THEREOF
|
US6833441B2
(en)
*
|
2001-08-01 |
2004-12-21 |
Abmaxis, Inc. |
Compositions and methods for generating chimeric heteromultimers
|
US20040235068A1
(en)
*
|
2001-09-05 |
2004-11-25 |
Levinson Arthur D. |
Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
|
NZ573831A
(en)
|
2001-09-18 |
2010-07-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of tumor, particularly breast tumor - TAT193
|
US7981863B2
(en)
|
2001-09-19 |
2011-07-19 |
Neuronova Ab |
Treatment of Parkinson's disease with PDGF
|
PL373594A1
(en)
|
2001-10-04 |
2005-09-05 |
Immunex Corporation |
Ul16 binding protein 4
|
AU2002337920A1
(en)
*
|
2001-10-19 |
2003-04-28 |
Zymogenetics, Inc. |
Dimerized growth factor and materials and methods for producing it
|
JP2005532253A
(ja)
*
|
2001-10-25 |
2005-10-27 |
ジェネンテック・インコーポレーテッド |
糖タンパク質組成物
|
US7175983B2
(en)
*
|
2001-11-02 |
2007-02-13 |
Abmaxis, Inc. |
Adapter-directed display systems
|
CA2467719C
(en)
|
2001-11-14 |
2015-03-17 |
Jill Giles-Komar |
Anti-il-6 antibodies, compositions, methods and uses
|
EP3960855A1
(en)
|
2001-12-28 |
2022-03-02 |
Chugai Seiyaku Kabushiki Kaisha |
Method for stabilizing proteins
|
NZ533933A
(en)
|
2002-01-02 |
2008-06-30 |
Genentech Inc |
Compositions and methods for the diagnosis and treatment of glioma tumor
|
ATE417858T1
(de)
|
2002-02-05 |
2009-01-15 |
Genentech Inc |
Proteinaufreinigung
|
EP1575480A4
(en)
|
2002-02-22 |
2008-08-06 |
Genentech Inc |
COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO THE IMMUNE SYSTEM
|
US20080254027A1
(en)
*
|
2002-03-01 |
2008-10-16 |
Bernett Matthew J |
Optimized CD5 antibodies and methods of using the same
|
US20080260731A1
(en)
*
|
2002-03-01 |
2008-10-23 |
Bernett Matthew J |
Optimized antibodies that target cd19
|
US8188231B2
(en)
|
2002-09-27 |
2012-05-29 |
Xencor, Inc. |
Optimized FC variants
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
US20070148171A1
(en)
*
|
2002-09-27 |
2007-06-28 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
US7317091B2
(en)
*
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
US8093357B2
(en)
|
2002-03-01 |
2012-01-10 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
AU2003224916B2
(en)
|
2002-04-10 |
2009-01-08 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
CA2481507A1
(en)
|
2002-04-16 |
2003-10-30 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US7622562B2
(en)
|
2002-06-26 |
2009-11-24 |
Zimmer Orthobiologics, Inc. |
Rapid isolation of osteoinductive protein mixtures from mammalian bone tissue
|
CA2489588A1
(en)
|
2002-07-08 |
2004-01-15 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
BR0312738A
(pt)
|
2002-07-15 |
2007-06-26 |
Wyeth Corp |
processos e composições para a modulação do desenvolvimento e da função de células t auxiliares (th)
|
JP5069843B2
(ja)
|
2002-07-15 |
2012-11-07 |
ジェネンテック, インコーポレイテッド |
抗ErbB2抗体を用いる処置に応答性である腫瘍を同定するための方法
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
EP1523496B1
(en)
|
2002-07-18 |
2011-06-29 |
Merus B.V. |
Recombinant production of mixtures of antibodies
|
AU2003267124A1
(en)
|
2002-09-09 |
2004-03-29 |
Dana-Farber Cancer Institute, Inc. |
Bh3 peptides and method of use thereof
|
CA2496060C
(en)
|
2002-09-11 |
2015-08-04 |
Genentech, Inc. |
Protein purification by ion exchange chromatography
|
EP2277532A1
(en)
|
2002-09-11 |
2011-01-26 |
Genentech, Inc. |
Novel composition and methods for the treatment of immune related diseases
|
AU2003276874B2
(en)
|
2002-09-11 |
2009-09-03 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
CA2498274A1
(en)
|
2002-09-16 |
2004-03-25 |
Genentech, Inc. |
Compositions and methods for the diagnosis of immune related diseases using pro7
|
DE10244457A1
(de)
*
|
2002-09-24 |
2004-04-01 |
Johannes-Gutenberg-Universität Mainz |
Verfahren zur rationalen Mutagenese von alpha/beta T-Zell Rezeptoren und entsprechend mutierte MDM2-Protein spezifische alpha/beta T-Zell Rezeptoren
|
EP1585482A4
(en)
|
2002-09-25 |
2009-09-09 |
Genentech Inc |
NEW COMPOSITIONS AND METHODS FOR TREATING PSORIASIS
|
US20060235208A1
(en)
*
|
2002-09-27 |
2006-10-19 |
Xencor, Inc. |
Fc variants with optimized properties
|
US9701754B1
(en)
|
2002-10-23 |
2017-07-11 |
City Of Hope |
Covalent disulfide-linked diabodies and uses thereof
|
WO2004039956A2
(en)
|
2002-10-29 |
2004-05-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
WO2004042017A2
(en)
*
|
2002-10-31 |
2004-05-21 |
Genentech, Inc. |
Methods and compositions for increasing antibody production
|
JP2006516094A
(ja)
|
2002-11-08 |
2006-06-22 |
ジェネンテック・インコーポレーテッド |
ナチュラルキラー細胞関連疾患の治療のための組成物と方法
|
EP2308968A1
(en)
|
2002-11-26 |
2011-04-13 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
US8084582B2
(en)
|
2003-03-03 |
2011-12-27 |
Xencor, Inc. |
Optimized anti-CD20 monoclonal antibodies having Fc variants
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
US20070275460A1
(en)
*
|
2003-03-03 |
2007-11-29 |
Xencor.Inc. |
Fc Variants With Optimized Fc Receptor Binding Properties
|
JP2007521791A
(ja)
|
2003-04-01 |
2007-08-09 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
PT1610820E
(pt)
|
2003-04-04 |
2010-12-16 |
Novartis Ag |
Formulações de elevada concentração de anticorpos e proteínas
|
RS51686B
(sr)
|
2003-04-09 |
2011-10-31 |
Genentech Inc. |
Lečenje autoimune bolesti kod pacijenata sa neadekvatnim odgovorom na tnf-alfa inhibitor
|
US9051373B2
(en)
|
2003-05-02 |
2015-06-09 |
Xencor, Inc. |
Optimized Fc variants
|
AU2004238263A1
(en)
*
|
2003-05-06 |
2004-11-25 |
Syntonix Pharmaceuticals, Inc. |
Inhibition of drug binding to serum albumin
|
DK2298347T3
(en)
*
|
2003-05-06 |
2016-01-11 |
Biogen Hemophilia Inc |
COAGULATION FACTOR CHEMICAL PROTEINS FOR TREATING A HEMOSTATIC DISORDER
|
US7348004B2
(en)
|
2003-05-06 |
2008-03-25 |
Syntonix Pharmaceuticals, Inc. |
Immunoglobulin chimeric monomer-dimer hybrids
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
UA101945C2
(uk)
|
2003-05-30 |
2013-05-27 |
Дженентек, Инк. |
Лікування злоякісного новоутворення за допомогою бевацизумабу
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
US9708410B2
(en)
|
2003-05-30 |
2017-07-18 |
Janssen Biotech, Inc. |
Anti-tissue factor antibodies and compositions
|
WO2005000896A2
(en)
*
|
2003-05-30 |
2005-01-06 |
Genentech, Inc. |
Polypeptides that bind an anti-tissue factor antibody and uses thereof
|
US20050118181A1
(en)
|
2003-06-05 |
2005-06-02 |
Stapleton Jack T. |
GB virus C (hepatitis G virus) for the treatment of HIV
|
PT1631313E
(pt)
|
2003-06-05 |
2015-07-02 |
Genentech Inc |
Terapêutica de combinação para distúrbios de células b
|
EP1636593B9
(en)
|
2003-06-06 |
2009-12-16 |
Genentech, Inc. |
Modulating the interaction between hgf beta chain and c-met
|
WO2005042582A1
(ja)
*
|
2003-11-04 |
2005-05-12 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の製造方法
|
WO2004111233A1
(ja)
|
2003-06-11 |
2004-12-23 |
Chugai Seiyaku Kabushiki Kaisha |
抗体の製造方法
|
JP5068072B2
(ja)
*
|
2003-06-27 |
2012-11-07 |
バイオジェン・アイデック・エムエイ・インコーポレイテッド |
連結ペプチドを含む改変された結合分子
|
EP2133362B1
(en)
|
2003-07-25 |
2012-04-18 |
Amgen, Inc |
Methods relating to LDCAM and CRTAM
|
WO2005016968A2
(en)
|
2003-07-28 |
2005-02-24 |
Genentech, Inc. |
Reducing protein a leaching during protein a affinity chromatography
|
WO2005012531A2
(en)
*
|
2003-08-01 |
2005-02-10 |
Genentech, Inc. |
Antibody cdr polypeptide sequences with restricted diversity
|
EP2311468B1
(en)
|
2003-08-08 |
2014-01-15 |
Perseus Proteomics Inc. |
Gene overexpressed in cancer
|
WO2005019258A2
(en)
|
2003-08-11 |
2005-03-03 |
Genentech, Inc. |
Compositions and methods for the treatment of immune related diseases
|
EP1663306A2
(en)
*
|
2003-09-05 |
2006-06-07 |
Genentech, Inc. |
Antibodies with altered effector functions
|
US8101720B2
(en)
|
2004-10-21 |
2012-01-24 |
Xencor, Inc. |
Immunoglobulin insertions, deletions and substitutions
|
US9714282B2
(en)
|
2003-09-26 |
2017-07-25 |
Xencor, Inc. |
Optimized Fc variants and methods for their generation
|
CN1326881C
(zh)
*
|
2003-09-29 |
2007-07-18 |
中国人民解放军军事医学科学院基础医学研究所 |
一种三价双特异性抗体,其制备方法及用途
|
WO2005035753A1
(ja)
|
2003-10-10 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
機能蛋白質を代替する二重特異性抗体
|
BR122018071808B8
(pt)
|
2003-11-06 |
2020-06-30 |
Seattle Genetics Inc |
conjugado
|
EP2385069A3
(en)
|
2003-11-12 |
2012-05-30 |
Biogen Idec MA Inc. |
Neonatal Fc rReceptor (FcRn)- binding polypeptide variants, dimeric Fc binding proteins and methods related thereto
|
PT2161283E
(pt)
|
2003-11-17 |
2014-08-29 |
Genentech Inc |
Composições que compreendem anticorpos contra cd79b conjugados a um agente de inibição do crescimento ou agente citotóxico e métodos para o tratamento de tumor de origem hematopoiética
|
US7312320B2
(en)
|
2003-12-10 |
2007-12-25 |
Novimmune Sa |
Neutralizing antibodies and methods of use thereof
|
KR101195291B1
(ko)
|
2003-12-11 |
2012-10-26 |
제넨테크, 인크. |
C-met 이량체화 및 활성화를 억제하는 방법 및조성물
|
US7371381B2
(en)
*
|
2003-12-12 |
2008-05-13 |
Amgen Inc. |
Anti-galanin antibodies and uses thereof
|
WO2005056602A1
(ja)
*
|
2003-12-12 |
2005-06-23 |
Chugai Seiyaku Kabushiki Kaisha |
アゴニスト活性を有する改変抗体のスクリーニング方法
|
EP1710255A4
(en)
*
|
2003-12-12 |
2008-09-24 |
Chugai Pharmaceutical Co Ltd |
MODIFIED ANTIBODIES RECOGNIZING A TRIMER OR LARGER RECEPTOR
|
TW200530269A
(en)
|
2003-12-12 |
2005-09-16 |
Chugai Pharmaceutical Co Ltd |
Anti-Mpl antibodies
|
JP2008504007A
(ja)
|
2003-12-19 |
2008-02-14 |
ジェネンテック・インコーポレーテッド |
治療薬として有用な一価抗体断片
|
EP1697520A2
(en)
*
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
US20050266425A1
(en)
*
|
2003-12-31 |
2005-12-01 |
Vaccinex, Inc. |
Methods for producing and identifying multispecific antibodies
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
JP5912211B2
(ja)
|
2004-01-20 |
2016-04-27 |
メルス ビー.ヴィー. |
結合タンパク質の混合物
|
DK1716181T3
(da)
|
2004-02-19 |
2010-03-01 |
Genentech Inc |
CDR-reparerede antistoffer
|
US7381794B2
(en)
*
|
2004-03-08 |
2008-06-03 |
Zymogenetics, Inc. |
Dimeric fusion proteins and materials and methods for producing them
|
EP2053062A1
(en)
*
|
2004-03-24 |
2009-04-29 |
Xencor, Inc. |
Immunoglobin variants outside the Fc region
|
AU2005230848B9
(en)
|
2004-03-31 |
2011-06-02 |
Genentech, Inc. |
Humanized anti-TGF-beta antibodies
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
US20060002930A1
(en)
*
|
2004-04-16 |
2006-01-05 |
Genentech, Inc. |
Treatment of disorders
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
JP2007532681A
(ja)
*
|
2004-04-16 |
2007-11-15 |
ジェネンテック・インコーポレーテッド |
B細胞の枯渇を増大させる方法
|
BRPI0510883B8
(pt)
|
2004-06-01 |
2021-05-25 |
Genentech Inc |
composto conjugado de droga e anticorpo, composição farmacêutica, método de fabricação de composto conjugado de droga e anticorpo e usos de uma formulação, de um conjugado de droga e anticorpo e um agente quimioterapêutico e de uma combinação
|
TW201422238A
(zh)
|
2004-06-04 |
2014-06-16 |
Genentech Inc |
Cd20抗體於治療多發性硬化症之用途及用於該用途之物品
|
US7973134B2
(en)
|
2004-07-07 |
2011-07-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in anaplastic large cell lymphoma signaling pathways
|
US20150010550A1
(en)
|
2004-07-15 |
2015-01-08 |
Xencor, Inc. |
OPTIMIZED Fc VARIANTS
|
ES2339789T3
(es)
|
2004-07-20 |
2010-05-25 |
Genentech, Inc. |
Inhibidores de proteina 4 de tipo angiopoyetina, combinaciones y su utilizacion.
|
WO2006017673A2
(en)
|
2004-08-03 |
2006-02-16 |
Biogen Idec Ma Inc. |
Taj in neuronal function
|
ZA200701656B
(en)
*
|
2004-08-05 |
2008-09-25 |
Genentech Inc |
Humanized anti-cment antagonists
|
US7662926B2
(en)
*
|
2004-09-02 |
2010-02-16 |
Genentech, Inc. |
Anti-Fc-gamma receptor antibodies, bispecific variants and uses therefor
|
WO2006028936A2
(en)
*
|
2004-09-02 |
2006-03-16 |
Genentech, Inc. |
Heteromultimeric molecules
|
US7655229B2
(en)
*
|
2004-09-02 |
2010-02-02 |
Chan Andrew C |
Anti-FC-gamma RIIB receptor antibody and uses therefor
|
BRPI0515589A
(pt)
*
|
2004-09-02 |
2008-07-29 |
Genentech Inc |
polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit
|
CN104710532B
(zh)
|
2004-09-03 |
2019-01-18 |
健泰科生物技术公司 |
人源化的抗-β7拮抗剂及其应用
|
WO2006031994A2
(en)
*
|
2004-09-14 |
2006-03-23 |
Xencor, Inc. |
Monomeric immunoglobulin fc domains
|
US7935790B2
(en)
|
2004-10-04 |
2011-05-03 |
Cell Singaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in T-cell receptor signaling pathways
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
RS52539B
(en)
|
2004-10-21 |
2013-04-30 |
Genentech Inc. |
METHOD FOR TREATMENT OF INTRAOCULAR NEOVASCULAR DISEASES
|
US8802820B2
(en)
|
2004-11-12 |
2014-08-12 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US8546543B2
(en)
|
2004-11-12 |
2013-10-01 |
Xencor, Inc. |
Fc variants that extend antibody half-life
|
WO2006053301A2
(en)
|
2004-11-12 |
2006-05-18 |
Xencor, Inc. |
Fc variants with altered binding to fcrn
|
US8367805B2
(en)
|
2004-11-12 |
2013-02-05 |
Xencor, Inc. |
Fc variants with altered binding to FcRn
|
US7807789B2
(en)
|
2004-12-21 |
2010-10-05 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in EGFR-signaling pathways
|
MY146381A
(en)
|
2004-12-22 |
2012-08-15 |
Amgen Inc |
Compositions and methods relating relating to anti-igf-1 receptor antibodies
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
DE602006013275D1
(de)
|
2005-01-07 |
2010-05-12 |
Diadexus Inc |
Ovr110-antikörperzusammensetzungen und verwendungsverfahren dafür
|
WO2006076594A2
(en)
*
|
2005-01-12 |
2006-07-20 |
Xencor, Inc. |
Antibodies and fc fusion proteins with altered immunogenicity
|
KR20190110637A
(ko)
|
2005-01-21 |
2019-09-30 |
제넨테크, 인크. |
Her 항체의 고정 용량 투여법
|
US8029783B2
(en)
*
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
AU2006214121B9
(en)
|
2005-02-15 |
2013-02-14 |
Duke University |
Anti-CD19 antibodies and uses in oncology
|
EP1871807B1
(en)
|
2005-02-18 |
2012-11-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against cxcr4 and methods of use thereof
|
RU2404806C2
(ru)
|
2005-02-23 |
2010-11-27 |
Дженентек, Инк. |
Продление времени до прогрессирования заболевания или продолжительности жизни у онкологических больных с применением ингибиторов димеризации her
|
TW200714289A
(en)
*
|
2005-02-28 |
2007-04-16 |
Genentech Inc |
Treatment of bone disorders
|
US20060204505A1
(en)
*
|
2005-03-08 |
2006-09-14 |
Sliwkowski Mark X |
Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
|
TW200722518A
(en)
|
2005-03-31 |
2007-06-16 |
Chugai Pharmaceutical Co Ltd |
Sc(fv)2 structural isomers
|
KR101374454B1
(ko)
*
|
2005-03-31 |
2014-03-17 |
추가이 세이야쿠 가부시키가이샤 |
회합제어에 의한 폴리펩티드 제조방법
|
PA8672101A1
(es)
|
2005-04-29 |
2006-12-07 |
Centocor Inc |
Anticuerpos anti-il-6, composiciones, métodos y usos
|
CA2607281C
(en)
|
2005-05-05 |
2023-10-03 |
Duke University |
Anti-cd19 antibody therapy for autoimmune disease
|
CN101212967A
(zh)
|
2005-05-10 |
2008-07-02 |
因塞特公司 |
吲哚胺2,3-双加氧酶调节剂及其用法
|
EP3805245A1
(en)
|
2005-05-17 |
2021-04-14 |
University of Connecticut |
Compositions and methods for immunomodulation in an organism
|
NZ563341A
(en)
|
2005-06-06 |
2009-10-30 |
Genentech Inc |
Methods for identifying agents that modulate a gene that encodes for a PRO1568 polypeptide
|
JP5068167B2
(ja)
|
2005-06-10 |
2012-11-07 |
中外製薬株式会社 |
メグルミンを含有するタンパク質製剤の安定化剤、およびその利用
|
US20090028854A1
(en)
*
|
2005-06-10 |
2009-01-29 |
Chugai Seiyaku Kabushiki Kaisha |
sc(Fv)2 SITE-DIRECTED MUTANT
|
JP5085322B2
(ja)
|
2005-06-10 |
2012-11-28 |
中外製薬株式会社 |
sc(Fv)2を含有する医薬組成物
|
EP1896073B1
(en)
|
2005-06-30 |
2013-03-06 |
Janssen Biotech, Inc. |
Anti-il-23 antibodies, compositions, methods and uses
|
WO2007008848A2
(en)
|
2005-07-07 |
2007-01-18 |
Seattle Genetics, Inc. |
Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus
|
JP5171621B2
(ja)
|
2005-07-07 |
2013-03-27 |
シアトル ジェネティックス, インコーポレイテッド |
フェニルアラニン側鎖修飾をc末端に有するモノメチルバリン化合物
|
KR101245462B1
(ko)
|
2005-07-08 |
2013-03-20 |
바이오겐 아이덱 엠에이 인코포레이티드 |
Sp35 항체 및 그의 용도
|
EP1913027B1
(en)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf specific monoclonal antibody and uses thereof
|
KR20080056714A
(ko)
|
2005-08-09 |
2008-06-23 |
지모제넥틱스, 인코포레이티드 |
TACI―Ig 융합 분자를 사용하여 B―세포 악성종양을치료하는 방법
|
WO2007019573A2
(en)
|
2005-08-09 |
2007-02-15 |
Zymogenetics, Inc. |
Methods for the treatment and prevention of abnormal cell proliferation using taci-fusion molecules
|
AU2006280321A1
(en)
|
2005-08-15 |
2007-02-22 |
Genentech, Inc. |
Gene disruptions, compositions and methods relating thereto
|
US20090220564A1
(en)
*
|
2005-08-19 |
2009-09-03 |
Baumbach William R |
Methods of treating and preventing acute myocardial infarction
|
WO2007027906A2
(en)
|
2005-08-31 |
2007-03-08 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in leukemia signaling pathways
|
DK1931709T3
(en)
*
|
2005-10-03 |
2017-03-13 |
Xencor Inc |
FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
|
US7422899B2
(en)
*
|
2005-10-05 |
2008-09-09 |
Biogen Idec Ma Inc. |
Antibodies to the human prolactin receptor
|
AU2006302254B2
(en)
|
2005-10-06 |
2011-05-26 |
Xencor, Inc. |
Optimized anti-CD30 antibodies
|
AR056142A1
(es)
|
2005-10-21 |
2007-09-19 |
Amgen Inc |
Metodos para generar el anticuerpo igg monovalente
|
WO2007053577A2
(en)
|
2005-10-31 |
2007-05-10 |
Oncomed Pharmaceuticals, Inc. |
Compositions and methods for diagnosing and treating cancer
|
ES2577292T3
(es)
|
2005-11-07 |
2016-07-14 |
Genentech, Inc. |
Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
|
KR20080082629A
(ko)
*
|
2005-11-10 |
2008-09-11 |
리셉터 바이오로직스 인크 |
간세포 성장인자 인트론 융합 단백질
|
MY149159A
(en)
|
2005-11-15 |
2013-07-31 |
Hoffmann La Roche |
Method for treating joint damage
|
RS54111B1
(en)
|
2005-11-18 |
2015-12-31 |
Glenmark Pharmaceuticals S.A. |
ANTI-ALPHA 2 INTEGRIN ANTIBODIES AND THEIR USES
|
ZA200804162B
(en)
|
2005-11-21 |
2009-12-30 |
Genentech Inc |
Novel gene disruptions, compositions and methods relating thereto
|
ES2547689T3
(es)
|
2005-12-02 |
2015-10-08 |
Genentech, Inc. |
Composiciones y métodos para el tratamiento de enfermedades y trastornos asociados con la señalización de citocinas que implican anticuerpos que se unen a IL-22 y a IL-22R
|
US8957187B2
(en)
*
|
2005-12-02 |
2015-02-17 |
Genentech, Inc. |
Binding polypeptides and uses thereof
|
EP1973951A2
(en)
*
|
2005-12-02 |
2008-10-01 |
Genentech, Inc. |
Binding polypeptides with restricted diversity sequences
|
US20070136826A1
(en)
*
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
ES2535856T3
(es)
|
2005-12-15 |
2015-05-18 |
Genentech, Inc. |
Métodos y composiciones para dirigirse a la poliubiquitina
|
HUE049832T2
(hu)
|
2005-12-29 |
2020-10-28 |
Janssen Biotech Inc |
Humán anti-IL-23 ellenanyagok, készítmények, eljárás és alkalmazások
|
EP1984024A2
(en)
|
2006-01-05 |
2008-10-29 |
Novartis AG |
Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis
|
PL2463305T3
(pl)
|
2006-01-12 |
2017-02-28 |
Alexion Pharmaceuticals, Inc. |
Przeciwciała przeciw OX-2/CD200 i ich zastosowania
|
WO2007092431A2
(en)
|
2006-02-06 |
2007-08-16 |
Rhode Island Hospital |
Gpr30 estrogen receptor in breast cancers
|
WO2007114979A2
(en)
|
2006-02-17 |
2007-10-11 |
Genentech, Inc. |
Gene disruptons, compositions and methods relating thereto
|
WO2007103282A2
(en)
*
|
2006-03-02 |
2007-09-13 |
Cythera, Inc. |
Endocrine precursor cells, pancreatic hormone-expressing cells and methods of production
|
US8389688B2
(en)
|
2006-03-06 |
2013-03-05 |
Aeres Biomedical, Ltd. |
Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
|
AU2007226627B2
(en)
|
2006-03-10 |
2012-09-20 |
Zymogenetics, Inc. |
Antibodies that bind both IL-17A and IL-17F and methods of using the same
|
CA2646329C
(en)
*
|
2006-03-20 |
2018-07-03 |
The Regents Of The University Of California |
Engineered anti-prostate stem cell antigen (psca) antibodies for cancer targeting
|
JP2009529915A
(ja)
|
2006-03-20 |
2009-08-27 |
ゾーマ テクノロジー リミテッド |
ガストリン物質に対して特異的なヒト抗体および方法
|
CA2647107A1
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
SI2004683T1
(sl)
*
|
2006-03-24 |
2016-09-30 |
Biogen Hemophilia Inc. |
Pc5 kot encim za obdelavo propeptida faktorja ix
|
AU2007229698B9
(en)
*
|
2006-03-24 |
2012-11-08 |
Merck Patent Gmbh |
Engineered heterodimeric protein domains
|
JP2009532033A
(ja)
|
2006-03-31 |
2009-09-10 |
ダナ ファーバー キャンサー インスティテュート,インコーポレイテッド |
細胞の化学感受性を定量する方法
|
EP2009101B1
(en)
|
2006-03-31 |
2017-10-25 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody modification method for purifying bispecific antibody
|
DK3056568T3
(da)
|
2006-03-31 |
2021-11-01 |
Chugai Pharmaceutical Co Ltd |
Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
|
US20090288176A1
(en)
|
2006-04-19 |
2009-11-19 |
Genentech, Inc. |
Novel Gene Disruptions, Compositions and Methods Relating Thereto
|
EP2035028A2
(en)
|
2006-05-15 |
2009-03-18 |
Ares Trading S.A. |
Methods for treating autoimmune diseases using a taci-ig fusion molecule
|
CA2652945C
(en)
|
2006-05-30 |
2015-06-02 |
Genentech, Inc. |
Antibodies and immunoconjugates and uses therefor
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
KR20090031897A
(ko)
*
|
2006-06-12 |
2009-03-30 |
리셉터 바이오로직스 인크 |
전-세포 표면 수용체-특이적 치료제
|
AU2007261247A1
(en)
*
|
2006-06-22 |
2007-12-27 |
Vaccinex, Inc. |
Anti-C35 antibodies for treating cancer
|
FR2902799B1
(fr)
|
2006-06-27 |
2012-10-26 |
Millipore Corp |
Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide
|
MX2009000696A
(es)
|
2006-07-19 |
2009-01-30 |
Univ Pennsylvania |
Wsx-1/p28 como un objetivo para respuestas anti-inflamatorias.
|
EP2057193B1
(en)
|
2006-08-04 |
2013-12-18 |
Novartis AG |
Ephb3-specific antibody and uses thereof
|
CA2660286A1
(en)
|
2006-08-09 |
2008-02-21 |
Homestead Clinical Corporation |
Organ-specific proteins and methods of their use
|
US7939636B2
(en)
|
2006-08-11 |
2011-05-10 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in c-Src signaling pathways
|
RS53263B
(en)
|
2006-08-14 |
2014-08-29 |
Xencor Inc. |
CD19 OPTIMIZED ANTIBODY
|
TWI454480B
(zh)
|
2006-08-18 |
2014-10-01 |
Novartis Ag |
催乳激素受體(prlr)之專一性抗體及其用途
|
RU2009110154A
(ru)
|
2006-08-22 |
2010-09-27 |
Джи2 ИНФЛЕММЕЙШН ПТИ ЛТД (AU) |
АНТИТЕЛА ПРОТИВ C5aR С УЛУЧШЕННЫМИ СВОЙСТВАМИ
|
WO2008023840A2
(en)
|
2006-08-25 |
2008-02-28 |
Oncotherapy Science, Inc. |
Prognostic markers and therapeutic targets for lung cancer
|
AU2007299843B2
(en)
|
2006-09-18 |
2012-03-08 |
Xencor, Inc |
Optimized antibodies that target HM1.24
|
US20080076139A1
(en)
|
2006-09-21 |
2008-03-27 |
Sharat Singh |
Methods and compositions for detecting the activation states of multiple signal transducers in rare circulating cells
|
WO2011008990A1
(en)
|
2009-07-15 |
2011-01-20 |
Prometheus Laboratories Inc. |
Drug selection for gastric cancer therapy using antibody-based arrays
|
ME02371B
(me)
|
2006-09-29 |
2016-06-20 |
Oncomed Pharm Inc |
Sastojci i postupci za dijagnstikovanje i tretman raka
|
WO2008063776A2
(en)
*
|
2006-10-12 |
2008-05-29 |
Genentech, Inc. |
Antibodies to lymphotoxin-alpha
|
GB0620705D0
(en)
|
2006-10-18 |
2006-11-29 |
Opsona Therapeutics |
Compounds for the modulation of toll-like receptor activity and assay methods for the identification of said compounds
|
WO2008055072A2
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
MX2009004532A
(es)
|
2006-10-27 |
2009-09-04 |
Lpath Inc |
Composiciones y metodos para unir esfingosina-1-fosfato.
|
PT2502938E
(pt)
|
2006-10-27 |
2015-06-05 |
Genentech Inc |
Anticorpos e imunoconjugados e suas utilizações
|
WO2008061019A2
(en)
|
2006-11-14 |
2008-05-22 |
Genentech, Inc. |
Modulators of neuronal regeneration
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EP2120998B1
(en)
|
2006-11-28 |
2013-08-07 |
HanAll Biopharma Co., Ltd. |
Modified erythropoietin polypeptides and uses thereof for treatment
|
WO2008070780A1
(en)
|
2006-12-07 |
2008-06-12 |
Novartis Ag |
Antagonist antibodies against ephb3
|
US8163886B2
(en)
|
2006-12-21 |
2012-04-24 |
Emd Millipore Corporation |
Purification of proteins
|
US8569464B2
(en)
|
2006-12-21 |
2013-10-29 |
Emd Millipore Corporation |
Purification of proteins
|
US8362217B2
(en)
|
2006-12-21 |
2013-01-29 |
Emd Millipore Corporation |
Purification of proteins
|
WO2008079849A2
(en)
*
|
2006-12-22 |
2008-07-03 |
Genentech, Inc. |
Antibodies to insulin-like growth factor receptor
|
US7989173B2
(en)
|
2006-12-27 |
2011-08-02 |
The Johns Hopkins University |
Detection and diagnosis of inflammatory disorders
|
EP2124998B8
(en)
*
|
2006-12-27 |
2015-05-06 |
The Johns Hopkins University |
Methods for detecting inflammation and auto-immune diseases
|
LT2740744T
(lt)
|
2007-01-09 |
2018-05-10 |
Biogen Ma Inc. |
Sp35 antikūnai ir jų panaudojimas
|
US8148147B2
(en)
*
|
2007-01-24 |
2012-04-03 |
The Regents Of The University Of Michigan |
Compositions and methods for treating and diagnosing pancreatic cancer
|
CA2676766A1
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
WO2008100995A1
(en)
|
2007-02-14 |
2008-08-21 |
Vaccinex, Inc. |
Humanized anti-cd100 antibodies
|
US9023352B2
(en)
|
2007-02-20 |
2015-05-05 |
Tufts University |
Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
PE20090681A1
(es)
|
2007-03-02 |
2009-06-10 |
Genentech Inc |
Prediccion de respuesta a un inhibidor her
|
US20090081659A1
(en)
|
2007-03-07 |
2009-03-26 |
Cell Signaling Technology, Inc. |
Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
US20090068684A1
(en)
|
2007-03-26 |
2009-03-12 |
Cell Signaling Technology, Inc. |
Serine and threoninephosphorylation sites
|
WO2008118324A2
(en)
|
2007-03-26 |
2008-10-02 |
Macrogenics, Inc. |
Composition and method of treating cancer with an anti-uroplakin ib antibody
|
ES2593484T3
(es)
|
2007-03-29 |
2016-12-09 |
Genmab A/S |
Anticuerpos biespecíficos y métodos de producción de los mismos
|
US20100183615A1
(en)
*
|
2007-04-03 |
2010-07-22 |
Micromet Ag |
Cross-species-specific bispecific binders
|
US7807168B2
(en)
*
|
2007-04-10 |
2010-10-05 |
Vaccinex, Inc. |
Selection of human TNFα specific antibodies
|
EP2144930A1
(en)
|
2007-04-18 |
2010-01-20 |
ZymoGenetics, Inc. |
Single chain fc, methods of making and methods of treatment
|
US7977462B2
(en)
|
2007-04-19 |
2011-07-12 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2145902A3
(en)
|
2007-04-19 |
2010-09-29 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP1983003A3
(en)
|
2007-04-19 |
2009-03-11 |
Peter Hornbeck |
Tyrosine phosphorylation sites and antibodies specific for them
|
EP2150564A2
(en)
|
2007-04-27 |
2010-02-10 |
ZymoGenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
US20090053831A1
(en)
|
2007-05-01 |
2009-02-26 |
Cell Signaling Technology, Inc. |
Tyrosine phosphorylation sites
|
EP2068925A4
(en)
|
2007-05-07 |
2011-08-31 |
Medimmune Llc |
ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
|
MX2009012343A
(es)
*
|
2007-05-14 |
2010-02-10 |
Biogen Idec Inc |
Regiones fc (sc fc) de cadena sencilla, polipeptidos de enlace que comprenden las mismas, y metodos relacionados con ello.
|
DK2164992T3
(en)
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
WO2008154249A2
(en)
|
2007-06-08 |
2008-12-18 |
Genentech, Inc. |
Gene expression markers of tumor resistance to her2 inhibitor treatment
|
US7580304B2
(en)
*
|
2007-06-15 |
2009-08-25 |
United Memories, Inc. |
Multiple bus charge sharing
|
SI2158315T1
(sl)
*
|
2007-06-25 |
2016-05-31 |
Esbatech, An Alcon Biomedical Research Unit Llc |
Postopki za spreminjanje protiteles in spremenjena protitelesa z izboljšanimi funkcionalnimi lastnostmi
|
CL2008001887A1
(es)
|
2007-06-29 |
2008-10-03 |
Amgen Inc |
Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
|
SI2173379T1
(sl)
|
2007-07-02 |
2015-12-31 |
Oncomed Pharmaceuticals, Inc. |
Sestavki in postopki za zdravljenje in diagnosticiranje raka
|
AU2008275229B2
(en)
|
2007-07-09 |
2014-11-06 |
Genentech, Inc. |
Prevention of disulfide bond reduction during recombinant production of polypeptides
|
CN101802013B
(zh)
|
2007-07-16 |
2014-07-02 |
健泰科生物技术公司 |
人源化抗cd79b抗体和免疫偶联物及使用方法
|
NZ583367A
(en)
|
2007-07-16 |
2012-10-26 |
Genentech Inc |
Anti-cd79b antibodies and immunoconjugates and methods of use
|
BRPI0814645A2
(pt)
|
2007-07-25 |
2015-01-27 |
Alexion Pharma Inc |
Métodos e composições para tratar de doença autoimune.
|
JP2010535032A
(ja)
|
2007-07-31 |
2010-11-18 |
メディミューン,エルエルシー |
多重特異性エピトープ結合性タンパク質およびその用途
|
EP2185719B1
(en)
|
2007-08-02 |
2013-11-13 |
NovImmune SA |
Anti-rantes antibodies and methods of use thereof
|
WO2009017833A2
(en)
|
2007-08-02 |
2009-02-05 |
Arresto Biosciences |
Methods and compositions for treatment and diagnosis of fibrosis, tumor invasion, angiogenesis, and metastasis
|
CN101772574B
(zh)
*
|
2007-08-21 |
2016-01-06 |
莫佛塞斯公司 |
改良的用于二硫键形成的方法
|
CA2698343C
(en)
*
|
2007-09-04 |
2018-06-12 |
The Regents Of The University Of California |
High affinity anti-prostate stem cell antigen (psca) antibodies for cancer targeting and detection
|
EP3789400A1
(en)
|
2007-09-26 |
2021-03-10 |
Chugai Seiyaku Kabushiki Kaisha |
Modified antibody constant region
|
JP5334319B2
(ja)
|
2007-09-26 |
2013-11-06 |
中外製薬株式会社 |
Cdrのアミノ酸置換により抗体の等電点を改変する方法
|
AU2008312406B2
(en)
|
2007-10-16 |
2014-03-06 |
Ares Trading S.A. |
Combination of BLyS inhibition and anti-CD 20 agents for treatment of autoimmune disease
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
LT2514436T
(lt)
|
2007-11-07 |
2018-04-10 |
Genentech, Inc. |
Il-22 panaudojimas mikrobinių sutrikimų gydymui
|
US20110033476A1
(en)
*
|
2007-11-12 |
2011-02-10 |
Theraclone Sciences Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2010135521A2
(en)
|
2009-05-20 |
2010-11-25 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
US20090203043A1
(en)
|
2007-11-21 |
2009-08-13 |
Peter Hornbeck |
Protein phosphorylation by basophilic serine/threonine kinases in insulin signaling pathways
|
KR101945394B1
(ko)
|
2007-11-27 |
2019-02-07 |
더 유니버시티 오브 브리티쉬 콜롬비아 |
관절염의 진단과 치료를 위한 14-3-3 에타 항체 및 이의 용도
|
JP5490714B2
(ja)
*
|
2007-11-28 |
2014-05-14 |
メディミューン,エルエルシー |
タンパク質製剤
|
CN101970689A
(zh)
|
2007-11-29 |
2011-02-09 |
健泰科生物技术公司 |
炎性肠病的基因表达标志物
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
KR101643005B1
(ko)
|
2007-12-05 |
2016-07-28 |
추가이 세이야쿠 가부시키가이샤 |
항nr10 항체 및 그의 이용
|
US8242247B2
(en)
*
|
2007-12-21 |
2012-08-14 |
Hoffmann-La Roche Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
*
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
WO2009085200A2
(en)
|
2007-12-21 |
2009-07-09 |
Amgen Inc. |
Anti-amyloid antibodies and uses thereof
|
SI2808343T1
(sl)
|
2007-12-26 |
2019-10-30 |
Xencor Inc |
Fc-variante s spremenjeno vezavo na FcRn
|
AU2008341050B2
(en)
|
2007-12-26 |
2013-10-24 |
Vaccinex, Inc. |
Anti-C35 antibody combination therapies and methods
|
CA2710761C
(en)
|
2007-12-27 |
2019-01-08 |
Abbott Laboratories |
Anti-t. cruzi antibodies and methods of use
|
CA2709847C
(en)
|
2008-01-07 |
2018-07-10 |
Amgen Inc. |
Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
|
ES2796085T3
(es)
|
2008-01-15 |
2020-11-25 |
Univ Leland Stanford Junior |
Marcadores de células madre de leucemia mieloide aguda
|
EP2080770A1
(en)
*
|
2008-01-21 |
2009-07-22 |
MorphoSys AG |
Proteinaceous binding molecules comprising purification tags
|
WO2009094551A1
(en)
|
2008-01-25 |
2009-07-30 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至her2結構域ii之抗體及其酸性變異體的組合物
|
MX2010008437A
(es)
|
2008-01-31 |
2010-11-25 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso.
|
DK2602623T3
(en)
|
2008-02-25 |
2015-11-09 |
Nestec Sa |
METHOD OF DETECTING INTRACELLULAR TRUNCTED RECEPTORS
|
US20110092452A1
(en)
*
|
2008-03-05 |
2011-04-21 |
The Regents Of The University Of Michigan |
Compositions and methods for diagnosing and treating pancreatic cancer
|
JP2011513432A
(ja)
*
|
2008-03-06 |
2011-04-28 |
ジェネンテック, インコーポレイテッド |
c−met及びHERアンタゴニストの併用療法
|
TW200940064A
(en)
*
|
2008-03-06 |
2009-10-01 |
Genentech Inc |
Combination therapy with C-MET and EGFR antagonists
|
MX2010009885A
(es)
*
|
2008-03-10 |
2010-11-30 |
Theraclone Sciences Inc |
Composiciones y métodos para la terapia y diagnóstico de citomegalovirus.
|
KR102070761B1
(ko)
*
|
2008-03-31 |
2020-01-29 |
제넨테크, 인크. |
천식을 치료 및 진단하기 위한 조성물 및 방법
|
EP2279412B1
(en)
|
2008-04-09 |
2017-07-26 |
Genentech, Inc. |
Novel compositions and methods for the treatment of immune related diseases
|
JP2011516078A
(ja)
|
2008-04-10 |
2011-05-26 |
セル・シグナリング・テクノロジー・インコーポレイテツド |
癌におけるegfr突然変異を検出する組成物および方法
|
CA2721052C
(en)
|
2008-04-11 |
2023-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
|
EP2816059A1
(en)
|
2008-05-01 |
2014-12-24 |
Amgen, Inc |
Anti-hepcidin antibodies and methods of use
|
CA2723614C
(en)
*
|
2008-05-16 |
2015-07-14 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US9226934B2
(en)
|
2008-06-02 |
2016-01-05 |
The University Of Tokyo |
Anti-cancer drug
|
WO2009151514A1
(en)
|
2008-06-11 |
2009-12-17 |
Millipore Corporation |
Stirred tank bioreactor
|
EP2671891A3
(en)
|
2008-06-27 |
2014-03-05 |
Amgen Inc. |
Ang-2 inhibition to treat multiple sclerosis
|
CN102112490B
(zh)
|
2008-07-08 |
2014-10-22 |
昂考梅德药品有限公司 |
Notch1受体结合剂和其使用方法
|
SI2824100T1
(en)
|
2008-07-08 |
2018-06-29 |
Incyte Holdings Corporation |
1,2,5-oxadiazoles as inhibitors of indolamine 2,3-dioxygenase
|
CA2729961C
(en)
|
2008-07-09 |
2018-05-01 |
Biogen Idec Ma Inc. |
Li113, li62 variant co2, anti-lingo antibodies
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
US20100069616A1
(en)
*
|
2008-08-06 |
2010-03-18 |
The Regents Of The University Of California |
Engineered antibody-nanoparticle conjugates
|
US8652843B2
(en)
|
2008-08-12 |
2014-02-18 |
Oncomed Pharmaceuticals, Inc. |
DDR1-binding agents and methods of use thereof
|
US20110223188A1
(en)
|
2008-08-25 |
2011-09-15 |
Solomon Langermann |
Targeted costimulatory polypeptides and methods of use to treat cancer
|
PE20110435A1
(es)
|
2008-08-25 |
2011-07-20 |
Amplimmune Inc |
Composiciones antagonistas del pd-1
|
WO2010027818A2
(en)
|
2008-08-25 |
2010-03-11 |
Dana-Farber Cancer Institute, Inc. |
Conserved hemagglutinin epitope, antibodies to the epitope, and methods of use
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
TW201438738A
(zh)
|
2008-09-16 |
2014-10-16 |
Genentech Inc |
治療進展型多發性硬化症之方法
|
CA2735900A1
(en)
|
2008-09-19 |
2010-03-25 |
Medimmune, Llc |
Antibodies directed to dll4 and uses thereof
|
TWI440469B
(zh)
|
2008-09-26 |
2014-06-11 |
Chugai Pharmaceutical Co Ltd |
Improved antibody molecules
|
PE20120080A1
(es)
|
2008-10-01 |
2012-02-17 |
Genentech Inc |
Anticuerpos anti-notch2 y metodos de uso
|
SI2344540T1
(en)
|
2008-10-02 |
2018-04-30 |
Aptevo Research And Development Llc |
CD86 ANTAGONIST MULTI-TARGETIC PROTECTIVE PROTEIN
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
NZ592611A
(en)
*
|
2008-10-10 |
2013-01-25 |
Emergent Product Dev Seattle |
A single chain fusion protein that binds to tcr complex and does not induce or induces a minimally detectable cytokine release
|
KR102100066B1
(ko)
|
2008-10-14 |
2020-04-10 |
제넨테크, 인크. |
이뮤노글로불린 변이체 및 그의 용도
|
AU2009308293B2
(en)
|
2008-10-22 |
2015-02-05 |
Genentech, Inc. |
Modulation of axon degeneration
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
US10118962B2
(en)
|
2008-10-29 |
2018-11-06 |
Ablynx N.V. |
Methods for purification of single domain antigen binding molecules
|
CN104740631B
(zh)
|
2008-10-29 |
2019-04-16 |
阿布林克斯公司 |
单域抗原结合性分子的制剂
|
JP5775458B2
(ja)
|
2008-11-06 |
2015-09-09 |
グレンマーク ファーマシューティカルズ, エセ.アー. |
抗α2インテグリン抗体を使用する処置
|
US8298533B2
(en)
|
2008-11-07 |
2012-10-30 |
Medimmune Limited |
Antibodies to IL-1R1
|
KR20110094029A
(ko)
|
2008-11-10 |
2011-08-19 |
알렉시온 파마슈티칼스, 인코포레이티드 |
보체-관련된 장애를 치료하는 방법 및 조성물
|
CN104634972B
(zh)
|
2008-11-11 |
2017-06-13 |
密执安大学评议会 |
抗cxcr1组合物和方法
|
JP5933975B2
(ja)
|
2008-11-12 |
2016-06-15 |
メディミューン,エルエルシー |
抗体製剤
|
BRPI0916092A2
(pt)
|
2008-11-25 |
2015-11-17 |
Genentech Inc |
"isoformas específicas de anticorpos anti-her4"
|
US8211434B2
(en)
*
|
2008-11-26 |
2012-07-03 |
Allergan, Inc. |
KLK-13 antibody inhibitor for treating dry eye
|
WO2010065921A2
(en)
*
|
2008-12-05 |
2010-06-10 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
US8401799B2
(en)
*
|
2008-12-05 |
2013-03-19 |
Lpath, Inc. |
Antibody design using anti-lipid antibody crystal structures
|
BRPI0917592B1
(pt)
|
2008-12-09 |
2021-08-17 |
Genentech, Inc |
Anticorpo anti-pd-l1, composição, artigos manufaturados e usos de uma composição
|
WO2010074953A1
(en)
|
2008-12-16 |
2010-07-01 |
Millipore Corporation |
Stirred tank reactor and method
|
US20110020327A1
(en)
|
2008-12-16 |
2011-01-27 |
Millipore Corporation |
Purification of proteins
|
SG172219A1
(en)
|
2008-12-17 |
2011-07-28 |
Genentech Inc |
Hepatitis c virus combination therapy
|
WO2010075249A2
(en)
|
2008-12-22 |
2010-07-01 |
Genentech, Inc. |
A method for treating rheumatoid arthritis with b-cell antagonists
|
US20120114667A1
(en)
|
2008-12-23 |
2012-05-10 |
Medimmune Limited |
TARGETED BINDING AGENTS DIRECTED TO a5BETA1 AND USES THEREOF
|
BRPI0918204A2
(pt)
|
2008-12-23 |
2015-12-08 |
Genentech Inc |
igv variante composição farmaceutica e kit
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
ES2712732T3
(es)
|
2009-02-17 |
2019-05-14 |
Cornell Res Foundation Inc |
Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
|
WO2010096394A2
(en)
*
|
2009-02-17 |
2010-08-26 |
Redwood Biosciences, Inc. |
Aldehyde-tagged protein-based drug carriers and methods of use
|
SI3260136T1
(sl)
|
2009-03-17 |
2021-05-31 |
Theraclone Sciences, Inc. |
Humani imunodeficientni virus (HIV)-nevtralizirajoča protitelesa
|
TWI544077B
(zh)
|
2009-03-19 |
2016-08-01 |
Chugai Pharmaceutical Co Ltd |
Antibody constant region change body
|
US9228017B2
(en)
|
2009-03-19 |
2016-01-05 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variant
|
KR101346530B1
(ko)
|
2009-03-20 |
2013-12-31 |
암젠 인크 |
알파-4-베타-7 이종이량체 특이적 길항제 항체
|
US20120121591A1
(en)
|
2009-03-20 |
2012-05-17 |
Amgen Inc. |
SELECTIVE AND POTENT PEPTIDE INHIBITORS OF Kv1.3
|
UA108199C2
(uk)
|
2009-03-25 |
2015-04-10 |
|
АНТИТІЛО ПРОТИ α5β1 І ЙОГО ЗАСТОСУВАННЯ
|
WO2010120561A1
(en)
|
2009-04-01 |
2010-10-21 |
Genentech, Inc. |
Anti-fcrh5 antibodies and immunoconjugates and methods of use
|
JP5795306B2
(ja)
|
2009-04-01 |
2015-10-14 |
ジェネンテック, インコーポレイテッド |
インスリン抵抗性疾患の治療
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
RU2598248C2
(ru)
|
2009-04-02 |
2016-09-20 |
Роше Гликарт Аг |
Полиспецифичные антитела, включающие антитела полной длины и одноцепочечные фрагменты fab
|
KR20110124368A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항―erbb―2/항―c―met 항체
|
AU2010234031B2
(en)
*
|
2009-04-07 |
2015-10-01 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
CN102378768A
(zh)
|
2009-04-07 |
2012-03-14 |
罗氏格黎卡特股份公司 |
双特异性抗-ErbB-3/抗-c-Met抗体
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
WO2010121093A2
(en)
|
2009-04-17 |
2010-10-21 |
Lpath, Inc. |
Humanized antibody compositions and methods for binding lysophosphatidic acid
|
CA2759506A1
(en)
*
|
2009-04-23 |
2010-10-28 |
Theraclone Sciences, Inc. |
Granulocyte-macrophage colony-stimulating factor (gm-csf) neutralizing antibodies
|
JP2012525149A
(ja)
|
2009-04-27 |
2012-10-22 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
ヘテロ多量体分子を作製するための方法
|
EP2427203B1
(en)
|
2009-05-05 |
2018-10-17 |
Novimmune S.A. |
Anti-il-17f antibodies and use thereof
|
KR20170080705A
(ko)
|
2009-05-08 |
2017-07-10 |
백시넥스 인코포레이티드 |
항-cd100 항체 및 이의 사용 방법
|
BRPI1007602A2
(pt)
*
|
2009-05-27 |
2016-02-16 |
Hoffmann La Roche |
"anticorpo tri ou tetraespecífico, método para preparação de um anticorpo triespecífico ou tetraespecífico, célula hospedeira, composição, composição farmacêutica e método para o tratamento de um paciente com necessidade de terapia"
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
EP2445937B1
(en)
|
2009-06-23 |
2017-05-24 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
WO2011000054A1
(en)
|
2009-07-03 |
2011-01-06 |
Avipep Pty Ltd |
Immuno-conjugates and methods for producing them
|
WO2011005715A1
(en)
|
2009-07-07 |
2011-01-13 |
Genentech, Inc. |
Diagnosis and treatment of autoimmune demyelinating diseases
|
EP2456890A1
(en)
|
2009-07-20 |
2012-05-30 |
Genentech, Inc. |
Gene expression markers for crohn's disease
|
TW201106972A
(en)
|
2009-07-27 |
2011-03-01 |
Genentech Inc |
Combination treatments
|
WO2011014671A1
(en)
|
2009-07-31 |
2011-02-03 |
Amgen Inc. |
Polypeptides that bind tissue inhibitor of metalloproteinase type three (timp-3), compositions and methods
|
WO2011014750A1
(en)
|
2009-07-31 |
2011-02-03 |
Genentech, Inc. |
Inhibition of tumor metastasis using bv8- or g-csf-antagonists
|
HUE038451T2
(hu)
|
2009-08-06 |
2018-10-29 |
Hoffmann La Roche |
Eljárás vírus eltávolításának javítására fehérjetisztítás során
|
US20110039300A1
(en)
|
2009-08-10 |
2011-02-17 |
Robert Bayer |
Antibodies with enhanced adcc functions
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
WO2011019679A1
(en)
|
2009-08-11 |
2011-02-17 |
Allergan, Inc. |
Ccr2 inhibitors for treating conditions of the eye
|
PL2464664T3
(pl)
|
2009-08-13 |
2016-02-29 |
Crucell Holland Bv |
Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
|
WO2011019622A1
(en)
|
2009-08-14 |
2011-02-17 |
Genentech, Inc. |
Cell culture methods to make antibodies with enhanced adcc function
|
CA2772199A1
(en)
|
2009-08-31 |
2011-03-03 |
Amplimmune, Inc. |
B7-h4 fusion proteins and methods of use thereof
|
EP3736338A1
(en)
|
2009-09-01 |
2020-11-11 |
F. Hoffmann-La Roche AG |
Enhanced protein purification through a modified protein a elution
|
US20110059111A1
(en)
|
2009-09-01 |
2011-03-10 |
Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center |
Mammalian receptors as targets for antibody and active vaccination therapy against mold infections
|
ES2599076T3
(es)
|
2009-09-02 |
2017-01-31 |
Genentech, Inc. |
Smoothened mutante y métodos de utilización del mismo
|
WO2011028952A1
(en)
|
2009-09-02 |
2011-03-10 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
SG179196A1
(en)
*
|
2009-09-16 |
2012-04-27 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
MX2012002909A
(es)
|
2009-09-17 |
2012-04-19 |
Hoffmann La Roche |
Metodos y composiciones para su uso en diagnostico de pacientes con cancer.
|
WO2011037158A1
(ja)
|
2009-09-24 |
2011-03-31 |
中外製薬株式会社 |
抗体定常領域改変体
|
WO2011038301A2
(en)
|
2009-09-25 |
2011-03-31 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
US9005926B2
(en)
|
2009-10-02 |
2015-04-14 |
Biogen Idec Ma Inc. |
Methods of preventing and removing trisulfide bonds
|
US9096877B2
(en)
|
2009-10-07 |
2015-08-04 |
Macrogenics, Inc. |
Fc region-containing polypeptides that exhibit improved effector function due to alterations of the extent of fucosylation, and methods for their use
|
EP2488643A4
(en)
|
2009-10-15 |
2013-07-03 |
Hoffmann La Roche |
CHIMERIC FIBROBLAST GROWTH FACTORS WITH CHANGED RECEPTOR SPECIFICITY
|
JP5965318B2
(ja)
|
2009-10-16 |
2016-08-03 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストおよび降圧剤の治療的併用およびそれらによる治療の方法
|
AR078667A1
(es)
|
2009-10-19 |
2011-11-23 |
Genentech Inc |
Moduladores de activador del factor de crecimiento de hepatocitos (hgfa)
|
AU2010310746B2
(en)
|
2009-10-20 |
2015-07-23 |
Nestec S.A. |
Proximity-mediated assays for detecting oncogenic fusion proteins
|
KR20120105446A
(ko)
|
2009-10-22 |
2012-09-25 |
제넨테크, 인크. |
대식세포-자극 단백질의 헵신 활성화를 조정하기 위한 방법 및 조성물
|
CN104043126A
(zh)
|
2009-10-22 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
轴突变性的调节
|
TW201120210A
(en)
|
2009-11-05 |
2011-06-16 |
Hoffmann La Roche |
Glycosylated repeat-motif-molecule conjugates
|
TW201129379A
(en)
|
2009-11-20 |
2011-09-01 |
Amgen Inc |
Anti-Orai1 antigen binding proteins and uses thereof
|
WO2011063348A1
(en)
|
2009-11-23 |
2011-05-26 |
Amgen Inc. |
Monomeric antibody fc
|
RS56469B1
(sr)
|
2009-11-24 |
2018-01-31 |
Medimmune Ltd |
Ciljano vezujući agensi usmereni na b7-h1
|
AU2010324686B2
(en)
|
2009-11-30 |
2016-05-19 |
Genentech, Inc. |
Antibodies for treating and diagnosing tumors expressing SLC34A2 (TAT211 = SEQID2 )
|
MX354143B
(es)
|
2009-12-02 |
2018-02-14 |
Imaginab Inc |
Minicuerpos j591 y diacuerpos-cys para apuntar con especificidad de objetivo a un antígeno de membrana específico para próstata de humano (psma) y métodos para su uso.
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
CA2781682A1
(en)
|
2009-12-04 |
2011-06-09 |
Genentech, Inc. |
Multispecific antibodies, antibody analogs, compositions, and methods
|
EP2509626B1
(en)
|
2009-12-11 |
2016-02-10 |
F.Hoffmann-La Roche Ag |
Anti-vegf-c antibodies and methods using same
|
WO2011084750A1
(en)
|
2009-12-21 |
2011-07-14 |
Genentech, Inc. |
Antibody formulation
|
CA2784385A1
(en)
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
JP2013514788A
(ja)
|
2009-12-23 |
2013-05-02 |
アビペップ ピーティーワイ リミテッド |
イムノコンジュゲート及びその作製方法2
|
WO2011080796A1
(en)
|
2009-12-28 |
2011-07-07 |
Oncotherapy Science, Inc. |
Anti-cdh3 antibodies and uses thereof
|
JP5856073B2
(ja)
*
|
2009-12-29 |
2016-02-09 |
エマージェント プロダクト デベロップメント シアトル, エルエルシー |
Ron結合構築体およびその使用方法
|
AU2011205316B2
(en)
|
2010-01-13 |
2015-05-28 |
Oncomed Pharmaceuticals, Inc. |
Notch1 binding agents and methods of use thereof
|
WO2011091078A2
(en)
|
2010-01-19 |
2011-07-28 |
Xencor, Inc. |
Antibody fc variants with enhanced complement activity
|
US9796788B2
(en)
|
2010-02-08 |
2017-10-24 |
Regeneron Pharmaceuticals, Inc. |
Mice expressing a limited immunoglobulin light chain repertoire
|
RU2724663C2
(ru)
|
2010-02-08 |
2020-06-25 |
Ридженерон Фармасьютикалз, Инк. |
Мышь с общей легкой цепью
|
US20130045492A1
(en)
|
2010-02-08 |
2013-02-21 |
Regeneron Pharmaceuticals, Inc. |
Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
|
RU2573994C2
(ru)
|
2010-02-10 |
2016-01-27 |
Иммьюноджен, Инк |
Антитела против cd20 и их применение
|
NZ601743A
(en)
|
2010-02-12 |
2014-11-28 |
Oncomed Pharm Inc |
Methods for identifying and isolating cells expressing a polypeptide
|
US9556249B2
(en)
|
2010-02-18 |
2017-01-31 |
Genentech, Inc. |
Neuregulin antagonists and use thereof in treating cancer
|
US8877897B2
(en)
|
2010-02-23 |
2014-11-04 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US8975376B2
(en)
|
2010-02-23 |
2015-03-10 |
Sanofi |
Anti-alpha2 integrin antibodies and their uses
|
NZ724971A
(en)
|
2010-02-24 |
2019-06-28 |
Immunogen Inc |
Folate receptor 1 antibodies and immunoconjugates and uses thereof
|
US20110212088A1
(en)
*
|
2010-02-26 |
2011-09-01 |
Sabbadini Roger A |
Anti-paf antibodies
|
WO2011107989A1
(en)
*
|
2010-03-01 |
2011-09-09 |
Lostam Biopharmaceuticals Ltd |
Improved therapeutic antibodies against flagellated pseudomonas aeruginosa
|
US10435458B2
(en)
|
2010-03-04 |
2019-10-08 |
Chugai Seiyaku Kabushiki Kaisha |
Antibody constant region variants with reduced Fcgammar binding
|
SG183847A1
(en)
|
2010-03-04 |
2012-10-30 |
Macrogenics Inc |
Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
|
US8802091B2
(en)
|
2010-03-04 |
2014-08-12 |
Macrogenics, Inc. |
Antibodies reactive with B7-H3 and uses thereof
|
ES2748347T3
(es)
|
2010-03-12 |
2020-03-16 |
Debiopharm Int Sa |
Moléculas de unión a CD37 e inmunoconjugados de las mismas
|
KR101899835B1
(ko)
|
2010-03-24 |
2018-09-19 |
제넨테크, 인크. |
항-lrp6 항체
|
US20150231215A1
(en)
|
2012-06-22 |
2015-08-20 |
Randolph J. Noelle |
VISTA Antagonist and Methods of Use
|
US10745467B2
(en)
|
2010-03-26 |
2020-08-18 |
The Trustees Of Dartmouth College |
VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
EP3153521B1
(en)
|
2010-03-26 |
2019-09-04 |
Trustees of Dartmouth College |
Vista regulatory t cell mediator protein, vista binding agents and use thereof
|
PE20130192A1
(es)
|
2010-03-30 |
2013-02-27 |
Centocor Ortho Biotech Inc |
Anticuerpos il-25 humanizados
|
AU2011237365B2
(en)
|
2010-04-09 |
2015-01-29 |
Amgen Inc. |
BTNL9 proteins, nucleic acids, and antibodies and uses thereof
|
US8481687B2
(en)
|
2010-04-09 |
2013-07-09 |
Aveo Pharmaceuticals, Inc. |
Anti-ErbB3 antibodies
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
JP2019048814A
(ja)
*
|
2010-04-20 |
2019-03-28 |
ゲンマブ エー/エス |
ヘテロ二量体抗体Fc含有タンパク質およびその産生方法
|
AU2013203221B2
(en)
*
|
2010-04-20 |
2016-06-02 |
Genmab A/S |
Heterodimeric antibody FC-containing proteins and methods for production thereof
|
NZ701825A
(en)
|
2010-04-20 |
2016-06-24 |
Genmab As |
Heterodimeric antibody fc-containing proteins and methods for production thereof
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
CA2796633C
(en)
*
|
2010-04-23 |
2020-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
WO2011135040A1
(en)
|
2010-04-30 |
2011-11-03 |
F. Hoffmann-La Roche Ag |
Fluorescent antibody fusion protein, its production and use
|
ES2623799T3
(es)
|
2010-04-30 |
2017-07-12 |
Alexion Pharmaceuticals, Inc. |
Anticuerpos anti-C5a y métodos para el uso de los anticuerpos
|
BR112012028010A2
(pt)
|
2010-05-03 |
2017-09-26 |
Genentech Inc |
anticorpo isolado, célula, ácido nucleíco isolado, método de identificação de um primeiro anticorpo que se liga a um epítopo antigênico tat425 ligado or um anticorpo, métodos de inibir o crescimento de uma célula, de tratamento terapêutico de determinação da presença de uma proteína de tat425 e de diagnóstico da presença de um tumor em um mamífero
|
BR112012027828A2
(pt)
|
2010-05-03 |
2016-08-09 |
Genentech Inc |
composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
|
KR20130066631A
(ko)
|
2010-05-06 |
2013-06-20 |
노파르티스 아게 |
치료적 저밀도 지단백질-관련 단백질 6 (lrp6) 다가 항체에 대한 조성물 및 사용 방법
|
EP4234698A3
(en)
|
2010-05-06 |
2023-11-08 |
Novartis AG |
Compositions and methods of use for therapeutic low density lipoprotein-related protein 6 (lrp6) antibodies
|
CA2797981C
(en)
|
2010-05-14 |
2019-04-23 |
Rinat Neuroscience Corporation |
Heterodimeric proteins and methods for producing and purifying them
|
US8691918B2
(en)
|
2010-05-17 |
2014-04-08 |
Emd Millipore Corporation |
Stimulus responsive polymers for the purification of biomolecules
|
WO2011146568A1
(en)
|
2010-05-19 |
2011-11-24 |
Genentech, Inc. |
Predicting response to a her inhibitor
|
SG185737A1
(en)
|
2010-05-25 |
2013-01-30 |
Genentech Inc |
Methods of purifying polypeptides
|
WO2011147834A1
(en)
|
2010-05-26 |
2011-12-01 |
Roche Glycart Ag |
Antibodies against cd19 and uses thereof
|
EP3539988A3
(en)
|
2010-05-27 |
2019-12-04 |
Genmab A/S |
Monoclonal antibodies against her2
|
PL2576580T3
(pl)
|
2010-05-28 |
2017-03-31 |
F.Hoffmann-La Roche Ag |
Zmniejszenie poziomu mleczanu i zwiększenie wytwarzania polipeptydu przez obniżenie poziomu ekspresji dehydrogenazy mleczanowej i kinazy dehydrogenazy pirogronianowej
|
RU2613886C2
(ru)
|
2010-06-03 |
2017-03-21 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты, визуализируемые при помощи иммуно-позитрон-эмиссионной томографии, и способы их применения
|
US20110311527A1
(en)
|
2010-06-16 |
2011-12-22 |
Allergan, Inc. |
IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
|
EP2582729A4
(en)
|
2010-06-18 |
2014-05-28 |
Hoffmann La Roche |
ANTI-AXL ANTIBODIES AND METHOD FOR THEIR USE
|
AU2011268110B2
(en)
|
2010-06-19 |
2016-05-19 |
Memorial Sloan-Kettering Cancer Center |
Anti-GD2 antibodies
|
WO2011161119A1
(en)
|
2010-06-22 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Antibodies against insulin-like growth factor i receptor and uses thereof
|
CA2803588A1
(en)
|
2010-06-22 |
2011-12-29 |
The Regents Of The University Of Colorado, A Body Corporate |
Antibodies to the c3d fragment of complement component 3
|
WO2011161189A1
(en)
|
2010-06-24 |
2011-12-29 |
F. Hoffmann-La Roche Ag |
Anti-hepsin antibodies and methods of use
|
WO2016030888A1
(en)
|
2014-08-26 |
2016-03-03 |
Compugen Ltd. |
Polypeptides and uses thereof as a drug for treatment of autoimmune disorders
|
US8735548B2
(en)
|
2010-06-30 |
2014-05-27 |
Amgen Inc. |
Antibodies which bind to SCNN1A/TNFRSF1A fusion proteins and methods of use thereof
|
AU2011272941B2
(en)
|
2010-06-30 |
2014-05-29 |
Compugen Ltd. |
C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
|
EP2591004A1
(en)
|
2010-07-09 |
2013-05-15 |
F.Hoffmann-La Roche Ag |
Anti-neuropilin antibodies and methods of use
|
NZ718973A
(en)
|
2010-07-09 |
2019-01-25 |
Janssen Vaccines & Prevention Bv |
Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
CN103119062A
(zh)
|
2010-07-16 |
2013-05-22 |
埃博灵克斯股份有限公司 |
修饰的单结构域抗原结合分子及其应用
|
WO2012010549A1
(en)
|
2010-07-19 |
2012-01-26 |
F. Hoffmann-La Roche Ag |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
SG187120A1
(en)
|
2010-07-19 |
2013-02-28 |
Hoffmann La Roche |
Method to identify a patient with an increased likelihood of responding to an anti-cancer therapy
|
US9127057B2
(en)
|
2010-07-20 |
2015-09-08 |
Teva Pharmaceuticals Ausralia Pty Ltd |
Anti-IL-23 heterodimer specific antibodies
|
WO2012010582A1
(en)
|
2010-07-21 |
2012-01-26 |
Roche Glycart Ag |
Anti-cxcr5 antibodies and methods of use
|
CA2806252C
(en)
|
2010-07-29 |
2019-05-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points
|
RU2013106216A
(ru)
|
2010-08-03 |
2014-09-10 |
Ф. Хоффманн-Ля Рош Аг |
Биомаркеры хронической лимфоцитарной лейкемии
|
WO2012019024A2
(en)
|
2010-08-04 |
2012-02-09 |
Immunogen, Inc. |
Her3-binding molecules and immunoconjugates thereof
|
WO2012019061A2
(en)
|
2010-08-05 |
2012-02-09 |
Stem Centrx, Inc. |
Novel effectors and methods of use
|
KR20130049196A
(ko)
|
2010-08-05 |
2013-05-13 |
에프. 호프만-라 로슈 아게 |
항-mhc 항체 항-바이러스성 사이토카인 융합 단백질
|
EP2420250A1
(en)
|
2010-08-13 |
2012-02-22 |
Universitätsklinikum Münster |
Anti-Syndecan-4 antibodies
|
EP2603237A4
(en)
|
2010-08-12 |
2014-05-21 |
Theraclone Sciences Inc |
ANTI-HEMAGGLUTININE ANTIBODY COMPOSITIONS AND METHOD FOR THEIR USE
|
CR20180142A
(es)
|
2010-08-13 |
2018-04-05 |
Roche Glycart Ag |
ANTICUERPOS ANTI-FAP Y MÉTODOS DE USO(Divisional Exp: 2013-0038)
|
CN104474546A
(zh)
|
2010-08-13 |
2015-04-01 |
弗·哈夫曼-拉罗切有限公司 |
用于疾病治疗的针对IL-1β和IL-18的抗体
|
WO2012020038A1
(en)
|
2010-08-13 |
2012-02-16 |
Roche Glycart Ag |
Anti-tenascin-c a2 antibodies and methods of use
|
CN103221426B
(zh)
|
2010-08-16 |
2016-01-13 |
安姆根公司 |
结合肌肉生长抑制素的抗体、组合物和方法
|
WO2012022734A2
(en)
|
2010-08-16 |
2012-02-23 |
Medimmune Limited |
Anti-icam-1 antibodies and methods of use
|
NZ604510A
(en)
|
2010-08-17 |
2013-10-25 |
Csl Ltd |
Dilutable biocidal compositions and methods of use
|
CA2807269A1
(en)
|
2010-08-24 |
2012-03-01 |
Roche Glycart Ag |
Activatable bispecific antibodies
|
WO2012025530A1
(en)
|
2010-08-24 |
2012-03-01 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising a disulfide stabilized - fv fragment
|
CN103080132B
(zh)
|
2010-08-25 |
2016-06-08 |
弗·哈夫曼-拉罗切有限公司 |
抗il-18r1的抗体及其用途
|
EP2608807A1
(en)
|
2010-08-27 |
2013-07-03 |
Stem Centrx, Inc. |
Notum protein modulators and methods of use
|
CA3201524A1
(en)
|
2010-08-31 |
2012-03-08 |
Theraclone Sciences, Inc. |
Human immunodeficiency virus (hiv)-neutralizing antibodies
|
DK2612151T3
(en)
|
2010-08-31 |
2017-10-02 |
Genentech Inc |
BIOMARKETS AND METHODS OF TREATMENT
|
US9963504B2
(en)
|
2010-09-02 |
2018-05-08 |
Vaccinex, Inc. |
Anti-CXCL13 antibodies and methods of using the same
|
EP2611464B1
(en)
|
2010-09-03 |
2018-04-25 |
AbbVie Stemcentrx LLC |
Novel modulators and methods of use
|
US8551479B2
(en)
|
2010-09-10 |
2013-10-08 |
Oncomed Pharmaceuticals, Inc. |
Methods for treating melanoma
|
US8999335B2
(en)
|
2010-09-17 |
2015-04-07 |
Compugen Ltd. |
Compositions and methods for treatment of drug resistant multiple myeloma
|
JP6159660B2
(ja)
|
2010-09-22 |
2017-07-05 |
アムジエン・インコーポレーテツド |
担体としての免疫グロブリンおよびその使用
|
DK2625197T3
(en)
|
2010-10-05 |
2016-10-03 |
Genentech Inc |
Smoothened MUTANT AND METHODS OF USING THE SAME
|
WO2012061129A1
(en)
|
2010-10-25 |
2012-05-10 |
Genentech, Inc |
Treatment of gastrointestinal inflammation and psoriasis a
|
CN105399831A
(zh)
|
2010-10-29 |
2016-03-16 |
伊缪诺金公司 |
非拮抗性egfr结合分子及其免疫偶联物
|
CN103298489A
(zh)
|
2010-10-29 |
2013-09-11 |
伊缪诺金公司 |
新型egfr结合分子及其免疫偶联物
|
EP2635674A4
(en)
|
2010-11-05 |
2014-11-05 |
Transbio Ltd |
MARKERS FOR ENDOTHELIAL STORAGE CELLS AND USES THEREOF
|
DK2635607T3
(da)
*
|
2010-11-05 |
2019-11-18 |
Zymeworks Inc |
Stabilt heterodimert antistofdesign med mutationer i fc-domænet
|
WO2012064792A2
(en)
|
2010-11-09 |
2012-05-18 |
Altimab Therapeutics, Inc. |
Protein complexes for antigen binding and methods of use
|
EP2638070B1
(en)
|
2010-11-10 |
2016-10-19 |
F.Hoffmann-La Roche Ag |
Methods and compositions for neural disease immunotherapy
|
US9511151B2
(en)
|
2010-11-12 |
2016-12-06 |
Uti Limited Partnership |
Compositions and methods for the prevention and treatment of cancer
|
DK2644698T3
(en)
|
2010-11-17 |
2018-01-22 |
Chugai Pharmaceutical Co Ltd |
MULTI-SPECIFIC ANTIGEN-BINDING MOLECULE WITH ALTERNATIVE FUNCTION TO BLOOD COAGULATION FACTOR FUNCTION VIII
|
WO2012071436A1
(en)
|
2010-11-24 |
2012-05-31 |
Genentech, Inc. |
Method of treating autoimmune inflammatory disorders using il-23r loss-of-function mutants
|
WO2012069466A1
(en)
|
2010-11-24 |
2012-05-31 |
Novartis Ag |
Multispecific molecules
|
TR201815863T4
(tr)
|
2010-11-30 |
2018-11-21 |
Chugai Pharmaceutical Co Ltd |
Sitotoksisiteyi indükleyen terapötik madde.
|
SG10201509790YA
(en)
|
2010-11-30 |
2015-12-30 |
Chugai Pharmaceutical Co Ltd |
Antigen-Binding Molecule Capable Of Binding To Plurality Of Antigen Molecules Repeatedly
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
SG190990A1
(en)
|
2010-12-08 |
2013-07-31 |
Stem Centrx Inc |
Novel modulators and methods of use
|
AR084342A1
(es)
|
2010-12-16 |
2013-05-08 |
Genentech Inc |
Diagnostico y tratamientos relacionados con la inhibicion de th2
|
JP6253987B2
(ja)
|
2010-12-20 |
2017-12-27 |
ジェネンテック, インコーポレイテッド |
抗メソテリン抗体及びイムノコンジュゲート
|
US20120195910A1
(en)
|
2010-12-22 |
2012-08-02 |
Genentech, Inc. |
Anti-pcsk9 antibodies and methods of use
|
AU2011348256A1
(en)
|
2010-12-23 |
2013-07-11 |
Nestec S.A. |
Drug selection for malignant cancer therapy using antibody-based arrays
|
JP5766296B2
(ja)
|
2010-12-23 |
2015-08-19 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ポリペプチド−ポリヌクレオチド複合体、およびエフェクター成分の標的化された送達におけるその使用
|
US20150018408A1
(en)
|
2013-07-10 |
2015-01-15 |
The Regents Of The University Of Michigan |
Therapeutic antibodies and uses thereof
|
CN103547288B
(zh)
|
2011-01-10 |
2016-03-16 |
密执安大学评议会 |
干细胞因子抑制剂
|
AU2012205301B2
(en)
|
2011-01-14 |
2017-01-05 |
Redwood Bioscience, Inc. |
Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
|
CA2825163C
(en)
*
|
2011-01-19 |
2019-12-03 |
Ferrumax Pharmaceuticals, Inc. |
Compositions for regulating iron homeostasis and methods of using same
|
MX2013008833A
(es)
|
2011-02-02 |
2013-12-06 |
Amgen Inc |
Metodos y composiciones relacionadas con la inhibicion de receptor del factor de crecimiento similar a la insulina 1 (igf-1r).
|
AU2012212066A1
(en)
|
2011-02-03 |
2013-08-15 |
Alexion Pharmaceuticals, Inc. |
Use of an anti-CD200 antibody for prolonging the survival of allografts
|
KR101913448B1
(ko)
|
2011-02-04 |
2018-10-30 |
제넨테크, 인크. |
Fc 변이체 및 그의 생산 방법
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
EP3971206A1
(en)
|
2011-02-10 |
2022-03-23 |
Roche Glycart AG |
Mutant interleukin-2 polypeptides
|
WO2012112489A2
(en)
|
2011-02-14 |
2012-08-23 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
SA112330278B1
(ar)
|
2011-02-18 |
2015-10-09 |
ستيم سينتركس، انك. |
مواد ضابطة جديدة وطرق للاستخدام
|
EP2681240B1
(en)
|
2011-02-28 |
2017-08-16 |
F. Hoffmann-La Roche AG |
Monovalent antigen binding proteins
|
BR112013019975A2
(pt)
|
2011-02-28 |
2017-08-01 |
Hoffmann La Roche |
proteínas de ligação de antígeno, composição farmacêutica, uso de uma proteína de ligação de antígeno, método para o tratamento de um paciente e método para a preparação de uma proteína de ligação de antígeno, ácido nucleico, vetor e célula hospedeira"
|
AU2012222833B2
(en)
|
2011-03-03 |
2017-03-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design and constructs
|
WO2012119989A2
(en)
|
2011-03-04 |
2012-09-13 |
Oryzon Genomics, S.A. |
Methods and antibodies for the diagnosis and treatment of cancer
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
CN103619876A
(zh)
|
2011-03-10 |
2014-03-05 |
Hco抗体股份有限公司 |
双特异性三链抗体样分子
|
WO2012122590A1
(en)
|
2011-03-14 |
2012-09-20 |
Cellmid Limited |
Antibody recognizing n-domain of midkine
|
WO2012125614A1
(en)
|
2011-03-15 |
2012-09-20 |
Theraclone Sciences, Inc. |
Compositions and methods for the therapy and diagnosis of influenza
|
WO2012125850A1
(en)
|
2011-03-16 |
2012-09-20 |
Amgen Inc. |
Fc variants
|
MX342135B
(es)
|
2011-03-17 |
2016-09-14 |
Ramot At Tel-Aviv Univ Ltd |
Anticuerpos asimetricos, biespecificos y monoespecificos, y metodos para generar los mismos.
|
MX358752B
(es)
|
2011-03-25 |
2018-08-31 |
Glenmark Pharmaceuticals Sa |
Inmunoglobulinas heterodiméricas.
|
WO2012130831A1
(en)
|
2011-03-29 |
2012-10-04 |
Roche Glycart Ag |
Antibody fc variants
|
AU2012237287B2
(en)
|
2011-03-30 |
2016-09-08 |
Ablynx Nv |
Methods of treating immune disorders with single domain antibodies against TNF-alpha
|
AU2012233313C1
(en)
|
2011-03-30 |
2017-08-03 |
Chugai Seiyaku Kabushiki Kaisha |
Method for altering plasma retention and immunogenicity of antigen-binding molecule
|
EP3412309A1
(en)
|
2011-03-31 |
2018-12-12 |
F. Hoffmann-La Roche AG |
Methods of administering beta7 integrin antagonists
|
MX342240B
(es)
|
2011-04-07 |
2016-09-21 |
Genentech Inc |
Anticuerpos anti-fgfr4 y metodos de uso.
|
ES2876421T3
(es)
|
2011-04-13 |
2021-11-12 |
Bristol Myers Squibb Co |
Proteínas de fusión Fc que comprenden enlazadores o disposiciones nuevos
|
WO2012140627A1
(en)
|
2011-04-15 |
2012-10-18 |
Compugen Ltd. |
Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
|
AU2012245116A1
(en)
|
2011-04-20 |
2013-11-07 |
Genmab A/S |
Bispecific antibodies against HER2 and CD3
|
CN103502273A
(zh)
|
2011-04-20 |
2014-01-08 |
罗氏格黎卡特股份公司 |
用于pH依赖性通过血脑屏障的方法和构建体
|
EP3103810A3
(en)
|
2011-04-21 |
2017-03-08 |
Garvan Institute of Medical Research |
Modified variable domain molecules and methods for producing and using them
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
JP5987053B2
(ja)
|
2011-05-12 |
2016-09-06 |
ジェネンテック, インコーポレイテッド |
フレームワークシグネチャーペプチドを用いて動物サンプルにおける治療抗体を検出するための多重反応モニタリングlc−ms/ms法
|
JP6236383B2
(ja)
|
2011-05-13 |
2017-11-22 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
トリスルフィド結合を防止および除去する方法
|
MX370233B
(es)
|
2011-05-16 |
2019-12-06 |
Genentech Inc |
Antagonistas de fgfr1 y sus metodos de uso.
|
WO2012158818A2
(en)
|
2011-05-16 |
2012-11-22 |
Fabion Pharmaceuticals, Inc. |
Multi-specific fab fusion proteins and methods of use
|
WO2012162561A2
(en)
|
2011-05-24 |
2012-11-29 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
ES2894398T3
(es)
|
2011-06-03 |
2022-02-14 |
Xoma Technology Ltd |
Anticuerpos específicos para TGF-beta
|
DK2718326T3
(da)
|
2011-06-13 |
2020-10-26 |
Csl Ltd |
Antistoffer mod g-csfr og anvendelser deraf
|
BR112013032235A2
(pt)
|
2011-06-15 |
2016-11-22 |
Hoffmann La Roche |
anticorpos do receptor de epo anti-humano e métodos de uso
|
EP2726503B1
(en)
|
2011-06-30 |
2019-09-04 |
Compugen Ltd. |
Polypeptides and uses thereof for treatment of autoimmune disorders and infection
|
KR20140045440A
(ko)
|
2011-06-30 |
2014-04-16 |
제넨테크, 인크. |
항-c-met 항체 제제
|
TWI687441B
(zh)
|
2011-06-30 |
2020-03-11 |
中外製藥股份有限公司 |
異源二聚化多胜肽
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
EP2543680A1
(en)
|
2011-07-07 |
2013-01-09 |
Centre National de la Recherche Scientifique |
Multispecific mutated antibody Fab fragments
|
MX349198B
(es)
|
2011-07-15 |
2017-07-18 |
Oncomed Pharmaceuticals Inc * |
Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
|
RU2014103185A
(ru)
|
2011-07-18 |
2015-08-27 |
Артс Байолоджикс А/С |
Биологически активное соединение на основе лютеинизирующего гормона (lh) с пролонгированным действием
|
RU2664232C2
(ru)
|
2011-08-05 |
2018-08-15 |
Регенерон Фармасьютикалз, Инк. |
Мыши с гуманизированной универсальной легкой цепью
|
CN103890007A
(zh)
|
2011-08-17 |
2014-06-25 |
霍夫曼-拉罗奇有限公司 |
神经调节蛋白抗体及其用途
|
KR20140068877A
(ko)
|
2011-08-17 |
2014-06-09 |
제넨테크, 인크. |
불응성 종양에서의 혈관신생의 억제
|
US20130078250A1
(en)
|
2011-08-23 |
2013-03-28 |
Oliver Ast |
Bispecific t cell activating antigen binding molecules
|
PT2748202T
(pt)
|
2011-08-23 |
2018-10-08 |
Roche Glycart Ag |
Moléculas de ligação ao antigénio biespecíficas
|
HUE038225T2
(hu)
|
2011-08-23 |
2018-10-29 |
Roche Glycart Ag |
Bispecifikus, T-sejtaktiváló antigénkötõ, molekulák
|
BR112014004168A2
(pt)
|
2011-08-23 |
2017-12-12 |
Roche Glycart Ag |
anticorpo biespecífico, composição farmacêutica, uso do anticorpo biespecífico, célula hospedeira procariótica ou eucariótica, método de produção de anticorpo e invenção
|
RU2014109038A
(ru)
|
2011-08-23 |
2015-09-27 |
Рош Гликарт Аг |
Антитела к хондроитинсульфат протеогликану меланомы
|
CA2843158A1
(en)
|
2011-08-26 |
2013-03-07 |
Merrimack Pharmaceuticals, Inc. |
Tandem fc bispecific antibodies
|
US8822651B2
(en)
|
2011-08-30 |
2014-09-02 |
Theraclone Sciences, Inc. |
Human rhinovirus (HRV) antibodies
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
EP2751562B1
(en)
|
2011-09-02 |
2015-09-16 |
Nestec S.A. |
Profiling of signal pathway proteins to determine therapeutic efficacy
|
MX2014003094A
(es)
|
2011-09-15 |
2014-04-25 |
Genentech Inc |
Metodos para promover diferenciacion.
|
GB201116092D0
(en)
|
2011-09-16 |
2011-11-02 |
Bioceros B V |
Antibodies and uses thereof
|
BR112014006419A2
(pt)
|
2011-09-19 |
2018-08-07 |
Genentech Inc |
métodos para tratar um paciente com câncer, kit e artigo
|
EP3485903B1
(en)
|
2011-09-23 |
2022-11-16 |
Mereo BioPharma 5, Inc. |
Vegf/dll4 binding agents and uses thereof
|
EP2758435A1
(en)
|
2011-09-23 |
2014-07-30 |
Roche Glycart AG |
Bispecific anti-egfr/anti igf-1r antibodies
|
EA035018B1
(ru)
|
2011-09-30 |
2020-04-17 |
Тева Фармасьютикал Австралия Пти Лтд. |
АНТИТЕЛА К TL1a И ИХ ПРИМЕНЕНИЕ
|
AU2012319150B2
(en)
|
2011-10-05 |
2017-08-17 |
Genentech, Inc. |
Methods of treating liver conditions using Notch2 antagonists
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
PL2766397T3
(pl)
|
2011-10-11 |
2018-10-31 |
F.Hoffmann-La Roche Ag |
Ulepszone składanie przeciwciał bispecyficznych
|
PT2766393T
(pt)
|
2011-10-14 |
2018-10-15 |
Hoffmann La Roche |
Anticorpos anti-htra1 e métodos de utilização
|
RU2014119426A
(ru)
|
2011-10-15 |
2015-11-20 |
Дженентек, Инк. |
Способы применения антагонистов scd1
|
WO2013059531A1
(en)
|
2011-10-20 |
2013-04-25 |
Genentech, Inc. |
Anti-gcgr antibodies and uses thereof
|
JP6162707B2
(ja)
|
2011-10-24 |
2017-07-12 |
ハロザイム インコーポレイテッド |
抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
|
EP2771364B1
(en)
|
2011-10-27 |
2019-05-22 |
Genmab A/S |
Production of heterodimeric proteins
|
CA2852709A1
(en)
|
2011-10-28 |
2013-05-02 |
Patrys Limited |
Pat-lm1 epitopes and methods for using same
|
AR088509A1
(es)
|
2011-10-28 |
2014-06-11 |
Genentech Inc |
Combinaciones terapeuticas y metodos para tratar el melanoma
|
ES2732712T3
(es)
|
2011-10-31 |
2019-11-25 |
Chugai Pharmaceutical Co Ltd |
Molécula de unión a antígeno que tiene una conjugación regulada entre la cadena pesada y la cadena ligera
|
WO2013067301A1
(en)
|
2011-11-02 |
2013-05-10 |
Genentech, Inc. |
Overload and elute chromatography
|
CN109897103A
(zh)
|
2011-11-04 |
2019-06-18 |
酵活有限公司 |
在Fc结构域中具有突变的稳定异源二聚的抗体设计
|
WO2013067355A1
(en)
|
2011-11-04 |
2013-05-10 |
Novartis Ag |
Low density lipoprotein-related protein 6 (lrp6) - half life extender constructs
|
MX2014005885A
(es)
|
2011-11-21 |
2014-09-04 |
Genentech Inc |
Purificacion de anticuerpos anti-c-met.
|
SG11201402343SA
(en)
|
2011-11-21 |
2014-06-27 |
Immunogen Inc |
Method of treatment of tumors that are resistant to egfr therapies by egfr antibody cytotoxic agent conjugate
|
WO2013078378A1
(en)
|
2011-11-23 |
2013-05-30 |
Amgen Inc. |
Methods of treatment using an antibody against interferon gamma
|
SG10201609301QA
(en)
|
2011-11-30 |
2016-12-29 |
Chugai Pharmaceutical Co Ltd |
Drug containing carrier into cell for forming immune complex
|
US20140335084A1
(en)
|
2011-12-06 |
2014-11-13 |
Hoffmann-La Roche Inc. |
Antibody formulation
|
WO2013096221A1
(en)
|
2011-12-21 |
2013-06-27 |
Amgen Inc. |
Variant fc-polypeptides with enhanced binding to the neonatal fc receptor
|
SG11201403223PA
(en)
|
2011-12-22 |
2014-07-30 |
Hoffmann La Roche |
Expression vector organization, novel production cell generation methods and their use for the recombinant production of polypeptides
|
WO2013092720A1
(en)
|
2011-12-22 |
2013-06-27 |
F. Hoffmann-La Roche Ag |
Full length antibody display system for eukaryotic cells and its use
|
SG10201700169PA
(en)
|
2011-12-22 |
2017-02-27 |
Hoffmann La Roche |
Expression vector element combinations, novel production cell generation methods and their use for the recombinant production of polypeptides
|
AR089434A1
(es)
|
2011-12-23 |
2014-08-20 |
Genentech Inc |
Procedimiento para preparar formulaciones con alta concentracion de proteinas
|
WO2013096812A1
(en)
|
2011-12-23 |
2013-06-27 |
Genentech, Inc. |
Articles of manufacture and methods for co-administration of antibodies
|
WO2013101771A2
(en)
|
2011-12-30 |
2013-07-04 |
Genentech, Inc. |
Compositions and method for treating autoimmune diseases
|
CN104066449B
(zh)
|
2012-01-18 |
2018-04-27 |
霍夫曼-拉罗奇有限公司 |
抗lrp5抗体及使用方法
|
CA2862424A1
(en)
|
2012-01-18 |
2013-07-25 |
Genentech, Inc. |
Methods of using fgf19 modulators
|
TW201334789A
(zh)
|
2012-01-31 |
2013-09-01 |
Genentech Inc |
抗ige抗體及其使用方法
|
MX366965B
(es)
|
2012-02-03 |
2019-07-31 |
Hoffmann La Roche |
Moleculas de anticuerpos biespecificos con celulas t transfectadas por antigeno y su uso en medicina.
|
CA2863834A1
(en)
|
2012-02-06 |
2013-08-15 |
Inhibrx Llc |
Cd47 antibodies and methods of use thereof
|
KR20140127854A
(ko)
|
2012-02-10 |
2014-11-04 |
제넨테크, 인크. |
단일-쇄 항체 및 다른 이종다량체
|
RU2014133069A
(ru)
|
2012-02-11 |
2016-04-10 |
Дженентек, Инк. |
Транслокации r-спондина и способы с их использованием
|
JP6152120B2
(ja)
|
2012-02-15 |
2017-06-21 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Fc受容体に基づくアフィニティークロマトグラフィー
|
RU2736349C2
(ru)
|
2012-02-24 |
2020-11-16 |
Чугаи Сейяку Кабусики Кайся |
АНТИГЕНСВЯЗЫВАЮЩАЯ МОЛЕКУЛА ДЛЯ УСКОРЕНИЯ ИСЧЕЗНОВЕНИЯ АНТИГЕНА ЧЕРЕЗ FcγRIIB
|
ES2812849T3
(es)
|
2012-02-24 |
2021-03-18 |
Abbvie Stemcentrx Llc |
Anticuerpos anti-DLL3 y procedimientos de utilización de los mismos
|
US9890213B2
(en)
|
2012-03-02 |
2018-02-13 |
Vaccinex, Inc. |
Methods for the treatment of B cell-mediated inflammatory diseases
|
WO2013134414A1
(en)
*
|
2012-03-06 |
2013-09-12 |
Galaxy Biotech, Llc |
Bispecific antibodies with an fgf2 binding domain
|
US10988516B2
(en)
|
2012-03-26 |
2021-04-27 |
Uti Limited Partnership |
Methods and compositions for treating inflammation
|
EP2830646B1
(en)
|
2012-03-27 |
2018-03-07 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
RU2014136886A
(ru)
|
2012-03-27 |
2016-05-20 |
Дженентек, Инк. |
Диагностика и виды лечения, связанные с ингибиторами her3
|
HUE037613T2
(hu)
|
2012-03-29 |
2018-09-28 |
Novimmune Sa |
Anti-TLR4 antitestek és azok felhasználása
|
CA2868883C
(en)
|
2012-03-30 |
2022-10-04 |
Sorrento Therapeutics Inc. |
Fully human antibodies that bind to vegfr2
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
KR101674784B1
(ko)
|
2012-04-05 |
2016-11-09 |
에프. 호프만-라 로슈 아게 |
인간 tweak 및 인간 il17에 대한 이중특이적 항체 및 이의 용도
|
AU2013267909B2
(en)
|
2012-04-06 |
2018-03-01 |
Omeros Corporation |
Compositions and methods of inhibiting MASP-1, MASP-2 and/or MASP-3 for treatment of paroxysmal nocturnal hemoglobinuria
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
RU2673153C2
(ru)
|
2012-04-20 |
2018-11-22 |
АПТЕВО РИСЁРЧ ЭНД ДИВЕЛОПМЕНТ ЭлЭлСи |
Полипептиды, связывающиеся с cd3
|
SG10201607371UA
(en)
|
2012-04-20 |
2016-10-28 |
Merus Nv |
Methods and means for the production of ig-like molecules
|
US9090694B2
(en)
|
2012-04-30 |
2015-07-28 |
Janssen Biotech, Inc. |
ST2L antibody antagonists
|
BR112014027166A2
(pt)
|
2012-05-01 |
2017-06-27 |
Genentech Inc |
anticorpo, ácido nucleico, célula hospedeira, método para produzir um anticorpo, imunoconjugado, formulação farmacêutica, método de tratamento, método de inibir proliferação e métodos de detecção.
|
WO2013164325A1
(en)
*
|
2012-05-02 |
2013-11-07 |
F. Hoffmann-La Roche Ag |
Multispecific antigen binding proteins
|
MX362705B
(es)
|
2012-05-10 |
2019-02-01 |
Bioatla Llc |
Anticuerpos monoclonales multiespecíficos.
|
WO2013170191A1
(en)
|
2012-05-11 |
2013-11-14 |
Genentech, Inc. |
Methods of using antagonists of nad biosynthesis from nicotinamide
|
EP2852618A2
(en)
|
2012-05-21 |
2015-04-01 |
F. Hoffmann-La Roche AG |
Methods for improving safety of blood-brain barrier transport
|
RU2625771C2
(ru)
|
2012-05-23 |
2017-07-18 |
Дженентек, Инк. |
Способ отбора терапевтических средств
|
KR20150013188A
(ko)
|
2012-05-24 |
2015-02-04 |
에프. 호프만-라 로슈 아게 |
다중특이적 항체
|
EP3795215A1
(en)
|
2012-05-30 |
2021-03-24 |
Chugai Seiyaku Kabushiki Kaisha |
Target tissue-specific antigen-binding molecule
|
EP3553086A1
(en)
|
2012-05-31 |
2019-10-16 |
Sorrento Therapeutics Inc. |
Antigen binding proteins that bind pd-l1
|
EP2858673A4
(en)
|
2012-06-06 |
2016-06-22 |
Oncomed Pharm Inc |
BINDING AGENTS MODULATING THE HIPPO SIGNALING PATH AND USES THEREOF
|
EP2862875B1
(en)
|
2012-06-14 |
2023-09-06 |
Chugai Seiyaku Kabushiki Kaisha |
ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED Fc REGION
|
MX2014014830A
(es)
|
2012-06-15 |
2015-05-11 |
Genentech Inc |
Anticuerpos anti-pcsk9, formulaciones, dosificacion y metodos de uso.
|
US20130344073A1
(en)
|
2012-06-18 |
2013-12-26 |
University Of Leicester |
Compositions and Methods of Inhibiting MASP-1 and/or MASP-2 and/or MASP-3 for the Treatment of Various Diseases and Disorders
|
CA2877573A1
(en)
|
2012-06-21 |
2013-12-27 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind c-met
|
WO2014039983A1
(en)
|
2012-09-07 |
2014-03-13 |
The Trustees Of Dartmouth College |
Vista modulators for diagnosis and treatment of cancer
|
US9890215B2
(en)
|
2012-06-22 |
2018-02-13 |
King's College London |
Vista modulators for diagnosis and treatment of cancer
|
US9315579B2
(en)
|
2012-06-22 |
2016-04-19 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind CCR2
|
US9499634B2
(en)
|
2012-06-25 |
2016-11-22 |
Zymeworks Inc. |
Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
|
CA2871880A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
BR112014028368A2
(pt)
|
2012-06-27 |
2017-11-14 |
Hoffmann La Roche |
método de produção de conjugado de região fc de anticorpo, conjugado de região fc de anticorpo e formulação farmacêutica
|
CN107973856B
(zh)
|
2012-07-04 |
2021-11-23 |
弗·哈夫曼-拉罗切有限公司 |
共价连接的抗原-抗体缀合物
|
BR112014030843A2
(pt)
|
2012-07-04 |
2019-10-15 |
Hoffmann La Roche |
anticorpo anti-teofilina, formulação farmacêutica e uso do anticorpo
|
CA2872192A1
(en)
|
2012-07-04 |
2014-01-09 |
F. Hoffmann-La Roche Ag |
Anti-biotin antibodies and methods of use
|
CN110042114A
(zh)
|
2012-07-05 |
2019-07-23 |
弗·哈夫曼-拉罗切有限公司 |
表达和分泌系统
|
SG10201605703TA
(en)
|
2012-07-06 |
2016-09-29 |
Genmab Bv |
Dimeric protein with triple mutations
|
EA201590173A1
(ru)
|
2012-07-09 |
2015-09-30 |
Дженентек, Инк. |
Иммуноконъюгаты, содержащие антитела к cd22
|
EP2684896A1
(en)
|
2012-07-09 |
2014-01-15 |
International-Drug-Development-Biotech |
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
|
IN2014DN10652A
(no)
|
2012-07-09 |
2015-09-11 |
Genentech Inc |
|
BR112015000441A2
(pt)
|
2012-07-09 |
2017-12-19 |
Genentech Inc |
imunoconjugados, formulação farmacêutica e método de tratamento e método para inbir a proliferação de uma célula positiva para cd22
|
CN104411337A
(zh)
|
2012-07-09 |
2015-03-11 |
基因泰克公司 |
包含抗cd79b抗体的免疫偶联物
|
ES2786263T3
(es)
|
2012-07-13 |
2020-10-09 |
Univ Pennsylvania |
Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico
|
WO2014012082A2
(en)
|
2012-07-13 |
2014-01-16 |
Zymeworks Inc. |
Multivalent heteromultimer scaffold design an constructs
|
MA37794B1
(fr)
|
2012-07-13 |
2017-07-31 |
Roche Glycart Ag |
Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le cadre du traitement de pathologies vasculaires oculaires
|
CN104703999A
(zh)
|
2012-07-19 |
2015-06-10 |
安姆根有限公司 |
人btnl3蛋白、核酸和抗体及其用途
|
TR201816437T4
(tr)
|
2012-08-07 |
2018-11-21 |
Roche Glycart Ag |
Azalmış ve artmış efektör fonksiyonuna sahip olacak şekilde tasarlanmış iki antikor içeren bileşim.
|
BR112015002085A2
(pt)
|
2012-08-08 |
2017-12-19 |
Roche Glycart Ag |
proteína, polinucleotídeo, vetor, célula hospedeira, método para produzir a proteína, composição farmacêutica, uso da proteína, método de tratamento e invenção
|
CN109705218B
(zh)
|
2012-08-09 |
2022-07-19 |
罗切格利卡特公司 |
Asgpr抗体及其用途
|
US20140044675A1
(en)
|
2012-08-10 |
2014-02-13 |
Roche Glycart Ag |
Interleukin-2 fusion proteins and uses thereof
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
DK2888283T3
(en)
|
2012-08-24 |
2018-11-19 |
Univ California |
ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE
|
JP6501521B2
(ja)
|
2012-08-24 |
2019-04-17 |
中外製薬株式会社 |
FcγRIIb特異的Fc領域改変体
|
KR20240005129A
(ko)
|
2012-08-31 |
2024-01-11 |
이뮤노젠 아이엔씨 |
엽산 수용체 1의 검출을 위한 진단성 검정 및 키트
|
KR101963231B1
(ko)
|
2012-09-11 |
2019-03-28 |
삼성전자주식회사 |
이중특이 항체의 제작을 위한 단백질 복합체 및 이를 이용한 이중특이 항체 제조 방법
|
US20140081003A1
(en)
|
2012-09-19 |
2014-03-20 |
Genentech, Inc. |
Methods and compositions for preventing norleucine misincorporation into proteins
|
EP2898327A1
(en)
|
2012-09-19 |
2015-07-29 |
Dana-Farber Cancer Institute, Inc. |
Dynamic bh3 profiling
|
EP3401337A1
(en)
|
2012-09-25 |
2018-11-14 |
Glenmark Pharmaceuticals S.A. |
Purification of hetero-dimeric immunoglobulins
|
SG10201705787VA
(en)
|
2012-09-27 |
2017-08-30 |
Merus Nv |
BISPECIFIC IgG ANTIBODIES AS T CELL ENGAGERS
|
AU2013326974B2
(en)
|
2012-10-03 |
2019-01-03 |
Zymeworks Bc Inc. |
Methods of quantitating heavy and light chain polypeptide pairs
|
WO2014055771A1
(en)
|
2012-10-05 |
2014-04-10 |
The Trustees Of The University Of Pennsylvania |
Human alpha-folate receptor chimeric antigen receptor
|
CA2884368C
(en)
|
2012-10-05 |
2022-01-18 |
Genentech, Inc. |
Methods for diagnosing and treating inflammatory bowel disease
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
US9603948B2
(en)
|
2012-10-11 |
2017-03-28 |
Uti Limited Partnership |
Methods and compositions for treating multiple sclerosis and related disorders
|
US9278124B2
(en)
|
2012-10-16 |
2016-03-08 |
Halozyme, Inc. |
Hypoxia and hyaluronan and markers thereof for diagnosis and monitoring of diseases and conditions and related methods
|
US9309318B2
(en)
|
2012-10-17 |
2016-04-12 |
Amgen, Inc. |
Compositions relating to anti-IL-21 receptor antibodies
|
JP6371294B2
(ja)
|
2012-10-31 |
2018-08-08 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Dll4アンタゴニストによる処置の方法およびモニタリング
|
CA2890207A1
(en)
|
2012-11-05 |
2014-05-08 |
Foundation Medicine, Inc. |
Novel ntrk1 fusion molecules and uses thereof
|
AU2013342163B2
(en)
|
2012-11-08 |
2018-08-16 |
F. Hoffmann-La Roche Ltd |
IL-6 antagonists and uses thereof
|
US9725512B2
(en)
|
2012-11-08 |
2017-08-08 |
Hoffmann-La Roche Inc. |
HER3 antibodies binding to the beta-hairpin of HER3
|
MA38176A1
(fr)
|
2012-11-13 |
2017-06-30 |
Genentech Inc |
Nouvel anticorps anti-hemagglutinine, utile pour le traitement, l'inhibition ou la prévention de l’infection virale a grippe a
|
BR112015011011A2
(pt)
|
2012-11-15 |
2019-12-17 |
Genentech Inc |
cromatografia por troca de íon com gradiente de ph mediada por força iônica
|
JP6385357B2
(ja)
|
2012-11-27 |
2018-09-05 |
アジュ ユニバーシティー インダストリー−アカデミック コーオペレイション ファウンデーションAjou University Industry−Academic Cooperation Foundation |
抗体重鎖不変部位の異種二量体、高効率の形成を誘導するch3ドメイン変異体対、その作製方法および用途
|
EP2925785A4
(en)
|
2012-11-28 |
2016-11-16 |
Zymeworks Inc |
MANIPULATED IMMUNOGLOBULIN HEAVY CHAIN LIGHT CHAIN COUPLES AND USES THEREOF
|
US9914785B2
(en)
|
2012-11-28 |
2018-03-13 |
Zymeworks Inc. |
Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
|
EP3725807A1
(en)
|
2012-12-03 |
2020-10-21 |
NovImmune SA |
Anti-cd47 antibodies and methods of use thereof
|
MX2015006973A
(es)
|
2012-12-04 |
2015-09-28 |
Oncomed Pharm Inc |
Inmunoterapia con agentes de enlace.
|
PT2928923T
(pt)
|
2012-12-10 |
2020-03-27 |
Biogen Ma Inc |
Anticorpos antígenos 2 de células dendríticas anti-sangue e os seus usos
|
JP2016502850A
(ja)
|
2012-12-18 |
2016-02-01 |
ノバルティス アーゲー |
ヒアルロナンに結合するペプチドタグを使用する組成物及び方法
|
KR102249779B1
(ko)
|
2012-12-27 |
2021-05-07 |
추가이 세이야쿠 가부시키가이샤 |
헤테로이량화 폴리펩티드
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
CA2897987A1
(en)
|
2013-01-15 |
2014-07-24 |
Xencor, Inc. |
Rapid clearance of antigen complexes using novel antibodies
|
US10980804B2
(en)
|
2013-01-18 |
2021-04-20 |
Foundation Medicine, Inc. |
Methods of treating cholangiocarcinoma
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
US9161966B2
(en)
|
2013-01-30 |
2015-10-20 |
Ngm Biopharmaceuticals, Inc. |
GDF15 mutein polypeptides
|
MX2015010023A
(es)
|
2013-02-01 |
2017-11-17 |
Transbio Ltd |
Anticuerpos anti-cd83 y su uso.
|
WO2014122143A1
(en)
|
2013-02-05 |
2014-08-14 |
Engmab Ag |
Method for the selection of antibodies against bcma
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
CA2900468A1
(en)
|
2013-02-06 |
2014-08-14 |
Inhibrx Llc |
Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
|
US9340618B2
(en)
|
2013-02-07 |
2016-05-17 |
Csl Limited |
IL-11R binding proteins
|
US10047163B2
(en)
|
2013-02-08 |
2018-08-14 |
Abbvie Stemcentrx Llc |
Multispecific constructs
|
EP3617220B1
(en)
|
2013-02-12 |
2021-03-24 |
Bristol-Myers Squibb Company |
High ph protein refolding methods
|
ES2813501T3
(es)
|
2013-02-12 |
2021-03-24 |
Bristol Myers Squibb Co |
Métodos de replegado de proteínas basados en filtración de flujo tangencial
|
EP3626741A1
(en)
|
2013-02-20 |
2020-03-25 |
The Trustees Of The University Of Pennsylvania |
Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
|
WO2014130635A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
BR112015019909A2
(pt)
|
2013-02-22 |
2017-08-29 |
Abbvie Stemcentrx Llc |
Conjugados anticorpo-fármaco, composição farmacêutica, usos dos mesmos, e kit
|
CN104994879A
(zh)
|
2013-02-22 |
2015-10-21 |
霍夫曼-拉罗奇有限公司 |
治疗癌症和预防药物抗性的方法
|
RU2015140573A
(ru)
|
2013-02-25 |
2017-03-30 |
Дженентек, Инк. |
Способы и композиции для обнаружения и лечения устойчивого к лекарственным средствам мутанта акт
|
KR20150122761A
(ko)
|
2013-02-26 |
2015-11-02 |
로슈 글리카트 아게 |
T 세포 활성화 항원 결합 분자
|
RU2015140917A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Биспецифические антигенсвязывающие молекулы, активирующие т-клетки
|
RU2015140921A
(ru)
|
2013-02-26 |
2017-04-03 |
Роше Гликарт Аг |
Антитела к mcsp
|
SG11201504497TA
(en)
|
2013-02-26 |
2015-09-29 |
Roche Glycart Ag |
Bispecific t cell activating antigen binding molecules
|
US9487587B2
(en)
|
2013-03-05 |
2016-11-08 |
Macrogenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
|
BR112015021462A2
(pt)
|
2013-03-06 |
2017-10-10 |
Adimab Llc |
anticorpos biespecíficos anti-c-met tandem fc
|
JP2016510751A
(ja)
|
2013-03-06 |
2016-04-11 |
ジェネンテック, インコーポレイテッド |
抗がん剤耐性を治療及び予防する方法
|
WO2014137355A1
(en)
|
2013-03-08 |
2014-09-12 |
Vaccinex, Inc. |
Anti-cxcl13 antibodies and associated epitope sequences
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
SG10201705525VA
(en)
|
2013-03-13 |
2017-08-30 |
Genentech Inc |
Formulations with reduced oxidation
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
CN105209058A
(zh)
|
2013-03-13 |
2015-12-30 |
豪夫迈·罗氏有限公司 |
具有降低的氧化的配制物
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US10653779B2
(en)
|
2013-03-13 |
2020-05-19 |
Genentech, Inc. |
Formulations with reduced oxidation
|
EP3744345B1
(en)
|
2013-03-13 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Antibody formulations
|
BR112015022604A2
(pt)
|
2013-03-14 |
2017-10-24 |
Genentech Inc |
usos de um modulador de modificador de cromatina e um antagonista de egfr
|
US9168300B2
(en)
|
2013-03-14 |
2015-10-27 |
Oncomed Pharmaceuticals, Inc. |
MET-binding agents and uses thereof
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
MX2015010777A
(es)
|
2013-03-14 |
2016-04-25 |
Genentech Inc |
Anticuerpos e inmunoconjugados anti-b7-h4.
|
EP2968520B1
(en)
|
2013-03-14 |
2021-05-12 |
MacroGenics, Inc. |
Bispecific molecules that are immunoreactive with immune effector cells that express an activating receptor
|
CA2903480A1
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
BR112015023262B8
(pt)
|
2013-03-15 |
2024-02-06 |
Ac Immune Sa |
Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
|
KR102207859B1
(ko)
|
2013-03-15 |
2021-01-27 |
메모리얼 슬로안 케터링 캔서 센터 |
고 친화도 항-gd2 항체
|
CN105143265A
(zh)
|
2013-03-15 |
2015-12-09 |
豪夫迈·罗氏有限公司 |
抗CRTh2抗体及其用途
|
PL3587448T3
(pl)
*
|
2013-03-15 |
2021-11-29 |
Xencor, Inc. |
Białka heterodimeryczne
|
JP6591395B2
(ja)
|
2013-03-15 |
2019-10-16 |
ジェネンテック, インコーポレイテッド |
抗酸化剤を含む細胞培養組成物およびポリペプチド産生のための方法
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
SG10201913874TA
(en)
|
2013-03-15 |
2020-03-30 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
WO2014152006A2
(en)
|
2013-03-15 |
2014-09-25 |
Intrinsic Lifesciences, Llc |
Anti-hepcidin antibodies and uses thereof
|
UA118843C2
(uk)
|
2013-03-15 |
2019-03-25 |
Дженентек, Інк. |
ХИМЕРНИЙ БІЛОК IL-22 Fc ТА ЙОГО ЗАСТОСУВАННЯ
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US10035860B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
CN105451767B
(zh)
|
2013-03-15 |
2019-10-18 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
WO2014151422A1
(en)
|
2013-03-15 |
2014-09-25 |
Janssen Biotech, Inc. |
Interferon alpha and omega antibody antagonists
|
US10035859B2
(en)
|
2013-03-15 |
2018-07-31 |
Biogen Ma Inc. |
Anti-alpha V beta 6 antibodies and uses thereof
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
EA201591806A1
(ru)
|
2013-03-15 |
2016-01-29 |
Байоджен Ма Инк. |
Лечение и профилактика острой почечной недостаточности с применением анти-альфа-v-бета-5 антител
|
KR102158924B1
(ko)
|
2013-03-15 |
2020-09-22 |
제넨테크, 인크. |
Pd-1 및 pd-l1 관련 상태를 치료하기 위한 바이오마커 및 방법
|
SG11201507427QA
(en)
|
2013-03-15 |
2015-10-29 |
Genentech Inc |
Compositions and methods for diagnosis and treatment of hepatic cancers
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
EP2970486B1
(en)
|
2013-03-15 |
2018-05-16 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
WO2014151834A2
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Methods and compositions relating to anti-ccr7 antigen binding proteins
|
EP3623380A1
(en)
|
2013-03-15 |
2020-03-18 |
Michael C. Milone |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
US20140302037A1
(en)
|
2013-03-15 |
2014-10-09 |
Amgen Inc. |
BISPECIFIC-Fc MOLECULES
|
EP2968537A1
(en)
|
2013-03-15 |
2016-01-20 |
Genentech, Inc. |
Methods of treating cancer and preventing cancer drug resistance
|
EP2968544A4
(en)
|
2013-03-15 |
2016-10-12 |
Hoffmann La Roche |
CELL CULTURE MEDIA AND METHOD FOR PRODUCING ANTIBODY
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
BR112015023862A2
(pt)
|
2013-03-18 |
2017-10-24 |
Biocerox Prod Bv |
anticorpo isolado, molécula de ácido nucléico isolada, vetor, célula hospedeira, método de realçar uma resposta imune, método de tratar câncer, composição farmacêutica, e, anticorpo agonístico isolado
|
EP3495814A3
(en)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
AU2014250434B2
(en)
|
2013-04-02 |
2019-08-08 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
US20160053023A1
(en)
|
2013-04-09 |
2016-02-25 |
Annexon, Inc. |
Methods of treatment for neuromyelitis optica
|
SG11201508297YA
(en)
|
2013-04-17 |
2015-11-27 |
Genzyme Corp |
Compositions and methods for treating and preventing macular degeneration
|
SG10201810481UA
(en)
|
2013-04-29 |
2018-12-28 |
Hoffmann La Roche |
Fcrn-binding abolished anti-igf-1r antibodies and their use in the treatment of vascular eye diseases
|
KR102282134B1
(ko)
|
2013-04-29 |
2021-07-27 |
에프. 호프만-라 로슈 아게 |
인간 fcrn-결합 변형된 항체 및 사용 방법
|
WO2014177459A2
(en)
|
2013-04-29 |
2014-11-06 |
F. Hoffmann-La Roche Ag |
Fc-receptor binding modified asymmetric antibodies and methods of use
|
CA2910945A1
(en)
|
2013-05-08 |
2014-11-13 |
Zymeworks Inc. |
Bispecific her2 and her3 antigen binding constructs
|
EP2997373A1
(en)
|
2013-05-17 |
2016-03-23 |
MedImmune, LLC |
Receptors for b7-h4
|
EP2999716A2
(en)
|
2013-05-20 |
2016-03-30 |
F. Hoffmann-La Roche AG |
Anti-transferrin receptor antibodies and methods of use
|
EP2999484B1
(en)
|
2013-05-23 |
2019-09-11 |
Shire Human Genetic Therapies, Inc. |
Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
|
MX367046B
(es)
|
2013-05-24 |
2019-08-02 |
Soc Des Produits Nestle S A Star |
Marcadores especificos de via para diagnosticar sindrome del intestino irritable.
|
US11098105B2
(en)
|
2013-05-31 |
2021-08-24 |
Zymeworks Inc. |
Heteromultimers with reduced or silenced effector function
|
CN111423511B
(zh)
|
2013-05-31 |
2024-02-23 |
索伦托药业有限公司 |
与pd-1结合的抗原结合蛋白
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3019240B1
(en)
|
2013-07-09 |
2024-03-13 |
Annexon, Inc. |
Anti-complement factor c1q antibodies and uses thereof
|
KR102251127B1
(ko)
|
2013-07-12 |
2021-05-11 |
제넨테크, 인크. |
이온 교환 크로마토그래피 입력 최적화의 설명
|
ES2819209T3
(es)
|
2013-07-16 |
2021-04-15 |
Hoffmann La Roche |
Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 e inhibidores de TIGIT
|
US10093978B2
(en)
|
2013-08-12 |
2018-10-09 |
Genentech, Inc. |
Compositions for detecting complement factor H (CFH) and complement factor I (CFI) polymorphisms
|
WO2015023851A1
(en)
|
2013-08-14 |
2015-02-19 |
The Governing Council Of The University Of Toronto |
Antibodies against frizzled proteins and methods of use thereof
|
CN105792836A
(zh)
|
2013-08-28 |
2016-07-20 |
施特姆森特克斯股份有限公司 |
新型sez6调节剂以及应用方法
|
AU2014312215B2
(en)
|
2013-08-28 |
2020-02-27 |
Abbvie Stemcentrx Llc |
Site-specific antibody conjugation methods and compositions
|
WO2015033223A2
(en)
|
2013-09-03 |
2015-03-12 |
Novimmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
MX2016002798A
(es)
|
2013-09-05 |
2016-07-21 |
Genentech Inc |
Metodo para reutilizacion de cromatografia.
|
EP3041862B1
(en)
*
|
2013-09-05 |
2020-05-06 |
IGM Biosciences, Inc. |
Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
|
CA2923579C
(en)
|
2013-09-06 |
2023-09-05 |
Academia Sinica |
Human inkt cell activation using glycolipids with altered glycosyl groups
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
WO2015042249A1
(en)
|
2013-09-19 |
2015-03-26 |
Dana-Farber Cancer Institute, Inc. |
Methods of bh3 profiling
|
WO2015048272A1
(en)
|
2013-09-25 |
2015-04-02 |
Amgen Inc. |
V-c-fc-v-c antibody
|
JP6534615B2
(ja)
|
2013-09-27 |
2019-06-26 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
MA38960A1
(fr)
|
2013-09-27 |
2017-10-31 |
Genentech Inc |
Formulations d'anticorps anti-pdl1
|
CA2922950A1
(en)
|
2013-09-30 |
2015-04-02 |
Shinya Ishii |
Method for producing antigen-binding molecule using modified helper phage
|
WO2015050959A1
(en)
|
2013-10-01 |
2015-04-09 |
Yale University |
Anti-kit antibodies and methods of use thereof
|
WO2015052230A1
(en)
|
2013-10-11 |
2015-04-16 |
F. Hoffmann-La Roche Ag |
Multispecific domain exchanged common variable light chain antibodies
|
WO2015054670A1
(en)
|
2013-10-11 |
2015-04-16 |
Genentech, Inc. |
Nsp4 inhibitors and methods of use
|
KR20160070136A
(ko)
|
2013-10-18 |
2016-06-17 |
제넨테크, 인크. |
항-rspo2 및/또는 항-rspo3 항체 및 그의 용도
|
WO2015057939A1
(en)
|
2013-10-18 |
2015-04-23 |
Biogen Idec Ma Inc. |
Anti-s1p4 antibodies and uses thereof
|
RU2016119425A
(ru)
|
2013-10-23 |
2017-11-28 |
Дженентек, Инк. |
Способы диагностики и лечения эозинофильных заболеваний
|
RU2696876C2
(ru)
|
2013-11-04 |
2019-08-07 |
Ютиай Лимитед Партнершип |
Способы и композиции для устойчивой иммунотерапии
|
EP3176185A1
(en)
|
2013-11-04 |
2017-06-07 |
Glenmark Pharmaceuticals S.A. |
Production of t cell retargeting hetero-dimeric immunoglobulins
|
SG11201603231XA
(en)
|
2013-11-06 |
2016-05-30 |
Janssen Biotech Inc |
Anti-ccl17 antibodies
|
JPWO2015068847A1
(ja)
|
2013-11-11 |
2017-03-09 |
中外製薬株式会社 |
改変された抗体可変領域を含む抗原結合分子
|
AU2014348552A1
(en)
|
2013-11-13 |
2016-06-02 |
Zymeworks Inc. |
Monovalent antigen binding constructs targeting EGFR and/or HER2 and uses thereof
|
EP3071597B1
(en)
|
2013-11-21 |
2020-07-29 |
F.Hoffmann-La Roche Ag |
Anti-alpha-synuclein antibodies and methods of use
|
AU2014357292B2
(en)
|
2013-11-27 |
2020-06-25 |
Zymeworks Bc Inc. |
Bispecific antigen-binding constructs targeting HER2
|
TWI664331B
(zh)
|
2013-12-04 |
2019-07-01 |
日商中外製藥股份有限公司 |
因應化合物濃度使抗原結合能力變化的抗原結合分子及其資料庫
|
WO2015089344A1
(en)
|
2013-12-13 |
2015-06-18 |
Genentech, Inc. |
Anti-cd33 antibodies and immunoconjugates
|
CA2934028A1
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
MX2016007958A
(es)
|
2013-12-17 |
2016-08-03 |
Genentech Inc |
Anticuerpos anti-cd3 y metodos de uso.
|
NZ720515A
(en)
|
2013-12-17 |
2022-12-23 |
Genentech Inc |
Methods of treating cancers using pd-1 axis binding antagonists and taxanes
|
CN105899535A
(zh)
|
2013-12-17 |
2016-08-24 |
豪夫迈·罗氏有限公司 |
用pd-1轴结合拮抗剂和抗cd20抗体治疗癌症的方法
|
AU2014366837B2
(en)
|
2013-12-18 |
2020-06-25 |
B-Creative Sweden Ab |
Method of treating wounds
|
CA2931684C
(en)
|
2013-12-19 |
2024-02-20 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
PL3083680T3
(pl)
|
2013-12-20 |
2020-06-29 |
F. Hoffmann-La Roche Ag |
Humanizowane przeciwciała przeciwko białku tau(pS422) i sposoby stosowania
|
JP6793902B2
(ja)
|
2013-12-20 |
2020-12-02 |
ノバルティス アーゲー |
調節可能キメラ抗原受容体
|
TWI670283B
(zh)
|
2013-12-23 |
2019-09-01 |
美商建南德克公司 |
抗體及使用方法
|
US11014987B2
(en)
|
2013-12-24 |
2021-05-25 |
Janssen Pharmaceutics Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
BR112016014810B1
(pt)
|
2013-12-24 |
2023-12-26 |
Argenx Bvba |
Antagonistas de fcrn e métodos de uso
|
CN106661107B
(zh)
|
2013-12-24 |
2021-12-24 |
杨森制药公司 |
抗vista抗体及片段
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
CN105873615B
(zh)
|
2014-01-03 |
2020-12-25 |
豪夫迈·罗氏有限公司 |
共价连接的helicar-抗helicar抗体缀合物及其用途
|
CN105873616B
(zh)
|
2014-01-03 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
共价连接的多肽毒素-抗体缀合物
|
WO2015103026A2
(en)
|
2014-01-03 |
2015-07-09 |
The Regents Of The University Of Michigan |
Treatment of neurological disorders
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
MX2016008631A
(es)
|
2014-01-08 |
2016-12-20 |
Shanghai hengrui pharmaceutical co ltd |
Proteina heterodimérica il-5 y usos de la misma.
|
EP3094648A1
(en)
|
2014-01-15 |
2016-11-23 |
F. Hoffmann-La Roche AG |
Fc-region variants with improved protein a-binding
|
CA2931986A1
(en)
|
2014-01-15 |
2015-07-23 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn- and maintained protein a-binding properties
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
TW201620939A
(zh)
|
2014-01-16 |
2016-06-16 |
中央研究院 |
治療及檢測癌症之組合物及方法
|
WO2015112626A1
(en)
|
2014-01-21 |
2015-07-30 |
June Carl H |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016015693A2
(pt)
|
2014-01-24 |
2017-10-24 |
Genentech Inc |
método para tratar um câncer de próstata e anticorpo
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106459190A
(zh)
|
2014-02-02 |
2017-02-22 |
麦迪穆有限责任公司 |
用于治疗疼痛的化合物和方法
|
DK3102197T3
(en)
|
2014-02-04 |
2018-11-19 |
Genentech Inc |
Smoothened mutant and methods for its use
|
CA2931114A1
(en)
|
2014-02-06 |
2015-08-13 |
F. Hoffmann-La Roche Ag |
Interleukin-2 fusion proteins and uses thereof
|
CN106163573A
(zh)
|
2014-02-06 |
2016-11-23 |
建新公司 |
用于治疗和预防黄斑变性的组合物及方法
|
AU2015214058B2
(en)
|
2014-02-08 |
2020-07-09 |
Genentech, Inc. |
Methods of treating Alzheimer's Disease
|
PL3102230T3
(pl)
|
2014-02-08 |
2021-11-15 |
F.Hoffmann-La Roche Ag |
Sposoby leczenia choroby Alzheimera
|
CN105992772A
(zh)
|
2014-02-10 |
2016-10-05 |
Igm生命科学股份有限公司 |
IgA多特异性结合分子
|
AR099465A1
(es)
|
2014-02-12 |
2016-07-27 |
Genentech Inc |
Anticuerpos anti-jagged1 y métodos de uso
|
MX2016010729A
(es)
|
2014-02-21 |
2016-10-26 |
Genentech Inc |
Anticuerpos biespecificos anti-il-13 / il-17 y sus usos.
|
KR20170008202A
(ko)
|
2014-02-21 |
2017-01-23 |
애브비 스템센트알엑스 엘엘씨 |
흑색종에 사용하기 위한 항-dll3 항체 및 약물 접합체
|
SG11201607109QA
(en)
|
2014-02-28 |
2016-09-29 |
Merus Nv |
Antibodies that bind egfr and erbb3
|
US9732154B2
(en)
|
2014-02-28 |
2017-08-15 |
Janssen Biotech, Inc. |
Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
|
EP3470435B1
(en)
|
2014-02-28 |
2020-08-05 |
Merus N.V. |
Antibody that binds erbb-2 and erbb-3
|
PL3116999T3
(pl)
|
2014-03-14 |
2021-12-27 |
F.Hoffmann-La Roche Ag |
Sposoby i kompozycje do wydzielania polipeptydów heterologicznych
|
PT3116909T
(pt)
|
2014-03-14 |
2020-01-30 |
Novartis Ag |
Moléculas de anticorpos para lag-3 e suas utilizações
|
EP3593812A3
(en)
|
2014-03-15 |
2020-05-27 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
RU2016141307A
(ru)
|
2014-03-21 |
2018-04-24 |
Регенерон Фармасьютикалз, Инк. |
Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
|
US20170107294A1
(en)
|
2014-03-21 |
2017-04-20 |
Nordlandssykehuset Hf |
Anti-cd14 antibodies and uses thereof
|
MA39776A
(fr)
|
2014-03-24 |
2017-02-01 |
Hoffmann La Roche |
Traitement du cancer avec des antagonistes de c-met et corrélation de ces derniers avec l'expression de hgf
|
JP6562942B2
(ja)
|
2014-03-27 |
2019-08-28 |
アカデミア シニカAcademia Sinica |
反応性標識化合物およびその使用
|
AR099856A1
(es)
|
2014-03-27 |
2016-08-24 |
Genentech Inc |
Métodos para diagnosticar y tratar la enfermedad de intestino inflamado
|
RS59907B1
(sr)
|
2014-03-28 |
2020-03-31 |
Xencor Inc |
Bispecifična antitela koja se vezuju za cd38 i cd3
|
MA51552A
(fr)
|
2014-03-31 |
2021-03-24 |
Hoffmann La Roche |
Anticorps anti-ox40 et procédés d'utilisation
|
RU2016142476A
(ru)
|
2014-03-31 |
2018-05-07 |
Дженентек, Инк. |
Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
|
EP3825326A1
(en)
|
2014-04-01 |
2021-05-26 |
Adimab, LLC |
Multispecific antibody analogs comprising a common light chain, and methods of their preparation and use
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
US9995746B2
(en)
|
2014-04-02 |
2018-06-12 |
The United States Of America, As Represented By The Secretary Of The Army |
Rapid dual direct fluorescent antibody assay for the identification of Bacillus antrhacis
|
SG11201608054YA
(en)
|
2014-04-02 |
2016-10-28 |
Hoffmann La Roche |
Method for detecting multispecific antibody light chain mispairing
|
AU2015244814B2
(en)
|
2014-04-07 |
2020-12-24 |
Chugai Seiyaku Kabushiki Kaisha |
Immunoactivating antigen-binding molecule
|
PL3129470T3
(pl)
|
2014-04-07 |
2021-11-29 |
Novartis Ag |
Leczenie nowotworu złośliwego z zastosowaniem chimerycznego receptora antygenowego anty-CD19
|
CN106456784A
(zh)
|
2014-04-16 |
2017-02-22 |
拜康有限公司 |
包含摩尔过量的山梨醇的稳定蛋白质制剂
|
US10040862B2
(en)
|
2014-04-18 |
2018-08-07 |
The Board Of Trustees Of The Leland Stanford Junior University |
Humanized and chimeric monoclonal antibodies to CD99
|
WO2015164615A1
(en)
|
2014-04-24 |
2015-10-29 |
University Of Oslo |
Anti-gluten antibodies and uses thereof
|
EP4299595A3
(en)
|
2014-05-02 |
2024-03-13 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
WO2015171822A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
AU2015260230A1
(en)
|
2014-05-13 |
2016-11-17 |
Chugai Seiyaku Kabushiki Kaisha |
T cell-redirected antigen-binding molecule for cells having immunosuppression function
|
WO2015175375A1
(en)
|
2014-05-13 |
2015-11-19 |
Short Jay M |
Conditionally active biological proteins
|
EP3143043B1
(en)
|
2014-05-16 |
2022-12-14 |
Pfizer Inc. |
Bispecific antibodies with engineered ch1-cl interfaces
|
RU2016150370A
(ru)
|
2014-05-22 |
2018-06-26 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против GPC3
|
KR20170005016A
(ko)
|
2014-05-23 |
2017-01-11 |
제넨테크, 인크. |
MiT 바이오마커 및 그의 사용 방법
|
JP2017518989A
(ja)
|
2014-05-27 |
2017-07-13 |
アカデミア シニカAcademia Sinica |
抗cd20糖操作抗体群およびその使用
|
AU2015267045B2
(en)
|
2014-05-27 |
2021-02-25 |
Academia Sinica |
Anti-HER2 glycoantibodies and uses thereof
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
WO2015184008A1
(en)
|
2014-05-27 |
2015-12-03 |
Academia Sinica |
Fucosidase from bacteroides and methods using the same
|
TWI732738B
(zh)
|
2014-05-28 |
2021-07-11 |
中央研究院 |
抗TNF-α醣抗體及其用途
|
DK3107938T3
(da)
|
2014-05-28 |
2022-07-11 |
Zymeworks Inc |
Modificerede, antigenbindende polypeptidkonstrukter og anvendelser heraf
|
TWI718098B
(zh)
|
2014-05-29 |
2021-02-11 |
美商宏觀基因股份有限公司 |
三特異性結合分子及其使用方法
|
GB201409558D0
(en)
|
2014-05-29 |
2014-07-16 |
Ucb Biopharma Sprl |
Method
|
JP6997619B2
(ja)
|
2014-06-11 |
2022-01-17 |
キャシー・エイ・グリーン |
液性免疫の抑制または増進のための、vistaアゴニスト及びvistaアンタゴニストの使用
|
CA2949982A1
(en)
|
2014-06-11 |
2015-12-17 |
Genentech, Inc. |
Anti-lgr5 antibodies and uses thereof
|
EP3154589A1
(en)
|
2014-06-13 |
2017-04-19 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
TWI695011B
(zh)
|
2014-06-18 |
2020-06-01 |
美商梅爾莎納醫療公司 |
抗her2表位之單株抗體及其使用之方法
|
TWI713453B
(zh)
|
2014-06-23 |
2020-12-21 |
美商健生生物科技公司 |
干擾素α及ω抗體拮抗劑
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
EP3160991A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
CA2947504A1
(en)
|
2014-06-26 |
2015-12-30 |
F. Hoffmann-La Roche Ag |
Anti-brdu antibodies and methods of use
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
TW201623329A
(zh)
|
2014-06-30 |
2016-07-01 |
亞佛瑞司股份有限公司 |
針對骨調素截斷變異體的疫苗及單株抗體暨其用途
|
EP3164417A1
(en)
|
2014-07-01 |
2017-05-10 |
Pfizer Inc. |
Bispecific heterodimeric diabodies and uses thereof
|
NZ728041A
(en)
|
2014-07-10 |
2023-01-27 |
Affiris Ag |
Substances and methods for the use in prevention and/or treatment in huntington’s disease
|
CN106488775A
(zh)
|
2014-07-11 |
2017-03-08 |
基因泰克公司 |
Notch途径抑制
|
JP7032929B2
(ja)
|
2014-07-11 |
2022-03-09 |
ヴェンタナ メディカル システムズ, インク. |
抗pd-l1抗体及びその診断上の使用
|
GB201412659D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
GB201412658D0
(en)
|
2014-07-16 |
2014-08-27 |
Ucb Biopharma Sprl |
Molecules
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
WO2016014530A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Combinations of low, immune enhancing. doses of mtor inhibitors and cars
|
TWI750110B
(zh)
|
2014-07-21 |
2021-12-21 |
瑞士商諾華公司 |
使用人類化抗-bcma嵌合抗原受體治療癌症
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
AR101262A1
(es)
|
2014-07-26 |
2016-12-07 |
Regeneron Pharma |
Plataforma de purificación para anticuerpos biespecíficos
|
PE20170771A1
(es)
|
2014-07-30 |
2017-07-04 |
Ngm Biopharmaceuticals Inc |
Composiciones y metodos de uso para tratar trastornos metabolicos
|
ES2781175T3
(es)
|
2014-07-31 |
2020-08-31 |
Novartis Ag |
Subconjunto optimizado de células T que contienen un receptor de antígeno quimérico
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
PE20170263A1
(es)
|
2014-08-04 |
2017-03-30 |
Hoffmann La Roche |
Moleculas biespecificas de union a antigeno activadoras de celulas t
|
US20170240631A1
(en)
|
2014-08-08 |
2017-08-24 |
Alector Llc |
Anti-trem2 antibodies and methods of use thereof
|
CA2958200A1
(en)
|
2014-08-14 |
2016-02-18 |
Novartis Ag |
Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
|
PT3183268T
(pt)
|
2014-08-19 |
2020-05-15 |
Novartis Ag |
Recetor de antigénio quimérico (car) anti-cd123 para uso no tratamento de cancro
|
AU2015305894A1
(en)
|
2014-08-22 |
2017-04-06 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind CXCR3
|
US11111288B2
(en)
|
2014-08-28 |
2021-09-07 |
Bioatla, Inc. |
Conditionally active chimeric antigen receptors for modified t-cells
|
JP7286267B2
(ja)
|
2014-08-28 |
2023-06-05 |
バイオアトラ インコーポレイテッド |
修飾t細胞に対する条件的活性型キメラ抗原受容体
|
TW201617368A
(zh)
|
2014-09-05 |
2016-05-16 |
史坦森特瑞斯公司 |
新穎抗mfi2抗體及使用方法
|
CA2960712A1
(en)
|
2014-09-08 |
2016-03-17 |
Academia Sinica |
Human inkt cell activation using glycolipids
|
PE20170676A1
(es)
|
2014-09-09 |
2017-05-22 |
Janssen Biotech Inc |
Terapias de combinacion con anticuerpos anti-cd38
|
PE20170670A1
(es)
|
2014-09-12 |
2017-06-06 |
Genentech Inc |
Anticuerpos anti-cll-1 e inmunoconjugados
|
TW201625689A
(zh)
|
2014-09-12 |
2016-07-16 |
建南德克公司 |
抗-b7-h4抗體及免疫結合物
|
SG11201701128YA
(en)
|
2014-09-12 |
2017-03-30 |
Genentech Inc |
Cysteine engineered antibodies and conjugates
|
JP7085837B2
(ja)
|
2014-09-12 |
2022-06-17 |
ジェネンテック, インコーポレイテッド |
抗her2抗体及び免疫複合体
|
CA2959545A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
US10934362B2
(en)
|
2014-09-15 |
2021-03-02 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
KR20170055521A
(ko)
|
2014-09-17 |
2017-05-19 |
제넨테크, 인크. |
항-her2 항체를 포함하는 면역콘주게이트
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
CN107072184A
(zh)
|
2014-09-19 |
2017-08-18 |
瑞泽恩制药公司 |
嵌合抗原受体
|
US10323088B2
(en)
|
2014-09-22 |
2019-06-18 |
Intrinsic Lifesciences Llc |
Humanized anti-hepcidin antibodies and uses thereof
|
LT3262071T
(lt)
|
2014-09-23 |
2020-06-25 |
F. Hoffmann-La Roche Ag |
Anti-cd79b imunokonjugatų naudojimo būdai
|
EP3197916A2
(en)
|
2014-09-25 |
2017-08-02 |
Amgen Inc. |
Protease-activatable bispecific proteins
|
MA40764A
(fr)
|
2014-09-26 |
2017-08-01 |
Chugai Pharmaceutical Co Ltd |
Agent thérapeutique induisant une cytotoxicité
|
CN107108721B
(zh)
|
2014-09-29 |
2021-09-07 |
杜克大学 |
包含hiv-1包膜靶向臂的双特异性分子
|
CN106922129B
(zh)
|
2014-10-01 |
2024-02-20 |
免疫医疗有限责任公司 |
轭合多肽的方法
|
JP6708635B2
(ja)
|
2014-10-09 |
2020-06-10 |
エンクマフ エスアーエールエル |
CD3εおよびROR1に対する二特異性抗体
|
MX2017004810A
(es)
|
2014-10-14 |
2017-10-16 |
Novartis Ag |
Moleculas de anticuerpo que se unen a pd-l1 y usos de las mismas.
|
BR112017007765B1
(pt)
|
2014-10-14 |
2023-10-03 |
Halozyme, Inc |
Composições de adenosina deaminase-2 (ada2), variantes do mesmo e métodos de usar o mesmo
|
US9732148B2
(en)
|
2014-10-16 |
2017-08-15 |
Genentech, Inc. |
Anti-α-synuclein antibodies and methods of use
|
US10870704B2
(en)
|
2014-10-23 |
2020-12-22 |
Kira Biotech Pty Limited |
CD83 binding proteins and uses thereof
|
EP3209697A4
(en)
|
2014-10-23 |
2018-05-30 |
La Trobe University |
Fn14-binding proteins and uses thereof
|
EP3701969A1
(en)
|
2014-10-31 |
2020-09-02 |
NGM Biopharmaceuticals, Inc. |
Compositions and methods of use for treating metabolic disorders
|
ES2808153T3
(es)
|
2014-10-31 |
2021-02-25 |
Mereo Biopharma 5 Inc |
Terapia de combinación para tratamiento de enfermedad
|
CN107109484B
(zh)
|
2014-11-03 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
用于ox40激动剂治疗的功效预测和评估的方法和生物标志物
|
CN106796235B
(zh)
|
2014-11-03 |
2021-01-29 |
豪夫迈·罗氏有限公司 |
用于检测t细胞免疫子集的测定法及其使用方法
|
US11773166B2
(en)
|
2014-11-04 |
2023-10-03 |
Ichnos Sciences SA |
CD3/CD38 T cell retargeting hetero-dimeric immunoglobulins and methods of their production
|
KR20170075793A
(ko)
|
2014-11-05 |
2017-07-03 |
제넨테크, 인크. |
박테리아 내 2쇄 단백질을 생산하는 방법
|
SG11201703667SA
(en)
|
2014-11-05 |
2017-06-29 |
Annexon Inc |
Humanized anti-complement factor c1q antibodies and uses thereof
|
SI3215525T1
(sl)
|
2014-11-05 |
2020-11-30 |
Genentech, Inc. |
Postopki produkcije dvoverižnih proteinov v bakterijah
|
WO2016073157A1
(en)
|
2014-11-06 |
2016-05-12 |
Genentech, Inc. |
Anti-ang2 antibodies and methods of use thereof
|
WO2016071376A2
(en)
|
2014-11-06 |
2016-05-12 |
F. Hoffmann-La Roche Ag |
Fc-region variants with modified fcrn-binding and methods of use
|
JP6576456B2
(ja)
|
2014-11-06 |
2019-09-18 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
修飾されたFcRn結合特性およびプロテインA結合特性を有するFc領域変種
|
UA122673C2
(uk)
|
2014-11-07 |
2020-12-28 |
Елевен Байотерапьютікс, Інк. |
Антитіло, що специфічно зв'язується з людським il-6
|
WO2016073894A1
(en)
|
2014-11-07 |
2016-05-12 |
Eleven Biotherapeutics, Inc. |
Therapeutic agents with increased ocular retention
|
EP3552488A1
(en)
|
2014-11-10 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Animal model for nephropathy and agents for treating the same
|
EP3218403B1
(en)
|
2014-11-10 |
2020-05-13 |
F.Hoffmann-La Roche Ag |
Anti-interleukin-33 antibodies and uses thereof
|
HUE049982T2
(hu)
|
2014-11-14 |
2020-11-30 |
Hoffmann La Roche |
TNF-családba tartozó ligandum-trimert tartalmazó antigénkötõ molekulák
|
BR112017010198A2
(pt)
|
2014-11-17 |
2017-12-26 |
Genentech Inc |
terapia de combinação compreendendo agonistas de ligação a ox40 e antagonistas de ligação ao eixo de pd-1
|
CN107108745B
(zh)
|
2014-11-19 |
2021-01-12 |
基因泰克公司 |
抗bace1的抗体和其用于神经疾病免疫疗法的用途
|
US10508151B2
(en)
|
2014-11-19 |
2019-12-17 |
Genentech, Inc. |
Anti-transferrin receptor antibodies and methods of use
|
US11008403B2
(en)
|
2014-11-19 |
2021-05-18 |
Genentech, Inc. |
Anti-transferrin receptor / anti-BACE1 multispecific antibodies and methods of use
|
EP3221353A1
(en)
|
2014-11-19 |
2017-09-27 |
Nestec S.A. |
Antibodies against serotonin, tryptophan and kynurenine metabolites and uses thereof
|
SI3221357T1
(sl)
|
2014-11-20 |
2020-09-30 |
F. Hoffmann-La Roche Ag |
Pogoste lahke verige in načini uporabe
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
SG11201704056XA
(en)
|
2014-11-20 |
2017-06-29 |
Hoffmann La Roche |
Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
|
EP3220900B1
(en)
|
2014-11-21 |
2020-09-23 |
University of Maryland, Baltimore |
Targeted structure-specific particulate delivery systems
|
KR20170084327A
(ko)
|
2014-11-26 |
2017-07-19 |
젠코어 인코포레이티드 |
Cd3 및 cd38에 결합하는 이형이량체 항체
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
CN116333153A
(zh)
|
2014-11-26 |
2023-06-27 |
森科股份有限公司 |
结合cd3和肿瘤抗原的异二聚体抗体
|
EP3227341A1
(en)
|
2014-12-02 |
2017-10-11 |
CeMM - Forschungszentrum für Molekulare Medizin GmbH |
Anti-mutant calreticulin antibodies and their use in the diagnosis and therapy of myeloid malignancies
|
US20180334490A1
(en)
|
2014-12-03 |
2018-11-22 |
Qilong H. Wu |
Methods for b cell preconditioning in car therapy
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
AU2015357463B2
(en)
|
2014-12-05 |
2021-10-07 |
Immunext, Inc. |
Identification of VSIG8 as the putative vista receptor and its use thereof to produce vista/VSIG8 modulators
|
US9975949B2
(en)
|
2014-12-05 |
2018-05-22 |
Genentech, Inc. |
Anti-CD79b antibodies and methods of use
|
WO2016094566A2
(en)
|
2014-12-10 |
2016-06-16 |
Genentech, Inc. |
Blood brain barrier receptor antibodies and methods of use
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
RU2698205C2
(ru)
|
2014-12-18 |
2019-08-23 |
Ф. Хоффманн-Ля Рош Аг |
Способ определения антител, вызывающих комплемент-зависимую цитотоксичность
|
US10865253B2
(en)
|
2014-12-19 |
2020-12-15 |
Genmab A/S |
Rodent bispecific heterodimeric proteins
|
US10940212B2
(en)
|
2014-12-19 |
2021-03-09 |
Monash University |
IL-21 agonist antibodies and methods of treatment using same
|
PT3233921T
(pt)
|
2014-12-19 |
2021-12-09 |
Chugai Pharmaceutical Co Ltd |
Anticorpos anti-c5 e processos para a sua utilização
|
US10428155B2
(en)
|
2014-12-22 |
2019-10-01 |
Xencor, Inc. |
Trispecific antibodies
|
KR20170093254A
(ko)
|
2014-12-29 |
2017-08-14 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포를 제조하는 방법
|
WO2016109415A1
(en)
|
2014-12-30 |
2016-07-07 |
Celgene Corporation |
Anti-cd47 antibodies and uses thereof
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
CN113956354A
(zh)
|
2015-01-22 |
2022-01-21 |
中外制药株式会社 |
两种以上抗-c5抗体的组合与使用方法
|
PL3247725T3
(pl)
|
2015-01-23 |
2021-01-11 |
Sanofi |
Przeciwciała anty-CD3, przeciwciała anty-CD123 i przeciwciała bispecyficzne specyficznie wiążące się z CD3 i/lub CD123
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
JP6779887B2
(ja)
|
2015-01-24 |
2020-11-04 |
アカデミア シニカAcademia Sinica |
新規なグリカンコンジュゲートおよびその使用方法
|
KR20170135824A
(ko)
|
2015-01-26 |
2017-12-08 |
셀렉티스 |
출아형 원형질 세포의 수지상 세포 신생물 또는 재발된/난치성 급성 골수성 림프종의 치료를 위한 cd123에 결합하는 키메라 항원 수용체들을 지닌 것으로 여겨지는, t 세포 수용체 넉 아웃 조작된 면역 세포들
|
JP2018506275A
(ja)
|
2015-01-28 |
2018-03-08 |
ジェネンテック, インコーポレイテッド |
多発性硬化症の遺伝子発現マーカー及び治療
|
US10828353B2
(en)
|
2015-01-31 |
2020-11-10 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for T cell delivery of therapeutic molecules
|
WO2016126608A1
(en)
|
2015-02-02 |
2016-08-11 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
JP2018512597A
(ja)
|
2015-02-04 |
2018-05-17 |
ジェネンテック, インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
US9969800B2
(en)
|
2015-02-05 |
2018-05-15 |
Chugai Seiyaku Kabushiki Kaisha |
IL-8 antibodies
|
AR103675A1
(es)
|
2015-02-13 |
2017-05-24 |
Sorrento Therapeutics Inc |
Anticuerpos anti-ctla4 terapéuticos
|
KR20170120601A
(ko)
|
2015-02-26 |
2017-10-31 |
제넨테크, 인크. |
인테그린 베타7 길항제 및 크론병을 치료하는 방법
|
AU2016224409B2
(en)
|
2015-02-27 |
2021-01-28 |
Chugai Seiyaku Kabushiki Kaisha |
Composition for treating IL-6-related diseases
|
WO2016141387A1
(en)
|
2015-03-05 |
2016-09-09 |
Xencor, Inc. |
Modulation of t cells with bispecific antibodies and fc fusions
|
EP3265557B1
(en)
|
2015-03-06 |
2019-10-16 |
F. Hoffmann-La Roche AG |
Ultrapurified dsba and dsbc and methods of making and using the same
|
PL3268391T3
(pl)
|
2015-03-09 |
2022-01-03 |
Argenx Bvba |
Sposoby zmniejszania poziomów środków zawierających Fc w surowicy z zastosowaniem antagonistów FcRn
|
MX2017011600A
(es)
|
2015-03-10 |
2018-06-13 |
Sorrento Therapeutics Inc |
Terapeuticos de anticuerpo que enlazan antigeno de membrana especifico de prostata.
|
JP6394444B2
(ja)
*
|
2015-03-10 |
2018-09-26 |
株式会社デンソー |
ブラシレスモータ
|
CN107430117A
(zh)
|
2015-03-16 |
2017-12-01 |
豪夫迈·罗氏有限公司 |
检测和定量IL‑13的方法和在诊断和治疗Th2相关疾病中的用途
|
WO2016149678A1
(en)
|
2015-03-19 |
2016-09-22 |
Regeneron Pharmaceuticals, Inc. |
Non-human animals that select for light chain variable regions that bind antigen
|
WO2016146833A1
(en)
|
2015-03-19 |
2016-09-22 |
F. Hoffmann-La Roche Ag |
Biomarkers for nad(+)-diphthamide adp ribosyltransferase resistance
|
EP3277305B1
(en)
|
2015-03-31 |
2021-07-21 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a trimeric tnf family ligand
|
SG11201707593UA
(en)
|
2015-03-31 |
2017-10-30 |
Medimmune Ltd |
A novel il33 form, mutated forms of il33, antibodies, assays and methods of using the same
|
JP7082484B2
(ja)
|
2015-04-01 |
2022-06-08 |
中外製薬株式会社 |
ポリペプチド異種多量体の製造方法
|
JP6901400B2
(ja)
|
2015-04-03 |
2021-07-14 |
ゾーマ テクノロジー リミテッド |
TGF−β及びPD−1の阻害物質を使用する癌の治療法
|
EP3277314A4
(en)
|
2015-04-03 |
2018-08-29 |
Eureka Therapeutics, Inc. |
Constructs targeting afp peptide/mhc complexes and uses thereof
|
MA41919A
(fr)
|
2015-04-06 |
2018-02-13 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
HUE054180T2
(hu)
|
2015-04-06 |
2021-08-30 |
Acceleron Pharma Inc |
Egykarú I. típusú és II. típusú receptorral rendelkezõ fúziós fehérjék, illetve ezek alkalmazásai
|
WO2016164089A2
(en)
|
2015-04-06 |
2016-10-13 |
Acceleron Pharma Inc. |
Tgf-beta superfamily type i and type ii receptor heteromultimers and uses thereof
|
EP4249916A3
(en)
|
2015-04-06 |
2023-11-01 |
President and Fellows of Harvard College |
Compositions and methods for non-myeloablative conditioning
|
MX2017012805A
(es)
|
2015-04-07 |
2018-04-11 |
Genentech Inc |
Complejo de unión a antígenos con actividad agonista y métodos de uso.
|
DK3280441T3
(da)
|
2015-04-07 |
2021-11-15 |
Alector Llc |
Anti-sortilin-antistoffer og fremgangsmåder til anvendelse deraf
|
JP7068825B2
(ja)
|
2015-04-08 |
2022-05-17 |
ソレント・セラピューティクス・インコーポレイテッド |
Cd38に結合する抗体治療剤
|
IL303972A
(en)
|
2015-04-08 |
2023-08-01 |
Novartis Ag |
CD20 treatments, CD22 treatments and combined treatments with CD19 chimeric antigen receptor expressing cell
|
JP6962819B2
(ja)
|
2015-04-10 |
2021-11-05 |
アディマブ, エルエルシー |
親ホモ二量体抗体種からのヘテロ二量体多重特異性抗体の精製方法
|
WO2016168595A1
(en)
|
2015-04-17 |
2016-10-20 |
Barrett David Maxwell |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
CN108064245A
(zh)
|
2015-04-17 |
2018-05-22 |
埃尔萨里斯生物技术公司 |
抗Tyro3抗体及其用途
|
US9901574B2
(en)
|
2015-04-20 |
2018-02-27 |
Tolero Pharmaceuticals, Inc. |
Predicting response to alvocidib by mitochondrial profiling
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
SI3286315T1
(sl)
|
2015-04-24 |
2021-09-30 |
F. Hoffmann-La Roche Ag |
Postopek identifikacije bakterij, ki obsegajo vezavne polipeptide
|
AU2016252773B2
(en)
|
2015-04-24 |
2022-06-02 |
Genentech, Inc. |
Multispecific antigen-binding proteins
|
CA2983022C
(en)
|
2015-04-27 |
2023-03-07 |
Dana-Farber Cancer Institute, Inc. |
High throughput bh3 profiling: a rapid and scalable technology to bh3 profile on low numbers of cells
|
EP3291832A4
(en)
|
2015-05-06 |
2018-09-12 |
UTI Limited Partnership |
Nanoparticle compositions for sustained therapy
|
EP3236996B1
(en)
|
2015-05-08 |
2022-03-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
JP6963508B2
(ja)
|
2015-05-11 |
2021-11-10 |
ジェネンテック, インコーポレイテッド |
ループス腎炎を治療する組成物及び方法
|
JP7048319B2
(ja)
|
2015-05-12 |
2022-04-05 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
CA2985816A1
(en)
|
2015-05-15 |
2016-11-24 |
The General Hospital Corporation |
Antagonistic anti-tumor necrosis factor receptor superfamily antibodies
|
EP3298021B1
(en)
|
2015-05-18 |
2019-05-01 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs having increased bioavailability
|
CN114634943A
(zh)
|
2015-05-18 |
2022-06-17 |
T细胞受体治疗公司 |
使用融合蛋白对tcr重编程的组合物和方法
|
EA201792546A1
(ru)
|
2015-05-20 |
2018-04-30 |
Янссен Байотек, Инк. |
Антитела к cd38 для лечения амилоидоза легких цепей и прочих cd38-положительных гематологических злокачественных опухолей
|
WO2016187594A1
(en)
|
2015-05-21 |
2016-11-24 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
WO2016191750A1
(en)
|
2015-05-28 |
2016-12-01 |
Genentech, Inc. |
Cell-based assay for detecting anti-cd3 homodimers
|
JP7144935B2
(ja)
|
2015-05-29 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
癌のための治療方法及び診断方法
|
CN107771182A
(zh)
|
2015-05-29 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
人源化抗埃博拉病毒糖蛋白抗体和使用方法
|
KR20180013881A
(ko)
|
2015-05-29 |
2018-02-07 |
제넨테크, 인크. |
암에서의 pd-l1 프로모터 메틸화
|
CN107810012A
(zh)
|
2015-06-02 |
2018-03-16 |
豪夫迈·罗氏有限公司 |
使用抗il‑34抗体治疗神经疾病的组合物和方法
|
US10112990B2
(en)
|
2015-06-05 |
2018-10-30 |
Genentech, Inc. |
Anti-Tau antibodies and methods of use
|
MX2017014740A
(es)
|
2015-06-08 |
2018-08-15 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40.
|
MX2017015937A
(es)
|
2015-06-08 |
2018-12-11 |
Genentech Inc |
Métodos de tratamiento del cáncer con anticuerpos anti-ox40 y antagonistas de unión al eje de pd-1.
|
SG10201912085WA
(en)
|
2015-06-12 |
2020-02-27 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
US11174313B2
(en)
|
2015-06-12 |
2021-11-16 |
Alector Llc |
Anti-CD33 antibodies and methods of use thereof
|
EP3307780A1
(en)
|
2015-06-15 |
2018-04-18 |
Genentech, Inc. |
Antibodies and immunoconjugates
|
JP6996983B2
(ja)
|
2015-06-16 |
2022-02-21 |
ジェネンテック, インコーポレイテッド |
抗cll-1抗体及び使用方法
|
JP2018526972A
(ja)
|
2015-06-16 |
2018-09-20 |
ジェネンテック, インコーポレイテッド |
抗cd3抗体及び使用方法
|
CR20180031A
(es)
|
2015-06-16 |
2018-05-07 |
Genentech Inc |
Anticuerpos madurados por afinidad y humanizados para fcrh5 y métodos para su uso
|
EP3310815A1
(en)
|
2015-06-17 |
2018-04-25 |
F. Hoffmann-La Roche AG |
Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
|
WO2016205531A2
(en)
|
2015-06-17 |
2016-12-22 |
Genentech, Inc. |
Anti-her2 antibodies and methods of use
|
CN107708734B
(zh)
|
2015-06-22 |
2022-01-11 |
詹森生物科技公司 |
用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
|
MY193727A
(en)
|
2015-06-24 |
2022-10-27 |
Janssen Biotech Inc |
Immune modulation and treatment of solid tumors with antibodies that specifically bind cd38
|
US9862763B2
(en)
|
2015-06-24 |
2018-01-09 |
Hoffmann-La Roche Inc. |
Humanized anti-tau(pS422) antibodies and methods of use
|
CN107922497B
(zh)
|
2015-06-24 |
2022-04-12 |
詹森药业有限公司 |
抗vista抗体和片段
|
EP3314255B1
(en)
|
2015-06-25 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
CA2989936A1
(en)
|
2015-06-29 |
2017-01-05 |
Genentech, Inc. |
Type ii anti-cd20 antibody for use in organ transplantation
|
WO2017001350A1
(en)
|
2015-06-29 |
2017-01-05 |
Ventana Medical Systems, Inc. |
Materials and methods for performing histochemical assays for human pro-epiregulin and amphiregulin
|
EP3722318A1
(en)
|
2015-07-06 |
2020-10-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific antigen-binding molecules and uses thereof
|
WO2017005649A1
(en)
|
2015-07-09 |
2017-01-12 |
Genmab A/S |
Bispecific and multispecific antibodies and method for isolation of such
|
CA2991880A1
(en)
|
2015-07-10 |
2017-01-19 |
Merus N.V. |
Human cd3 binding antibody
|
US20180305451A1
(en)
|
2015-07-13 |
2018-10-25 |
Compugen Ltd. |
Hide1 compositions and methods
|
JP2018524373A
(ja)
|
2015-07-15 |
2018-08-30 |
ザイムワークス,インコーポレイテッド |
薬物がコンジュゲートされた二重特異性抗原結合コンストラクト
|
GB201601075D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies molecules
|
GB201601077D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibody molecule
|
GB201601073D0
(en)
|
2016-01-20 |
2016-03-02 |
Ucb Biopharma Sprl |
Antibodies
|
AU2016297014B2
(en)
|
2015-07-21 |
2021-06-17 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
DK3317301T3
(da)
|
2015-07-29 |
2021-06-28 |
Immutep Sas |
Kombinationsterapier omfattende antistofmolekyler mod lag-3
|
US20180207273A1
(en)
|
2015-07-29 |
2018-07-26 |
Novartis Ag |
Combination therapies comprising antibody molecules to tim-3
|
HUE048939T2
(hu)
|
2015-08-03 |
2020-09-28 |
Engmab Sarl |
Human B sejt érési antigén elleni monoklonális antitestek (BCMA)
|
EP3331510A4
(en)
|
2015-08-03 |
2019-04-03 |
Tolero Pharmaceuticals, Inc. |
COMBINATORIAL THERAPIES FOR THE TREATMENT OF CANCER
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
EA201890434A1
(ru)
|
2015-08-05 |
2018-10-31 |
Янссен Байотек, Инк. |
Антитела к cd154 и способы их применения
|
WO2017027392A1
(en)
|
2015-08-07 |
2017-02-16 |
Novartis Ag |
Treatment of cancer using chimeric cd3 receptor proteins
|
EP4137158A1
(en)
|
2015-08-07 |
2023-02-22 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
IL256989B
(en)
|
2015-08-07 |
2022-08-01 |
Alx Oncology Inc |
Constructs with a sirp-alpha site or a variant thereof
|
EA034582B1
(ru)
|
2015-08-07 |
2020-02-21 |
АЭлЭкс ОНКОЛОДЖИ ИНК. |
Конструкции варианта sirp-альфа и их применение
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
WO2017034770A1
(en)
|
2015-08-26 |
2017-03-02 |
Bison Therapeutics Inc. |
Multispecific antibody platform and related methods
|
WO2017040195A1
(en)
|
2015-08-28 |
2017-03-09 |
The Trustees Of The University Of Pennsylvania |
Methods and compositions for cells expressing a chimeric intracellular signaling molecule
|
CN108135932A
(zh)
|
2015-08-28 |
2018-06-08 |
宾夕法尼亚大学董事会 |
表达嵌合细胞内信号传导分子的细胞的方法和组合物
|
KR20180054639A
(ko)
|
2015-08-28 |
2018-05-24 |
알렉터 엘엘씨 |
항-siglec-7 항체 및 이의 사용 방법
|
US20170073399A1
(en)
|
2015-09-11 |
2017-03-16 |
Alexion Pharmaceuticals, Inc. |
Recombinant glycosylated eculizumab and eculizumab variants
|
WO2017048902A1
(en)
|
2015-09-15 |
2017-03-23 |
Board Of Regents, The University Of Texas System |
T-cell receptor (tcr)-binding antibodies and uses thereof
|
MX2018003183A
(es)
|
2015-09-15 |
2018-08-23 |
Amgen Inc |
Proteinas de enlace de antigeno biespecifico y tetraespecifico tetravalentes y usos de las mismas.
|
JP6266164B2
(ja)
|
2015-09-18 |
2018-01-31 |
中外製薬株式会社 |
Il−8に結合する抗体およびその使用
|
EA201890613A1
(ru)
|
2015-09-21 |
2018-10-31 |
Аптево Рисёрч Энд Девелопмент Ллс |
Полипептиды, связывающие cd3
|
JP6904947B2
(ja)
|
2015-09-22 |
2021-07-21 |
スプリング バイオサイエンス コーポレーション |
抗ox40抗体及びその診断用途
|
CN116987187A
(zh)
|
2015-09-23 |
2023-11-03 |
豪夫迈·罗氏有限公司 |
抗-vegf抗体的优化的变体
|
WO2017053705A1
(en)
|
2015-09-23 |
2017-03-30 |
Oncomed Pharmaceuticals, Inc. |
Methods and compositions for treatment of cancer
|
BR112018005931A2
(pt)
|
2015-09-24 |
2018-10-09 |
Abvitro Llc |
composições de anticorpo para hiv e métodos de uso
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
PE20240096A1
(es)
|
2015-10-02 |
2024-01-18 |
Hoffmann La Roche |
Anticuerpos biespecificos especificos para un receptor de tnf coestimulador
|
WO2017055392A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
|
CN107849137B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗ceaxcd3 t细胞活化性抗原结合分子
|
WO2017055399A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Cellular based fret assay for the determination of simultaneous binding
|
WO2017055393A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
|
US20170096485A1
(en)
|
2015-10-02 |
2017-04-06 |
Hoffmann-La Roche Inc. |
Bispecific t cell activating antigen binding molecules
|
EP3150637A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Multispecific antibodies
|
US20170129962A1
(en)
*
|
2015-10-02 |
2017-05-11 |
Hoffmann-La Roche Inc. |
Multispecific antibodies
|
WO2017055385A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
|
AR106199A1
(es)
|
2015-10-02 |
2017-12-20 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas activadoras de células t
|
WO2017055395A1
(en)
|
2015-10-02 |
2017-04-06 |
F. Hoffmann-La Roche Ag |
Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
|
KR102072317B1
(ko)
|
2015-10-02 |
2020-01-31 |
에프. 호프만-라 로슈 아게 |
항-pd1 항체 및 사용 방법
|
EP3150636A1
(en)
|
2015-10-02 |
2017-04-05 |
F. Hoffmann-La Roche AG |
Tetravalent multispecific antibodies
|
CN108026177B
(zh)
|
2015-10-02 |
2021-11-26 |
豪夫迈·罗氏有限公司 |
双特异性抗cd19xcd3 t细胞活化性抗原结合分子
|
MA43345A
(fr)
|
2015-10-02 |
2018-08-08 |
Hoffmann La Roche |
Conjugués anticorps-médicaments de pyrrolobenzodiazépine et méthodes d'utilisation
|
MY192202A
(en)
|
2015-10-02 |
2022-08-06 |
Hoffmann La Roche |
Bispecific antibodies specific for pd1 and tim3
|
EP3359572A2
(en)
|
2015-10-06 |
2018-08-15 |
H. Hoffnabb-La Roche Ag |
Method for treating multiple sclerosis
|
CN117069841A
(zh)
|
2015-10-06 |
2023-11-17 |
艾利妥 |
抗trem2抗体及其使用方法
|
US11203634B2
(en)
|
2015-10-07 |
2021-12-21 |
Alexion Pharmaceuticals, Inc. |
Methods of treating age-related macular degeneration in a patient comprising administering an anti-C5a antibody
|
JP7074665B2
(ja)
|
2015-10-07 |
2022-05-24 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激tnf受容体に対する四価の二重特異性抗体発明の分野
|
RU2731202C2
(ru)
|
2015-10-08 |
2020-08-31 |
Макродженикс, Инк. |
Комбинированная терапия для лечения рака
|
US11161915B2
(en)
|
2015-10-08 |
2021-11-02 |
Zymeworks Inc. |
Antigen-binding polypeptide constructs comprising kappa and lambda light chains and uses thereof
|
KR101851380B1
(ko)
|
2015-10-12 |
2018-04-23 |
아주대학교산학협력단 |
효모접합을 이용한 항체 ch3 도메인 이종이중체 돌연변이쌍 제조 방법 및 이에 의하여 제조된 ch3 돌연변이체 쌍
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
MA45326A
(fr)
|
2015-10-20 |
2018-08-29 |
Genentech Inc |
Conjugués calichéamicine-anticorps-médicament et procédés d'utilisation
|
ES2865482T3
(es)
|
2015-10-23 |
2021-10-15 |
Merus Nv |
Moléculas de unión que inhiben el crecimiento del cáncer
|
CA3002664A1
(en)
|
2015-10-25 |
2017-05-04 |
Sanofi |
Trispecific and/or trivalent binding proteins for prevention or treatment of hiv infection
|
WO2017072210A1
(en)
|
2015-10-29 |
2017-05-04 |
F. Hoffmann-La Roche Ag |
Anti-variant fc-region antibodies and methods of use
|
EP3184547A1
(en)
|
2015-10-29 |
2017-06-28 |
F. Hoffmann-La Roche AG |
Anti-tpbg antibodies and methods of use
|
EP3368575A2
(en)
|
2015-10-29 |
2018-09-05 |
Alector LLC |
Anti-siglec-9 antibodies and methods of use thereof
|
MX2018004509A
(es)
|
2015-10-30 |
2018-08-01 |
Genentech Inc |
Anticuerpos anti-htra1 y metodos de uso de los mismos.
|
WO2017075173A2
(en)
|
2015-10-30 |
2017-05-04 |
Genentech, Inc. |
Anti-factor d antibodies and conjugates
|
CN109195626B
(zh)
|
2015-10-30 |
2022-09-13 |
银河生物技术有限责任公司 |
结合死亡受体4和死亡受体5的抗体
|
PT3827845T
(pt)
|
2015-11-03 |
2022-07-08 |
Janssen Biotech Inc |
Formulações subcutâneas de anticorpos anti-cd38 e suas utilizações
|
WO2017079768A1
(en)
|
2015-11-08 |
2017-05-11 |
Genentech, Inc. |
Methods of screening for multispecific antibodies
|
US11649293B2
(en)
|
2015-11-18 |
2023-05-16 |
Chugai Seiyaku Kabushiki Kaisha |
Method for enhancing humoral immune response
|
JP6931329B2
(ja)
|
2015-11-18 |
2021-09-01 |
中外製薬株式会社 |
免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法
|
EP3380620A1
(en)
|
2015-11-23 |
2018-10-03 |
Novartis AG |
Optimized lentiviral transfer vectors and uses thereof
|
CN106729743B
(zh)
|
2015-11-23 |
2021-09-21 |
四川科伦博泰生物医药股份有限公司 |
抗ErbB2抗体-药物偶联物及其组合物、制备方法和应用
|
GB201521389D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Method
|
GB201521391D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521382D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521393D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl |
Antibodies
|
GB201521383D0
(en)
|
2015-12-03 |
2016-01-20 |
Ucb Biopharma Sprl And Ucb Celltech |
Method
|
US11623957B2
(en)
|
2015-12-07 |
2023-04-11 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and PSMA
|
EP3178848A1
(en)
|
2015-12-09 |
2017-06-14 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
|
WO2017097723A2
(en)
|
2015-12-09 |
2017-06-15 |
F. Hoffmann-La Roche Ag |
Treatment method
|
UA125611C2
(uk)
|
2015-12-14 |
2022-05-04 |
Макродженікс, Інк. |
Біспецифічні молекули, що мають імунореактивність відносно pd-1 і ctla-4, і способи їх застосування
|
CN106883297B
(zh)
*
|
2015-12-16 |
2019-12-13 |
苏州康宁杰瑞生物科技有限公司 |
基于ch3结构域的异二聚体分子、其制备方法及用途
|
EP3389712B1
(en)
|
2015-12-17 |
2024-04-10 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
MA44072A
(fr)
|
2015-12-17 |
2018-10-24 |
Janssen Biotech Inc |
Anticorps se liant spécifiquement à hla-dr et leurs utilisations
|
US20200261573A1
(en)
|
2015-12-17 |
2020-08-20 |
Novartis Ag |
Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof
|
CA3005592C
(en)
|
2015-12-18 |
2024-01-23 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-c5 antibodies and methods of use
|
EP3398965A4
(en)
|
2015-12-28 |
2019-09-18 |
Chugai Seiyaku Kabushiki Kaisha |
METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
|
WO2017117304A1
(en)
|
2015-12-30 |
2017-07-06 |
Genentech, Inc. |
Use of tryptophan derivatives for protein formulations
|
ES2944597T3
(es)
|
2015-12-30 |
2023-06-22 |
Novartis Ag |
Terapias con células efectoras inmunitarias de eficacia mejorada
|
CN115400220A
(zh)
|
2015-12-30 |
2022-11-29 |
豪夫迈·罗氏有限公司 |
减少聚山梨酯降解的制剂
|
ES2837428T3
(es)
|
2016-01-08 |
2021-06-30 |
Hoffmann La Roche |
Procedimientos de tratamiento de cánceres positivos para CEA usando antagonistas de unión al eje PD-1 y anticuerpos biespecíficos anti-CEA/anti-CD3
|
CN109195988B
(zh)
|
2016-01-10 |
2023-12-01 |
尼奥克斯医疗有限公司 |
用于增强超抗原介导的癌症免疫疗法效力的方法和组合物
|
CN114113625A
(zh)
|
2016-01-20 |
2022-03-01 |
基因泰克公司 |
用于阿尔茨海默氏病的高剂量治疗
|
ES2847155T3
(es)
|
2016-01-21 |
2021-08-02 |
Novartis Ag |
Moléculas multiespecíficas que fijan como objetivo CLL-1
|
EP3408671B1
(en)
|
2016-01-25 |
2023-11-01 |
F. Hoffmann-La Roche AG |
Methods for assaying t-cell dependent bispecific antibodies
|
BR112018015259A2
(pt)
|
2016-01-27 |
2018-12-18 |
Medimmune Llc |
métodos para preparação de anticorpos com um padrão de glicosilação definido
|
CN116333124A
(zh)
|
2016-01-29 |
2023-06-27 |
索伦托药业有限公司 |
与pd-l1结合的抗原结合蛋白
|
JP2019509721A
(ja)
|
2016-02-04 |
2019-04-11 |
キュリス,インコーポレイテッド |
突然変異体スムースンド及びその使用方法
|
EP3413910A1
(en)
|
2016-02-12 |
2018-12-19 |
Janssen Pharmaceutica NV |
Anti-vista (b7h5) antibodies
|
JP6821693B2
(ja)
|
2016-02-29 |
2021-01-27 |
ジェネンテック, インコーポレイテッド |
がんのための治療方法及び診断方法
|
US11472877B2
(en)
|
2016-03-04 |
2022-10-18 |
Alector Llc |
Anti-TREM1 antibodies and methods of use thereof
|
US20200281973A1
(en)
|
2016-03-04 |
2020-09-10 |
Novartis Ag |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
CN109195996A
(zh)
|
2016-03-08 |
2019-01-11 |
中央研究院 |
N-聚醣及其阵列的模组化合成方法
|
AU2017233658B2
(en)
|
2016-03-14 |
2023-09-21 |
Chugai Seiyaku Kabushiki Kaisha |
Cell injury inducing therapeutic drug for use in cancer therapy
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
CA3016563A1
(en)
|
2016-03-21 |
2017-09-28 |
Elstar Therapeutics, Inc. |
Multispecific and multifunctional molecules and uses thereof
|
PT3433280T
(pt)
|
2016-03-22 |
2023-06-15 |
Hoffmann La Roche |
Moléculas biespecíficas das células t ativadas pela protease
|
ES2947230T3
(es)
|
2016-03-22 |
2023-08-03 |
Hoffmann La Roche |
Moléculas biespecíficas para linfocitos T activadas por proteasa
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
CN108700598A
(zh)
|
2016-03-25 |
2018-10-23 |
豪夫迈·罗氏有限公司 |
多路总抗体和抗体缀合的药物量化测定法
|
RS65129B1
(sr)
|
2016-03-28 |
2024-02-29 |
Incyte Corp |
Jedinjenja pirolotriazina kao inhibitori tam
|
CN109071653A
(zh)
|
2016-03-29 |
2018-12-21 |
詹森生物科技公司 |
用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
|
EP3231813A1
(en)
|
2016-03-29 |
2017-10-18 |
F. Hoffmann-La Roche AG |
Trimeric costimulatory tnf family ligand-containing antigen binding molecules
|
WO2017172981A2
(en)
|
2016-03-29 |
2017-10-05 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
WO2017175058A1
(en)
|
2016-04-07 |
2017-10-12 |
Janssen Pharmaceutica Nv |
Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
|
HRP20231188T1
(hr)
|
2016-04-13 |
2024-02-02 |
Sanofi |
Trispecifični i/ili trovalentni vezujući proteini
|
US20170319688A1
(en)
|
2016-04-14 |
2017-11-09 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
SG11201808994YA
(en)
|
2016-04-15 |
2018-11-29 |
Bioatla Llc |
Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereof
|
WO2017181079A2
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
KR20190003958A
(ko)
|
2016-04-15 |
2019-01-10 |
제넨테크, 인크. |
암의 치료 및 모니터링 방법
|
CA3021027A1
(en)
|
2016-04-15 |
2017-10-19 |
Novartis Ag |
Compositions and methods for selective expression of chimeric antigen receptors
|
UA125382C2
(uk)
|
2016-04-15 |
2022-03-02 |
Імьюнекст Інк. |
Антитіла проти людського vista та їх застосування
|
WO2017180813A1
(en)
|
2016-04-15 |
2017-10-19 |
Macrogenics, Inc. |
Novel b7-h3 binding molecules, antibody drug conjugates thereof and methods of use thereof
|
KR20190006495A
(ko)
|
2016-04-15 |
2019-01-18 |
알파인 이뮨 사이언시즈, 인코포레이티드 |
Cd80 변이체 면역조절 단백질 및 그의 용도
|
EP3442999A2
(en)
|
2016-04-15 |
2019-02-20 |
Alpine Immune Sciences, Inc. |
Icos ligand variant immunomodulatory proteins and uses thereof
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
WO2017189432A1
(en)
|
2016-04-26 |
2017-11-02 |
R.P. Scherer Technologies, Llc |
Antibody conjugates and methods of making and using the same
|
US11352446B2
(en)
|
2016-04-28 |
2022-06-07 |
Regeneron Pharmaceuticals, Inc. |
Methods of making multispecific antigen-binding molecules
|
PE20181890A1
(es)
|
2016-05-02 |
2018-12-11 |
Hoffmann La Roche |
Contorsbody - un ligante de diana monocatenario
|
KR20230124093A
(ko)
|
2016-05-10 |
2023-08-24 |
제넨테크, 인크. |
폴리펩타이드의 재조합 생산 동안 트리설파이드 결합을감소시키기 위한 방법
|
CN109071652B
(zh)
|
2016-05-11 |
2022-09-23 |
豪夫迈·罗氏有限公司 |
包含tnf家族配体三聚体和生腱蛋白结合模块的抗原结合分子
|
EP3243836A1
(en)
|
2016-05-11 |
2017-11-15 |
F. Hoffmann-La Roche AG |
C-terminally fused tnf family ligand trimer-containing antigen binding molecules
|
CN109071640B
(zh)
|
2016-05-11 |
2022-10-18 |
豪夫迈·罗氏有限公司 |
经修饰抗生腱蛋白抗体及使用方法
|
EP3243832A1
(en)
|
2016-05-13 |
2017-11-15 |
F. Hoffmann-La Roche AG |
Antigen binding molecules comprising a tnf family ligand trimer and pd1 binding moiety
|
ES2930255T3
(es)
|
2016-05-13 |
2022-12-09 |
Bioatla Inc |
Anticuerpos anti-Ror2, fragmentos de anticuerpos, sus inmunoconjugados y usos de los mismos
|
AU2017268234A1
(en)
|
2016-05-17 |
2018-12-13 |
Genentech, Inc. |
Stromal gene signatures for diagnosis and use in immunotherapy
|
US10100106B2
(en)
|
2016-05-20 |
2018-10-16 |
Harpoon Therapeutics, Inc. |
Single domain serum albumin binding protein
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
JP2019522633A
(ja)
|
2016-05-20 |
2019-08-15 |
ジェネンテック, インコーポレイテッド |
Protac抗体コンジュゲート及び使用方法
|
EP3484514B1
(en)
|
2016-05-23 |
2023-12-06 |
Momenta Pharmaceuticals, Inc. |
Compositions and methods related to engineered fc constructs
|
JP7301540B2
(ja)
|
2016-05-26 |
2023-07-03 |
チールー ピュージェット サウンド バイオセラピューティクス コーポレイション |
抗体の混合物
|
WO2017205741A1
(en)
|
2016-05-27 |
2017-11-30 |
Genentech, Inc. |
Bioanalytical method for the characterization of site-specific antibody-drug conjugates
|
WO2017210617A2
(en)
|
2016-06-02 |
2017-12-07 |
Porter, David, L. |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
CA3059010A1
(en)
|
2016-06-02 |
2018-12-06 |
F. Hoffmann-La Roche Ag |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
EP3252078A1
(en)
|
2016-06-02 |
2017-12-06 |
F. Hoffmann-La Roche AG |
Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
|
HUE061619T2
(hu)
|
2016-06-03 |
2023-07-28 |
Regeneron Pharma |
Exogén terminális dezoxinukleotid-transzferázt expresszáló rágcsálók
|
EP3464280B1
(en)
|
2016-06-06 |
2021-10-06 |
F. Hoffmann-La Roche AG |
Silvestrol antibody-drug conjugates and methods of use
|
RU2767357C2
(ru)
|
2016-06-14 |
2022-03-17 |
Ксенкор, Инк. |
Биспецифические антитела-ингибиторы контрольных точек
|
AU2017286676A1
(en)
|
2016-06-17 |
2018-12-13 |
F. Hoffmann La-Roche Ag |
Purification of multispecific antibodies
|
JP7133477B2
(ja)
|
2016-06-24 |
2022-09-08 |
ジェネンテック, インコーポレイテッド |
抗ポリユビキチン多重特異性抗体
|
EP3475304B1
(en)
|
2016-06-28 |
2022-03-23 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
WO2018002181A1
(en)
|
2016-06-28 |
2018-01-04 |
Umc Utrecht Holding B.V. |
TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
|
KR20190025855A
(ko)
|
2016-06-30 |
2019-03-12 |
에프. 호프만-라 로슈 아게 |
개선된 입양 t-세포 요법
|
EP3478830B1
(en)
|
2016-07-01 |
2024-04-10 |
Resolve Therapeutics, LLC |
Optimized binuclease fusions and methods
|
JP6983824B2
(ja)
|
2016-07-04 |
2021-12-17 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
新規抗体フォーマット
|
WO2018011691A1
(en)
|
2016-07-12 |
2018-01-18 |
Nestec S.A. |
Competitive immunoassay methods
|
SG11201811431VA
(en)
|
2016-07-14 |
2019-01-30 |
Genmab As |
Multispecific antibodies against cd40 and cd137
|
US10722558B2
(en)
|
2016-07-15 |
2020-07-28 |
Acceleron Pharma Inc. |
Compositions and methods for treating pulmonary hypertension
|
WO2018013918A2
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
CA3031469A1
(en)
|
2016-07-22 |
2018-01-25 |
Amgen Inc. |
Methods of purifying fc-containing proteins
|
WO2018022479A1
(en)
|
2016-07-25 |
2018-02-01 |
Biogen Ma Inc. |
Anti-hspa5 (grp78) antibodies and uses thereof
|
BR112019001615A2
(pt)
|
2016-07-27 |
2019-04-30 |
Acceleron Pharma Inc. |
métodos e composições para tratar mielofibrose
|
US11834490B2
(en)
|
2016-07-28 |
2023-12-05 |
Alpine Immune Sciences, Inc. |
CD112 variant immunomodulatory proteins and uses thereof
|
EP3491013A1
(en)
|
2016-07-28 |
2019-06-05 |
Alpine Immune Sciences, Inc. |
Cd155 variant immunomodulatory proteins and uses thereof
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
US11471488B2
(en)
|
2016-07-28 |
2022-10-18 |
Alpine Immune Sciences, Inc. |
CD155 variant immunomodulatory proteins and uses thereof
|
MX2018015721A
(es)
|
2016-07-29 |
2019-05-27 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos biespecificos que exhiben actividad de funcion de cofactor fviii alternativa mejorada.
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
KR20190036551A
(ko)
|
2016-08-01 |
2019-04-04 |
노파르티스 아게 |
Pro-m2 대식세포 분자의 억제제를 병용하는, 키메라 항원 수용체를 이용한 암의 치료
|
CA3032498A1
(en)
|
2016-08-02 |
2018-02-08 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
EP3494139B1
(en)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
SG11201801024XA
(en)
|
2016-08-05 |
2018-05-30 |
Chugai Pharmaceutical Co Ltd |
Therapeutic or preventive compositions for il-8-related diseases
|
SG11201900027XA
(en)
|
2016-08-05 |
2019-02-27 |
Medimmune Llc |
Anti-o2 antibodies and uses thereof
|
CN109476748B
(zh)
|
2016-08-08 |
2023-05-23 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
EP3511340A4
(en)
|
2016-08-10 |
2020-03-18 |
Ajou University Industry-Academic Cooperation Foundation |
CYTOKINE CONDENSED TO IMMUNOGLOBULIN-FC HETERODIMER AND PHARMACEUTICAL COMPOSITION THEREFOR
|
WO2018030806A1
(ko)
|
2016-08-10 |
2018-02-15 |
아주대학교산학협력단 |
항체 중쇄불변부위 이종이중체에 융합된 사이토카인 및 이를 포함하는 약제학적 조성물
|
WO2018031662A1
(en)
|
2016-08-11 |
2018-02-15 |
Genentech, Inc. |
Pyrrolobenzodiazepine prodrugs and antibody conjugates thereof
|
SG11201901228QA
(en)
|
2016-08-15 |
2019-03-28 |
Genentech Inc |
Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide
|
CA3034057A1
(en)
|
2016-08-22 |
2018-03-01 |
CHO Pharma Inc. |
Antibodies, binding fragments, and methods of use
|
WO2018038046A1
(ja)
|
2016-08-22 |
2018-03-01 |
中外製薬株式会社 |
ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
KR101928981B1
(ko)
|
2016-09-02 |
2018-12-13 |
고려대학교 산학협력단 |
항체 중쇄불변부위 이종이중체 (heterodimeric Fc)에 융합된 IL-21 (heterodimeric Fc-fused IL-21) 및 이를 포함하는 약제학적 조성물
|
US10870694B2
(en)
|
2016-09-02 |
2020-12-22 |
Dana Farber Cancer Institute, Inc. |
Composition and methods of treating B cell disorders
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
PE20190976A1
(es)
|
2016-09-14 |
2019-07-09 |
Teneobio Inc |
Anticuerpos de union a cd3
|
SG10201607778XA
(en)
|
2016-09-16 |
2018-04-27 |
Chugai Pharmaceutical Co Ltd |
Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
|
EP3515932B1
(en)
|
2016-09-19 |
2023-11-22 |
F. Hoffmann-La Roche AG |
Complement factor based affinity chromatography
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
MX2019003225A
(es)
|
2016-09-21 |
2019-06-10 |
Aptevo Res & Development Llc |
Proteínas de unión a cd123 y composiciones y métodos relacionados.
|
EP3515948A4
(en)
|
2016-09-23 |
2020-04-08 |
CSL Limited |
COAGULATION FACTOR BINDING PROTEINS AND USES THEREOF
|
EP4268845A3
(en)
|
2016-09-23 |
2024-02-28 |
F. Hoffmann-La Roche AG |
Uses of il-13 antagonists for treating atopic dermatitis
|
JP7424727B2
(ja)
*
|
2016-09-29 |
2024-01-30 |
ベイジン・ハンミ・ファーマシューティカル・カンパニー・リミテッド |
ヘテロダイマー免疫グロブリン構造体及びその製造方法
|
JP2020500152A
(ja)
|
2016-09-30 |
2020-01-09 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で乾癬を治療する安全かつ有効な方法
|
WO2018060035A1
(en)
|
2016-09-30 |
2018-04-05 |
F. Hoffmann-La Roche Ag |
Spr-based dual-binding assay for the functional analysis of multispecific molecules
|
CN109843926B
(zh)
|
2016-09-30 |
2023-01-20 |
豪夫迈·罗氏有限公司 |
针对cd3的双特异性抗体
|
MA46472A
(fr)
|
2016-10-05 |
2019-08-14 |
Acceleron Pharma Inc |
Hétéromultimères alk4:actriib et leurs utilisations
|
JP7050770B2
(ja)
|
2016-10-05 |
2022-04-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
抗体薬物コンジュゲートの調製方法
|
CN116650622A
(zh)
|
2016-10-05 |
2023-08-29 |
艾科赛扬制药股份有限公司 |
用于治疗肾脏疾病的组合物和方法
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
CN110225927B
(zh)
|
2016-10-07 |
2024-01-12 |
诺华股份有限公司 |
用于治疗癌症的嵌合抗原受体
|
CA3036745A1
(en)
|
2016-10-07 |
2018-04-12 |
TCR2 Therapeutics Inc. |
Compositions and methods for t-cell receptors reprogramming using fusion proteins
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
US10550185B2
(en)
|
2016-10-14 |
2020-02-04 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15-IL-15Rα Fc-fusion proteins and PD-1 antibody fragments
|
US11828683B2
(en)
|
2016-10-19 |
2023-11-28 |
Alexion Pharmaceuticals, Inc. |
Method of quantitating unbound C5a in a sample
|
AU2017345454A1
(en)
|
2016-10-19 |
2019-05-30 |
Invenra Inc. |
Antibody constructs
|
WO2018075758A1
(en)
|
2016-10-19 |
2018-04-26 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5 in a sample
|
CN109843917B
(zh)
|
2016-10-19 |
2023-10-03 |
免疫医疗有限责任公司 |
抗o1抗体及其用途
|
JP2019535250A
(ja)
|
2016-10-29 |
2019-12-12 |
ジェネンテック, インコーポレイテッド |
抗mic抗体及び使用方法
|
SG11201903359RA
(en)
|
2016-11-02 |
2019-05-30 |
Engmab Sarl |
Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
|
AU2017353936A1
(en)
|
2016-11-04 |
2019-05-02 |
Novimmune Sa |
Anti-CD19 antibodies and methods of use thereof
|
WO2018144097A1
(en)
|
2016-11-04 |
2018-08-09 |
Akeagen Llc |
Genetically modified non-human animals and methods for producing heavy chain-only antibodies
|
CA3042249A1
(en)
|
2016-11-08 |
2018-05-17 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-pd1 and anti-ctla4 antibodies
|
US20230137351A1
(en)
|
2016-11-14 |
2023-05-04 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
EP3541843A1
(en)
|
2016-11-15 |
2019-09-25 |
Genentech, Inc. |
Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
|
MX2019005661A
(es)
|
2016-11-16 |
2019-10-07 |
Janssen Biotech Inc |
Método para tratar la psoriasis con el anticuerpo específico anti-il23.
|
TW201829463A
(zh)
|
2016-11-18 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
抗hla-g抗體及其用途
|
WO2018094275A1
(en)
|
2016-11-18 |
2018-05-24 |
Tolero Pharmaceuticals, Inc. |
Alvocidib prodrugs and their use as protein kinase inhibitors
|
EA201990894A9
(ru)
*
|
2016-11-18 |
2019-11-27 |
|
Анти-pd-1/анти-her2 гетеродимерное биспецифическое антитело со структурой природного антитела и способ его получения
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
KR20190087539A
(ko)
|
2016-11-23 |
2019-07-24 |
하푼 테라퓨틱스, 인크. |
Psma 표적화 삼중특이성 단백질 및 사용 방법
|
KR102275008B1
(ko)
|
2016-11-23 |
2021-07-13 |
하푼 테라퓨틱스, 인크. |
전립선 특이 막 항원 결합 단백질
|
WO2018098363A2
(en)
|
2016-11-23 |
2018-05-31 |
Bioverativ Therapeutics Inc. |
Bispecific antibodies binding to coagulation factor ix and coagulation factor x
|
EP3548622A1
(en)
|
2016-12-02 |
2019-10-09 |
Juno Therapeutics, Inc. |
Engineered b cells and related compositions and methods
|
CN117820467A
(zh)
|
2016-12-07 |
2024-04-05 |
基因泰克公司 |
抗tau抗体和使用方法
|
KR20190091325A
(ko)
|
2016-12-07 |
2019-08-05 |
프로제너티, 인크. |
위장관 검출 방법, 디바이스 및 시스템
|
KR20230146126A
(ko)
|
2016-12-07 |
2023-10-18 |
제넨테크, 인크. |
항-타우 항체 및 이의 이용 방법
|
BR112019011582A2
(pt)
|
2016-12-07 |
2019-10-22 |
Agenus Inc. |
anticorpos e métodos de utilização dos mesmos
|
WO2018112069A1
(en)
*
|
2016-12-13 |
2018-06-21 |
Delinia, Inc. |
Multivalent regulatory t cell modulators
|
CN110114674B
(zh)
|
2016-12-13 |
2023-05-09 |
豪夫迈·罗氏有限公司 |
确定肿瘤样品中存在靶抗原的方法
|
WO2018112255A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
WO2018112215A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
US20200315540A1
(en)
|
2016-12-14 |
2020-10-08 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
US11426566B2
(en)
|
2016-12-14 |
2022-08-30 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a TLR modulator
|
US10980739B2
(en)
|
2016-12-14 |
2021-04-20 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
JP7237834B2
(ja)
|
2016-12-14 |
2023-03-13 |
ビオラ・セラピューティクス・インコーポレイテッド |
消化管疾病のil-12/il-23阻害薬による治療
|
WO2018112235A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
|
US11033490B2
(en)
|
2016-12-14 |
2021-06-15 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
|
EP3554342A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
EP3362471B1
(en)
|
2016-12-19 |
2021-11-17 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Profiling peptides and methods for sensitivity profiling
|
TWI829628B
(zh)
|
2016-12-19 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
與靶向4-1bb (cd137)促效劑併用之組合療法
|
EP3555120A1
(en)
|
2016-12-19 |
2019-10-23 |
Abcam Plc |
Monovalent and divalent binding proteins
|
WO2018114748A1
(en)
|
2016-12-20 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-cd20/anti-cd3 bispecific antibodies and 4-1bb (cd137) agonists
|
CA3044920C
(en)
|
2016-12-21 |
2022-06-28 |
Roberto Falkenstein |
In vitro glycoengineering of antibodies
|
JP7215999B2
(ja)
|
2016-12-21 |
2023-01-31 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗体またはリガンドの結合および機能を決定するためのアッセイ法
|
AU2017381656B2
(en)
|
2016-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Re-use of enzymes in in vitro glycoengineering of antibodies
|
WO2018119215A1
(en)
|
2016-12-21 |
2018-06-28 |
Teneobio, Inc. |
Anti-bcma heavy chain-only antibodies
|
BR112019010294A2
(pt)
|
2016-12-21 |
2019-09-03 |
Hoffmann La Roche |
método para a produção enzimática de um anticorpo, anticorpo e formulação farmacêutica
|
EP3360898A1
(en)
|
2017-02-14 |
2018-08-15 |
Boehringer Ingelheim International GmbH |
Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
TW201829469A
(zh)
|
2017-01-03 |
2018-08-16 |
瑞士商赫孚孟拉羅股份公司 |
包含抗4-1bb純系20h4.9之雙特異性抗原結合分子
|
WO2018129029A1
(en)
|
2017-01-04 |
2018-07-12 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
DK3565579T3
(da)
|
2017-01-05 |
2023-09-04 |
Kahr Medical Ltd |
Pd1-41bbl-fusionsprotein og fremgangsmåder til anvendelse deraf
|
US11566060B2
(en)
|
2017-01-05 |
2023-01-31 |
Kahr Medical Ltd. |
PD1-CD70 fusion protein and methods of use thereof
|
US11299530B2
(en)
|
2017-01-05 |
2022-04-12 |
Kahr Medical Ltd. |
SIRP alpha-CD70 fusion protein and methods of use thereof
|
HRP20220230T1
(hr)
|
2017-01-05 |
2022-04-29 |
Kahr Medical Ltd. |
Sirp1 alfa-41bbl fuzijski protein i metoda njegove upotrebe
|
US11390685B2
(en)
|
2017-01-06 |
2022-07-19 |
Biosion, Inc. |
ErbB2 antibodies and uses therefore
|
CN110650748B
(zh)
|
2017-01-06 |
2024-01-02 |
动量制药公司 |
与经工程改造的Fc构建体相关的组合物和方法
|
EP3565833A1
(en)
|
2017-01-09 |
2019-11-13 |
Torch Therapeutics |
Conditionally effective bispecific therapeutics
|
US11274157B2
(en)
|
2017-01-12 |
2022-03-15 |
Eureka Therapeutics, Inc. |
Constructs targeting histone H3 peptide/MHC complexes and uses thereof
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
MX2019008989A
(es)
|
2017-01-30 |
2019-10-09 |
Janssen Biotech Inc |
Anticuerpos anti-tnf, composiciones y metodos para el tratamiento de la artritis psoriasica activa.
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
EP3576789A4
(en)
|
2017-02-01 |
2020-11-25 |
Centrymed Pharmaceuticals Inc. |
MONOMER HUMAN IGG1-FC AND BISPECIFIC ANTIBODIES
|
BR112019016204A2
(pt)
|
2017-02-07 |
2020-07-07 |
Daiichi Sankyo Company, Limited |
anticorpo ou fragmento de ligação a antígeno do anticorpo, polinucleotídeo, vetor, célula, imunócito artificial, métodos para produzir um anticorpo ou um fragmento de ligação a antígeno do anticorpo, para produzir uma molécula que se liga ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, composição medicinal para tratamento e/ou prevenção, moléculas tendo atividade de ligação a antígeno e que se ligam ao cd3 humano e cd3 de macaco cinomolgo e ao gprc5d humano, e, usos para preparar um medicamento para tratar e/ou prevenir um câncer, para induzir citotoxicidade para as células expressando gprc5d e para redirecionamento de células t para as células expressando gprc5d
|
CN110418652A
(zh)
|
2017-02-07 |
2019-11-05 |
詹森生物科技公司 |
用于治疗活动性强直性脊柱炎的抗tnf抗体、组合物和方法
|
SG11201907299XA
(en)
|
2017-02-08 |
2019-09-27 |
Dragonfly Therapeutics Inc |
Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
|
US11266745B2
(en)
|
2017-02-08 |
2022-03-08 |
Imaginab, Inc. |
Extension sequences for diabodies
|
MY197534A
(en)
|
2017-02-10 |
2023-06-21 |
Genentech Inc |
Anti-tryptase antibodies, compositions thereof, and uses thereof
|
US20200291089A1
(en)
|
2017-02-16 |
2020-09-17 |
Elstar Therapeutics, Inc. |
Multifunctional molecules comprising a trimeric ligand and uses thereof
|
JP2020508049A
(ja)
|
2017-02-17 |
2020-03-19 |
デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. |
操作されたトランスフェリン受容体結合ポリペプチド
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
US10626169B2
(en)
|
2017-02-17 |
2020-04-21 |
Sanofi |
Multispecific binding molecules having specificity to dystroglycan and laminin-2
|
KR102654105B1
(ko)
|
2017-02-17 |
2024-04-04 |
사노피 |
디스트로글리칸 및 라미닌-2에 대한 특이성을 갖는 다중특이적 결합 분자
|
AU2018220736A1
(en)
|
2017-02-20 |
2019-09-05 |
Dragonfly Therapeutics, Inc. |
Proteins binding HER2, NKG2D and CD16
|
US20190382484A1
(en)
|
2017-02-24 |
2019-12-19 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition, antigen-binding molecules, treatment method, and screening method
|
EP3589662A4
(en)
|
2017-02-28 |
2020-12-30 |
Harpoon Therapeutics, Inc. |
INDUCTIBLE MONOVALENT ANTIGBINDING PROTEIN
|
MX2019010295A
(es)
|
2017-03-01 |
2019-11-21 |
Genentech Inc |
Métodos de diagnóstico y terapéuticos para el cáncer.
|
US11685776B2
(en)
|
2017-03-02 |
2023-06-27 |
Novartis Ag |
Engineered heterodimeric proteins
|
US20200239579A1
(en)
|
2017-03-09 |
2020-07-30 |
Genmab A/S |
Antibodies against pd-l1
|
NZ756132A
(en)
|
2017-03-10 |
2022-02-25 |
Hoffmann La Roche |
Method for producing multispecific antibodies
|
WO2018170026A2
(en)
|
2017-03-16 |
2018-09-20 |
Alpine Immune Sciences, Inc. |
Cd80 variant immunomodulatory proteins and uses thereof
|
AU2018235835A1
(en)
|
2017-03-16 |
2019-09-05 |
Alpine Immune Sciences, Inc. |
PD-L2 variant immunomodulatory proteins and uses thereof
|
PT3596116T
(pt)
|
2017-03-16 |
2023-12-04 |
Alpine Immune Sciences Inc |
Proteínas imunomoduladoras de pd-l1 variante e suas utilizações
|
PT3443006T
(pt)
|
2017-03-17 |
2023-10-26 |
Sanofi Sa |
Proteínas de ligação triespecíficas e/ou trivalentes
|
KR20200007776A
(ko)
|
2017-03-22 |
2020-01-22 |
제넨테크, 인크. |
히드로겔 가교된 히알루론산 전구약물 조성물 및 방법
|
EP3600442A1
(en)
|
2017-03-22 |
2020-02-05 |
Genentech, Inc. |
Optimized antibody compositions for treatment of ocular disorders
|
WO2018174274A1
(ja)
|
2017-03-24 |
2018-09-27 |
全薬工業株式会社 |
抗IgM/B細胞表面抗原二重特異性抗体
|
BR112019019998A2
(pt)
|
2017-03-27 |
2020-04-28 |
Biomunex Pharmaceuticals |
anticorpos multiespecíficos estáveis
|
SG11201908678XA
(en)
|
2017-03-27 |
2019-10-30 |
Celgene Corp |
Methods and compositions for reduction of immunogenicity
|
SG10201911225WA
(en)
|
2017-03-28 |
2020-01-30 |
Genentech Inc |
Methods of treating neurodegenerative diseases
|
WO2018178074A1
(en)
|
2017-03-29 |
2018-10-04 |
F. Hoffmann-La Roche Ag |
Trimeric antigen binding molecules specific for a costimulatory tnf receptor
|
EP3601345A1
(en)
|
2017-03-29 |
2020-02-05 |
H. Hoffnabb-La Roche Ag |
Bispecific antigen binding molecule for a costimulatory tnf receptor
|
JP7205995B2
(ja)
|
2017-03-29 |
2023-01-17 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
共刺激性tnf受容体に対する二重特異性抗原結合分子
|
JP2020515579A
(ja)
|
2017-03-30 |
2020-05-28 |
プロジェニティ, インコーポレイテッド |
消化管疾病の生菌生物学的製剤による治療
|
US20210138213A1
(en)
|
2017-03-30 |
2021-05-13 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
CA3054156A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with il-10 or an il-10 agonist
|
WO2018183934A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
MX2019011660A
(es)
|
2017-03-31 |
2019-11-18 |
Merus Nv |
Anticuerpos biespecificos que se unen al receptor 2 del factor de crecimiento humano (erbb-2) y receptor 3 del factor de crecimiento humano (erbb3) para usarse en el tratamiento de celulas que tienen un gen de fusion de neuregulina-1 (nrg1).
|
SG11201908772TA
(en)
|
2017-03-31 |
2019-10-30 |
Genmab Holding B V |
Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
|
BR112019020448A2
(pt)
|
2017-04-01 |
2020-06-09 |
Beijing hanmi pharm co ltd |
anticorpo biespecífico heterodimérico similar à estrutura do anticorpo anti-pd-l1/anti-pd-1 natural e preparação do mesmo
|
ES2955852T3
(es)
|
2017-04-03 |
2023-12-07 |
Hoffmann La Roche |
Anticuerpos de unión a STEAP-1
|
MX2019011770A
(es)
|
2017-04-03 |
2020-01-09 |
Hoffmann La Roche |
Inmunoconjugados de un anticuerpo anti-pd-1 con un mutante il-2 o con il-15.
|
AU2018249493A1
(en)
|
2017-04-03 |
2019-09-19 |
Oncxerna Therapeutics, Inc. |
Methods for treating cancer using PS-targeting antibodies with immuno-oncology agents
|
EP3606947B1
(en)
|
2017-04-03 |
2022-12-21 |
F. Hoffmann-La Roche AG |
Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
|
RU2766234C2
(ru)
|
2017-04-04 |
2022-02-10 |
Ф. Хоффманн-Ля Рош Аг |
Новые биспецифические антигенсвязывающие молекулы, обладающие способностью специфически связываться с cd40 и fap
|
SI3606954T1
(sl)
|
2017-04-05 |
2022-10-28 |
F. Hoffmann - La Roche Ag |
Protitelesa proti LAG3
|
CN116375876A
(zh)
|
2017-04-05 |
2023-07-04 |
豪夫迈·罗氏有限公司 |
特异性结合pd1和lag3的双特异性抗体
|
CN110770255A
(zh)
|
2017-04-11 |
2020-02-07 |
印希彼有限公司 |
具有受限cd3结合的多特异性多肽构建体及其使用方法
|
AU2018250875A1
(en)
|
2017-04-13 |
2019-10-03 |
F. Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a CD40 agonist, and optionally a PD-1 axis binding antagonist for use in methods of treating cancer
|
RU2665790C1
(ru)
|
2017-04-17 |
2018-09-04 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело к pd-l1
|
SG11201909048TA
(en)
|
2017-04-21 |
2019-11-28 |
Genentech Inc |
Use of klk5 antagonists for treatment of a disease
|
WO2018200742A1
(en)
|
2017-04-25 |
2018-11-01 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
|
KR20200012860A
(ko)
|
2017-04-26 |
2020-02-05 |
유레카 쎄라퓨틱스, 인코포레이티드 |
글리피칸 3을 특이적으로 인식하는 구축물 및 그의 용도
|
WO2018197533A1
(en)
|
2017-04-28 |
2018-11-01 |
F. Hoffmann-La Roche Ag |
Antibody selection method
|
WO2018201051A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018203545A1
(ja)
|
2017-05-02 |
2018-11-08 |
国立研究開発法人国立精神・神経医療研究センター |
Il-6及び好中球の関連する疾患の治療効果の予測及び判定方法
|
JP7209936B2
(ja)
|
2017-05-12 |
2023-01-23 |
ハープーン セラピューティクス,インク. |
Msln標的三重特異性タンパク質及びその使用方法
|
WO2018209298A1
(en)
|
2017-05-12 |
2018-11-15 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
JOP20190256A1
(ar)
|
2017-05-12 |
2019-10-28 |
Icahn School Med Mount Sinai |
فيروسات داء نيوكاسل واستخداماتها
|
US11359014B2
(en)
|
2017-05-16 |
2022-06-14 |
Alector Llc |
Anti-siglec-5 antibodies and methods of use thereof
|
EP3630830A1
(en)
|
2017-05-23 |
2020-04-08 |
Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) |
Novel cd73 antibody, preparation and uses thereof
|
US11260117B2
(en)
|
2017-05-26 |
2022-03-01 |
Novimmune Sa |
Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
EP3630836A1
(en)
|
2017-05-31 |
2020-04-08 |
Elstar Therapeutics, Inc. |
Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
|
EP3409322A1
(en)
|
2017-06-01 |
2018-12-05 |
F. Hoffmann-La Roche AG |
Treatment method
|
EP3634994A4
(en)
|
2017-06-05 |
2021-06-30 |
Janssen Biotech, Inc. |
SURFACE LOAD ENGINEERING PROCESSES FOR THE PRODUCTION OF A BISPECIFIC ANTIBODY
|
CN110809583A
(zh)
|
2017-06-07 |
2020-02-18 |
瑞泽恩制药公司 |
用于内化酶的组合物和方法
|
UY37758A
(es)
|
2017-06-12 |
2019-01-31 |
Novartis Ag |
Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
|
EP3638295A1
(en)
|
2017-06-13 |
2020-04-22 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
US20190062428A1
(en)
|
2017-06-19 |
2019-02-28 |
Surface Oncology, Inc. |
Combination of anti-cd47 antibodies and cell death-inducing agents, and uses thereof
|
MX2019015563A
(es)
|
2017-06-20 |
2020-07-28 |
Teneoone Inc |
Anticuerpos anti-bcma unicamente de cadena pesada.
|
KR102324568B1
(ko)
|
2017-06-21 |
2021-11-10 |
길리애드 사이언시즈, 인코포레이티드 |
HIV gp120 및 CD3을 표적화하는 다중특이적 항체
|
CN110785187B
(zh)
|
2017-06-22 |
2024-04-05 |
诺华股份有限公司 |
针对cd73的抗体分子及其用途
|
GB201709970D0
(en)
|
2017-06-22 |
2017-08-09 |
Kymab Ltd |
Bispecific antigen-binding molecules
|
JP2020525483A
(ja)
|
2017-06-27 |
2020-08-27 |
ノバルティス アーゲー |
抗tim−3抗体のための投与レジメンおよびその使用
|
WO2019006472A1
(en)
|
2017-06-30 |
2019-01-03 |
Xencor, Inc. |
TARGETED HETETRODIMERIC FUSION PROTEINS CONTAINING IL-15 / IL-15RA AND ANTIGEN-BINDING DOMAINS
|
GB201710984D0
(en)
|
2017-07-07 |
2017-08-23 |
Kymab Ltd |
Cells, vertebrates, populations & methods
|
AR112603A1
(es)
|
2017-07-10 |
2019-11-20 |
Lilly Co Eli |
Anticuerpos biespecíficos inhibidores de punto de control
|
AU2018301393A1
(en)
|
2017-07-11 |
2020-02-06 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
EP3652540A4
(en)
|
2017-07-12 |
2021-04-07 |
The Johns Hopkins University |
PROTEOLIPOSOME-BASED ZNT8 SELF-ANTIGEN FOR DIAGNOSIS OF TYPE 1 DIABETES
|
EP3655430A1
(en)
|
2017-07-19 |
2020-05-27 |
The U.S.A. as represented by the Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
|
AU2018302283A1
(en)
|
2017-07-20 |
2020-02-06 |
Novartis Ag |
Dosage regimens of anti-LAG-3 antibodies and uses thereof
|
AU2018304458B2
(en)
|
2017-07-21 |
2021-12-09 |
Foundation Medicine, Inc. |
Therapeutic and diagnostic methods for cancer
|
ES2963157T3
(es)
|
2017-07-26 |
2024-03-25 |
Forty Seven Inc |
Anticuerpos anti-SIRP-alfa y métodos relacionados
|
CN110869050A
(zh)
|
2017-07-28 |
2020-03-06 |
豪夫迈·罗氏有限公司 |
双特异性抗体配制剂
|
KR20200041897A
(ko)
|
2017-08-01 |
2020-04-22 |
에이비 스튜디오 인코포레이티드 |
이중특이 항체 및 그의 용도
|
CN111182951A
(zh)
|
2017-08-01 |
2020-05-19 |
指南针制药有限责任公司 |
过滤和层析荚以及使用其的方法
|
MD3601358T2
(ro)
|
2017-08-03 |
2023-10-31 |
Alector Llc |
Anticorpi anti-TREM2 și metode de utilizare a acestora
|
EP3589658A1
(en)
|
2017-08-03 |
2020-01-08 |
Alector LLC |
Anti-cd33 antibodies and methods of use thereof
|
AU2018309339A1
(en)
|
2017-08-04 |
2020-02-20 |
BioNTech SE |
Binding agents binding to PD-L1 and CD137 and use thereof
|
MX2020001432A
(es)
|
2017-08-09 |
2020-03-20 |
Merus Nv |
Anticuerpos que se unen al receptor del factor de crecimiento epidermico (egfr) y tirosina-proteina cinasa met (cmet).
|
MX2020000903A
(es)
|
2017-08-11 |
2020-07-22 |
Genentech Inc |
Anticuerpos anti-cd8 y usos de los mismos.
|
WO2019036363A1
(en)
|
2017-08-14 |
2019-02-21 |
Progenity Inc. |
TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
EP3684811A2
(en)
|
2017-08-17 |
2020-07-29 |
Massachusetts Institute of Technology |
Multiple specificity binders of cxc chemokines and uses thereof
|
BR112020003459A2
(pt)
|
2017-08-21 |
2020-08-25 |
Adagene Inc. |
bibliotecas, animal não humano, fago, cadeia leve de anticorpo, anticorpos, métodos para preparar uma biblioteca, para produzir uma biblioteca de anticorpos e para gerar um anticorpo biespecífico e kit
|
JP2020537632A
(ja)
|
2017-08-21 |
2020-12-24 |
アダジーン インコーポレイテッド |
ダイナミックヒト重鎖抗体ライブラリー
|
CA3073537A1
(en)
|
2017-08-22 |
2019-02-28 |
Sanabio, Llc |
Soluble interferon receptors and uses thereof
|
AU2018328291B2
(en)
|
2017-09-08 |
2022-10-27 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
WO2019051122A2
(en)
|
2017-09-08 |
2019-03-14 |
Maverick Therapeutics, Inc. |
CONDITIONAL ACTIVATED BOND FRACTIONS CONTAINING FC REGIONS
|
US11497756B2
(en)
|
2017-09-12 |
2022-11-15 |
Sumitomo Pharma Oncology, Inc. |
Treatment regimen for cancers that are insensitive to BCL-2 inhibitors using the MCL-1 inhibitor alvocidib
|
EP3457139A1
(en)
|
2017-09-19 |
2019-03-20 |
Promise Advanced Proteomics |
Antibody-like peptides for quantifying therapeutic antibodies
|
US11761963B2
(en)
|
2017-09-27 |
2023-09-19 |
Alexion Pharmaceuticals, Inc. |
Biomarker signature for predicting tumor response to anti-CD200 therapy
|
AU2018338859A1
(en)
|
2017-09-29 |
2020-02-06 |
Chugai Seiyaku Kabushiki Kaisha |
Multispecific antigen-binding molecule having blood coagulation factor VIII (FVIII) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
|
EA039662B1
(ru)
|
2017-10-03 |
2022-02-24 |
Закрытое Акционерное Общество "Биокад" |
Антитела, специфичные к cd47 и pd-l1
|
RU2698048C2
(ru)
|
2017-10-03 |
2019-08-21 |
Закрытое Акционерное Общество "Биокад" |
МОНОКЛОНАЛЬНОЕ АНТИТЕЛО К IL-5Rα
|
AU2018348093A1
(en)
|
2017-10-10 |
2020-05-28 |
Sanofi |
Anti-CD38 antibodies and combinations with anti-CD3 and anti-CD28 antibodies
|
EP4219540A3
(en)
|
2017-10-10 |
2023-12-06 |
Alpine Immune Sciences, Inc. |
Ctla-4 variant immunomodulatory proteins and uses thereof
|
CA3078974A1
(en)
|
2017-10-12 |
2019-04-18 |
Immunowake Inc. |
Vegfr-antibody light chain fusion protein
|
CA3078799A1
(en)
|
2017-10-13 |
2019-04-18 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
US11136403B2
(en)
|
2017-10-13 |
2021-10-05 |
Harpoon Therapeutics, Inc. |
Trispecific proteins and methods of use
|
CN111630069A
(zh)
|
2017-10-13 |
2020-09-04 |
勃林格殷格翰国际有限公司 |
针对Thomsen-nouvelle(Tn)抗原的人抗体
|
CN111247165B
(zh)
|
2017-10-18 |
2023-11-10 |
Csl有限公司 |
人血清白蛋白变体及其应用
|
US20200283500A1
(en)
|
2017-10-18 |
2020-09-10 |
Alpine Immune Sciences, Inc. |
Variant icos ligand immunomodulatory proteins and related compositions and methods
|
CA3079407A1
(en)
|
2017-10-18 |
2019-04-25 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
WO2019077092A1
(en)
|
2017-10-20 |
2019-04-25 |
F. Hoffmann-La Roche Ag |
METHOD FOR GENERATING MULTISPECIFIC ANTIBODIES FROM MONOSPECIFIC ANTIBODIES
|
WO2019084288A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
METHODS FOR DESIGNING CHIMERIC ANTIGENIC RECEPTOR EXPRESSION CELLS
|
JP7438942B2
(ja)
|
2017-10-30 |
2024-02-27 |
エフ. ホフマン-ラ ロシュ アーゲー |
単一特異性抗体から多重特異性抗体をインビボ生成させるための方法
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
EP3703821A2
(en)
|
2017-11-01 |
2020-09-09 |
F. Hoffmann-La Roche AG |
Bispecific 2+1 contorsbodies
|
JP2021500930A
(ja)
|
2017-11-01 |
2021-01-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
Compボディ−多価標的結合物質
|
CN111246884A
(zh)
|
2017-11-01 |
2020-06-05 |
豪夫迈·罗氏有限公司 |
新颖的含有tnf家族配体三聚体的抗原结合分子
|
CN111278856A
(zh)
|
2017-11-01 |
2020-06-12 |
豪夫迈·罗氏有限公司 |
三Fab-康特斯体
|
CA3079036A1
(en)
|
2017-11-01 |
2019-05-09 |
F. Hoffmann-La Roche Ag |
Combination therapy with targeted ox40 agonists
|
WO2019089544A1
(en)
|
2017-11-01 |
2019-05-09 |
Tufts Medical Center, Inc. |
Bispecific antibody constructs and methods of use
|
CA3185525A1
(en)
|
2017-11-02 |
2019-05-09 |
Bayer Aktiengesellschaft |
Bispecific antibodies binding alk-1 and bmpr-2
|
EP3703751A2
(en)
|
2017-11-03 |
2020-09-09 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
MX2020004567A
(es)
|
2017-11-06 |
2020-08-13 |
Genentech Inc |
Metodos diagnosticos y terapeuticos para el cancer.
|
CA3082383A1
(en)
|
2017-11-08 |
2019-05-16 |
Xencor, Inc. |
Bispecific and monospecific antibodies using novel anti-pd-1 sequences
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
US11484573B2
(en)
|
2017-11-09 |
2022-11-01 |
Keros Therapeutics, Inc. |
Activin receptor type IIa variants and methods of use thereof
|
WO2019092181A1
(en)
|
2017-11-10 |
2019-05-16 |
Agency For Science, Technology And Research |
Il2rbeta/common gamma chain antibodies
|
MX2020004756A
(es)
|
2017-11-16 |
2020-08-20 |
Novartis Ag |
Terapias de combinacion.
|
US11851497B2
(en)
|
2017-11-20 |
2023-12-26 |
Compass Therapeutics Llc |
CD137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
KR20240023192A
(ko)
|
2017-11-24 |
2024-02-20 |
유큐(베이징) 바이오파마 코., 엘티디 |
항―ox40 항체 및 그의 용도
|
ES2939461T3
(es)
|
2017-11-29 |
2023-04-24 |
Csl Ltd |
Método para tratar o prevenir la lesión por isquemia-reperfusión
|
EA202091410A1
(ru)
|
2017-12-08 |
2021-01-13 |
Ардженкс Бвба |
Применение антагонистов fcrn для лечения генерализованной миастении гравис
|
JP2021506817A
(ja)
|
2017-12-14 |
2021-02-22 |
エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト |
がんを治療するための投与計画におけるcea cd3二重特異性抗体及びpd−1軸結合アンタゴニストの使用
|
CN111655718A
(zh)
|
2017-12-19 |
2020-09-11 |
Xencor股份有限公司 |
经过工程化的il-2 fc融合蛋白
|
JP7317016B2
(ja)
|
2017-12-19 |
2023-07-28 |
スロゼン オペレーティング, インコーポレイテッド |
抗lrp5/6抗体及び使用方法
|
EP3732201A4
(en)
|
2017-12-19 |
2022-04-20 |
Surrozen Operating, Inc. |
WNT SUBSTITUTION MOLECULES AND THEIR USES
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
EP3502140A1
(en)
|
2017-12-21 |
2019-06-26 |
F. Hoffmann-La Roche AG |
Combination therapy of tumor targeted icos agonists with t-cell bispecific molecules
|
AU2018390881A1
(en)
|
2017-12-21 |
2020-07-02 |
F. Hoffmann-La Roche Ag |
Antibodies binding to HLA-A2/WT1
|
US20190218310A1
(en)
|
2017-12-22 |
2019-07-18 |
Argenx Bvba |
Bispecific antigen binding construct
|
JP7074859B2
(ja)
|
2017-12-22 |
2022-05-24 |
エフ.ホフマン-ラ ロシュ アーゲー |
疎水性相互作用クロマトグラフィーによる軽鎖誤対合抗体変種の枯渇の方法
|
TW201929907A
(zh)
|
2017-12-22 |
2019-08-01 |
美商建南德克公司 |
Pilra結合劑用於治療疾病之用途
|
EP3732199A1
(en)
|
2017-12-27 |
2020-11-04 |
TeneoBio, Inc. |
Cd3-delta/epsilon heterodimer specific antibodies
|
KR20200104886A
(ko)
|
2017-12-28 |
2020-09-04 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-l1에 대한 항체 및 변이체
|
EP3732202A4
(en)
|
2017-12-28 |
2022-06-15 |
Nanjing Legend Biotech Co., Ltd. |
SINGLE DOMAIN ANTIBODIES AND VARIANTS THEREOF AGAINST TIGIT
|
TWI817974B
(zh)
|
2017-12-28 |
2023-10-11 |
日商中外製藥股份有限公司 |
細胞毒性誘導治療劑
|
EP3732193A1
(en)
|
2017-12-29 |
2020-11-04 |
Alector LLC |
Anti-tmem106b antibodies and methods of use thereof
|
JP7436365B2
(ja)
|
2017-12-29 |
2024-02-21 |
エフ. ホフマン-ラ ロシュ アーゲー |
抗vegf抗体及び使用の方法
|
BR112020013236A2
(pt)
|
2018-01-03 |
2020-12-01 |
Alpine Immune Sciences, Inc. |
proteínas imunomoduladoras de múltiplos domínios e métodos de seu uso
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
EP3737949A1
(en)
|
2018-01-12 |
2020-11-18 |
Genzyme Corporation |
Methods for the quantitation of polypeptides
|
WO2019137541A1
(en)
|
2018-01-15 |
2019-07-18 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against pd-1
|
EP3740505A1
(en)
|
2018-01-16 |
2020-11-25 |
Lakepharma Inc. |
Bispecific antibody that binds cd3 and another target
|
BR112020013405A2
(pt)
|
2018-01-25 |
2020-12-01 |
Acm Biolabs Pte Ltd. |
polimerossomas compreendendo um antígeno encapsulado solúvel, assim como métodos de sua fabricação e uso
|
KR20200115546A
(ko)
|
2018-01-26 |
2020-10-07 |
제넨테크, 인크. |
IL-22 Fc 융합 단백질 및 사용 방법
|
BR112020015016A2
(pt)
|
2018-01-26 |
2020-12-29 |
Genentech, Inc. |
Composições farmacêuticas, métodos de tratamento da doença inflamatória intestinal, de inibição da infecção microbiana no intestino e de aceleração ou melhora da cicatrização de feridas
|
WO2019152660A1
(en)
|
2018-01-31 |
2019-08-08 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
JP2021511782A
(ja)
|
2018-01-31 |
2021-05-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
安定化された免疫グロブリンドメイン
|
EP3746476A1
(en)
|
2018-01-31 |
2020-12-09 |
Alector LLC |
Anti-ms4a4a antibodies and methods of use thereof
|
WO2019149716A1
(en)
|
2018-01-31 |
2019-08-08 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies comprising an antigen-binding site binding to lag3
|
FR3077296A1
(fr)
|
2018-02-01 |
2019-08-02 |
Laboratoire Francais Du Fractionnement Et Des Biotechnologies |
Dimeres de variants du facteur x
|
WO2019148412A1
(en)
|
2018-02-01 |
2019-08-08 |
Merck Sharp & Dohme Corp. |
Anti-pd-1/lag3 bispecific antibodies
|
CN111699004A
(zh)
|
2018-02-06 |
2020-09-22 |
豪夫迈·罗氏有限公司 |
眼科疾病的治疗
|
EP3749363A1
(en)
|
2018-02-08 |
2020-12-16 |
Amgen Inc. |
Low ph pharmaceutical antibody formulation
|
EP3749346A4
(en)
|
2018-02-08 |
2021-12-15 |
Dragonfly Therapeutics, Inc. |
VARIABLE DOMAINS OF ANTIBODIES TARGETING THE NKG2D RECEIVER
|
PE20211116A1
(es)
|
2018-02-08 |
2021-06-23 |
Genentech Inc |
Moleculas biespecificas de union al antigeno y metodos de uso
|
WO2019153200A1
(zh)
|
2018-02-08 |
2019-08-15 |
北京韩美药品有限公司 |
抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
|
CA3226165A1
(en)
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases
|
TWI829667B
(zh)
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
CN111712522A
(zh)
|
2018-02-11 |
2020-09-25 |
北京韩美药品有限公司 |
抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备
|
JP7466442B2
(ja)
|
2018-02-14 |
2024-04-12 |
中外製薬株式会社 |
抗原結合分子および組合せ
|
AU2019226085A1
(en)
|
2018-02-21 |
2020-09-17 |
Genentech, Inc. |
Dosing for treatment with IL-22 Fc fusion proteins
|
KR102608723B1
(ko)
|
2018-02-23 |
2023-12-01 |
유큐(베이징) 바이오파마 코., 엘티디 |
항―pd-1 항체 및 그의 용도
|
CA3092470A1
(en)
|
2018-02-27 |
2019-09-06 |
Incyte Corporation |
Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
|
EP3762015A4
(en)
|
2018-03-05 |
2022-04-27 |
Janssen Biotech, Inc. |
METHODS OF TREATING CROHN'S DISEASE WITH SPECIFIC ANTI-IL23 ANTIBODY
|
AU2019236372A1
(en)
|
2018-03-13 |
2020-07-30 |
F. Hoffmann-La Roche Ag |
Therapeutic combination of 4-1 BB agonists with anti-CD20 antibodies
|
TW202003561A
(zh)
|
2018-03-13 |
2020-01-16 |
瑞士商赫孚孟拉羅股份公司 |
使用靶向4-1bb (cd137)之促效劑的組合療法
|
JP2021515793A
(ja)
|
2018-03-13 |
2021-06-24 |
ザイムワークス,インコーポレイテッド |
抗her2バイパラトピック抗体−薬物コンジュゲート及び使用方法
|
US20210238280A1
(en)
|
2018-03-14 |
2021-08-05 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
EP3765516A2
(en)
|
2018-03-14 |
2021-01-20 |
Elstar Therapeutics, Inc. |
Multifunctional molecules and uses thereof
|
US11203646B2
(en)
|
2018-03-14 |
2021-12-21 |
Novimmune Sa |
Anti-CD3 epsilon antibodies and methods of use thereof
|
EP3765524A4
(en)
|
2018-03-14 |
2021-12-22 |
Surface Oncology, Inc. |
Antibodies for binding CD39 and uses thereof
|
US20200040103A1
(en)
|
2018-03-14 |
2020-02-06 |
Genentech, Inc. |
Anti-klk5 antibodies and methods of use
|
US11485782B2
(en)
|
2018-03-14 |
2022-11-01 |
Beijing Xuanyi Pharmasciences Co., Ltd. |
Anti-claudin 18.2 antibodies
|
CN116327926A
(zh)
|
2018-03-15 |
2023-06-27 |
中外制药株式会社 |
对寨卡病毒具有交叉反应性的抗登革热病毒抗体及使用方法
|
WO2019175380A2
(en)
|
2018-03-16 |
2019-09-19 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
|
US20210024603A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from urocortin 3 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
US20210023209A1
(en)
|
2018-03-16 |
2021-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antigenic peptides deriving from pcsk2 and uses thereof for the diagnosis and treatment of type 1 diabetes
|
JP7438180B2
(ja)
|
2018-03-20 |
2024-02-26 |
ウーシー バイオロジクス アイルランド リミテッド |
新規抗lag-3抗体ポリペプチド
|
PE20201265A1
(es)
|
2018-03-21 |
2020-11-19 |
Alx Oncology Inc |
Anticuerpos contra proteina alfa reguladora de senal y metodos de uso
|
US11332524B2
(en)
|
2018-03-22 |
2022-05-17 |
Surface Oncology, Inc. |
Anti-IL-27 antibodies and uses thereof
|
GB201804701D0
(en)
|
2018-03-23 |
2018-05-09 |
Gammadelta Therapeutics Ltd |
Lymphocytes expressing heterologous targeting constructs
|
CA3093995A1
(en)
|
2018-03-24 |
2019-10-03 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified non-human animals for generating therapeutic antibodies against peptide-mhc complexes, methods of making and uses thereof
|
US11576984B2
(en)
|
2018-03-26 |
2023-02-14 |
Regeneron Pharmaceuticals, Inc. |
Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes and method of using
|
WO2019185163A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Vista antigen-binding molecules
|
US20190300610A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Pte. Ltd. |
Vista antigen-binding molecules
|
WO2019185164A1
(en)
|
2018-03-29 |
2019-10-03 |
Hummingbird Bioscience Holdings Pte. Ltd. |
Her3 antigen-binding molecules
|
KR20200135510A
(ko)
|
2018-03-29 |
2020-12-02 |
제넨테크, 인크. |
포유류 세포들에서 젖분비자극 활성의 조절
|
CN111886254B
(zh)
|
2018-03-30 |
2023-12-08 |
南京传奇生物科技有限公司 |
针对lag-3的单结构域抗体及其用途
|
TW202011029A
(zh)
|
2018-04-04 |
2020-03-16 |
美商建南德克公司 |
偵測及定量fgf21之方法
|
US10982006B2
(en)
|
2018-04-04 |
2021-04-20 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
EP3774883A1
(en)
|
2018-04-05 |
2021-02-17 |
Gilead Sciences, Inc. |
Antibodies and fragments thereof that bind hepatitis b virus protein x
|
WO2019195561A2
(en)
|
2018-04-06 |
2019-10-10 |
BioLegend, Inc. |
Anti-tetraspanin 33 agents and compositions and methods for making and using the same
|
US10654944B2
(en)
|
2018-04-10 |
2020-05-19 |
Y-Biologics Inc. |
Cell engaging binding molecules
|
AU2019251488A1
(en)
|
2018-04-11 |
2020-10-22 |
Inhibrx, Inc. |
Multispecific polypeptide constructs having constrained CD3 binding and related methods and uses
|
WO2019200357A1
(en)
|
2018-04-12 |
2019-10-17 |
Surface Oncology, Inc. |
Biomarker for cd47 targeting therapeutics and uses therefor
|
WO2019197600A1
(en)
|
2018-04-13 |
2019-10-17 |
F. Hoffmann-La Roche Ag |
Her2-targeting antigen binding molecules comprising 4-1bbl
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CN113195534A
(zh)
|
2018-04-18 |
2021-07-30 |
Xencor股份有限公司 |
包含il-15/il-15ra fc融合蛋白和lag-3抗原结合结构域的靶向lag-3的异源二聚体融合蛋白
|
MA52289A
(fr)
|
2018-04-18 |
2021-02-24 |
Xencor Inc |
Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
|
JP2021521784A
(ja)
|
2018-04-18 |
2021-08-30 |
ゼンコア インコーポレイテッド |
IL−15/IL−15RaFc融合タンパク質とPD−1抗原結合ドメインを含むPD−1標的化ヘテロダイマー融合タンパク質およびそれらの使用
|
WO2019204655A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
|
AR115052A1
(es)
|
2018-04-18 |
2020-11-25 |
Hoffmann La Roche |
Anticuerpos multiespecíficos y utilización de los mismos
|
AR114789A1
(es)
|
2018-04-18 |
2020-10-14 |
Hoffmann La Roche |
Anticuerpos anti-hla-g y uso de los mismos
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
WO2019213282A1
(en)
|
2018-05-01 |
2019-11-07 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
EP3788071A1
(en)
|
2018-05-02 |
2021-03-10 |
The United States Of America, As Represented By The Secretary, Department of Health and Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
JP2021523138A
(ja)
|
2018-05-11 |
2021-09-02 |
ヤンセン バイオテツク,インコーポレーテツド |
Il−23抗体を使用してうつを治療する方法
|
BR112020023118A2
(pt)
|
2018-05-14 |
2021-04-13 |
Werewolf Therapeutics, Inc. |
Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
|
KR20210021467A
(ko)
|
2018-05-14 |
2021-02-26 |
웨어울프 세라퓨틱스, 인크. |
활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
|
EP3793599A1
(en)
|
2018-05-16 |
2021-03-24 |
Janssen Biotech, Inc. |
Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy
|
CA3100071A1
(en)
|
2018-05-16 |
2019-11-21 |
Csl Limited |
Soluble complement receptor type 1 variants and uses thereof
|
MX2020012350A
(es)
|
2018-05-17 |
2021-01-29 |
Regeneron Pharma |
Anticuerpos anti-cd63, conjugados y usos de estos.
|
CN112166196A
(zh)
|
2018-05-18 |
2021-01-01 |
豪夫迈·罗氏有限公司 |
大核酸的靶向细胞内递送
|
JP7391046B2
(ja)
|
2018-05-18 |
2023-12-04 |
インサイト・コーポレイション |
A2a/a2b阻害剤としての縮合ピリミジン誘導体
|
WO2019226658A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Multispecific antigen-binding compositions and methods of use
|
JP2021525243A
(ja)
|
2018-05-21 |
2021-09-24 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
Nk細胞による標的細胞の殺傷を増進するための組成物および方法
|
EP3801769A1
(en)
|
2018-05-25 |
2021-04-14 |
Novartis AG |
Combination therapy with chimeric antigen receptor (car) therapies
|
UA128113C2
(uk)
|
2018-05-25 |
2024-04-10 |
ЕЛЕКТОР ЕлЕлСі |
Анти-sirpa антитіла і способи їхнього застосування
|
WO2019232244A2
(en)
|
2018-05-31 |
2019-12-05 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
SG11202011461TA
(en)
|
2018-06-01 |
2020-12-30 |
Compugen Ltd |
Anti-pvrig/anti-tigit bispecific antibodies and methods of use
|
EP3802611A2
(en)
|
2018-06-01 |
2021-04-14 |
Novartis AG |
Binding molecules against bcma and uses thereof
|
WO2019236965A1
(en)
|
2018-06-08 |
2019-12-12 |
Alector Llc |
Anti-siglec-7 antibodies and methods of use thereof
|
WO2019237035A1
(en)
|
2018-06-08 |
2019-12-12 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
TW202016151A
(zh)
|
2018-06-09 |
2020-05-01 |
德商百靈佳殷格翰國際股份有限公司 |
針對癌症治療之多特異性結合蛋白
|
CN112203725A
(zh)
|
2018-06-13 |
2021-01-08 |
诺华股份有限公司 |
Bcma嵌合抗原受体及其用途
|
FR3082427B1
(fr)
|
2018-06-14 |
2020-09-25 |
Lab Francais Du Fractionnement |
Combinaison de facteur vii et d'un anticorps bispecifique anti-facteurs ix et x
|
IL305557A
(en)
|
2018-06-14 |
2023-10-01 |
Regeneron Pharma |
Non-human animals with transgenic DH–DH rearrangement capacity, and their uses
|
US20210363219A1
(en)
|
2018-06-15 |
2021-11-25 |
Alpine Immune Sciences, Inc. |
Pd-1 variant immunomodulatory proteins and uses thereof
|
CA3104295A1
(en)
|
2018-06-19 |
2019-12-26 |
Atarga, Llc |
Antibody molecules to complement component 5 and uses thereof
|
US20210261669A1
(en)
|
2018-06-20 |
2021-08-26 |
Chugai Seiyaku Kabushiki Kaisha |
Method for activating immune response of target cell and composition therefor
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
CA3104467A1
(en)
|
2018-06-20 |
2019-12-26 |
Incyte Corporation |
Anti-pd-1 antibodies and uses thereof
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
SG11202012706PA
(en)
|
2018-06-21 |
2021-01-28 |
Yumanity Therapeutics Inc |
Compositions and methods for the treatment and prevention of neurological disorders
|
WO2019244107A1
(en)
|
2018-06-21 |
2019-12-26 |
Daiichi Sankyo Company, Limited |
Compositions including cd3 antigen binding fragments and uses thereof
|
CN112654633A
(zh)
|
2018-06-22 |
2021-04-13 |
科优基因公司 |
基于细胞因子的可生物活化药物及其使用方法
|
BR112020026384A2
(pt)
|
2018-06-23 |
2021-03-30 |
Genentech, Inc. |
Métodos para tratar um indivíduo com câncer de pulmão e para tratar um indivíduo com câncer de pulmão de pequenas células, kits, anticorpo anti-pd-l1 e composição
|
CA3099176A1
(en)
|
2018-06-29 |
2020-01-02 |
Alector Llc |
Anti-sirp-beta1 antibodies and methods of use thereof
|
PE20211805A1
(es)
|
2018-06-29 |
2021-09-14 |
Incyte Corp |
Formulaciones de un inhibidor de axl/mer
|
JOP20200343A1
(ar)
|
2018-07-02 |
2020-12-31 |
Xencor Inc |
بروتين ربط مولد ضد مضاد لـ steap1
|
EP3818083A2
(en)
|
2018-07-03 |
2021-05-12 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
AU2019297324B9
(en)
|
2018-07-03 |
2022-07-07 |
Gilead Sciences, Inc. |
Antibodies that target HIV gp120 and methods of use
|
TW202035447A
(zh)
|
2018-07-04 |
2020-10-01 |
瑞士商赫孚孟拉羅股份公司 |
新穎雙特異性促效性4-1bb抗原結合分子
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020014306A1
(en)
|
2018-07-10 |
2020-01-16 |
Immunogen, Inc. |
Met antibodies and immunoconjugates and uses thereof
|
LT3618928T
(lt)
|
2018-07-13 |
2023-04-11 |
Alector Llc |
Anti-sortilino antikūnai ir jų panaudojimo būdai
|
WO2020018556A1
(en)
|
2018-07-16 |
2020-01-23 |
Amgen Inc. |
Method of treating multiple myeloma
|
CA3104147A1
(en)
|
2018-07-18 |
2020-01-23 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, an antimetabolite, and a platinum agent
|
JP2021530697A
(ja)
|
2018-07-18 |
2021-11-11 |
ヤンセン バイオテツク,インコーポレーテツド |
抗il23特異的抗体で治療した後の持続応答予測因子
|
BR112021000727A2
(pt)
|
2018-07-20 |
2021-04-13 |
Surface Oncology, Inc. |
Composições anti-cd112r e métodos
|
CA3105875A1
(en)
|
2018-07-20 |
2020-01-23 |
Eucure (Beijing) Biopharma Co., Ltd |
Anti-cd40 antibodies and uses thereof
|
JP2021531785A
(ja)
|
2018-07-24 |
2021-11-25 |
インヒブルクス インコーポレイテッド |
制約されたcd3結合ドメインおよび受容体結合領域を含有する多重特異性ポリペプチド構築物ならびにそれを使用する方法
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
EP3830123A1
(en)
|
2018-07-27 |
2021-06-09 |
Alector LLC |
Anti-siglec-5 antibodies and methods of use thereof
|
JPWO2020027330A1
(ja)
|
2018-08-03 |
2021-08-19 |
中外製薬株式会社 |
互いに連結された2つの抗原結合ドメインを含む抗原結合分子
|
BR112021002130A2
(pt)
|
2018-08-08 |
2021-05-04 |
Genentech, Inc. |
formulação líquida, artigo de fabricação ou kit e método para reduzir a oxidação de um polipeptídeo
|
US20210309746A1
(en)
|
2018-08-09 |
2021-10-07 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
WO2020033923A1
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
EP3608674A1
(en)
|
2018-08-09 |
2020-02-12 |
Regeneron Pharmaceuticals, Inc. |
Methods for assessing binding affinity of an antibody variant to the neonatal fc receptor
|
SG10202106830VA
(en)
|
2018-08-10 |
2021-08-30 |
Chugai Pharmaceutical Co Ltd |
Anti-cd137 antigen-binding molecule and utilization thereof
|
CN112638946A
(zh)
|
2018-08-16 |
2021-04-09 |
坎塔吉亚有限责任公司 |
抗il1rap抗体组合物
|
WO2020037174A1
(en)
|
2018-08-16 |
2020-02-20 |
The Johns Hopkins University |
Antibodies to human znt8
|
TW202021618A
(zh)
|
2018-08-17 |
2020-06-16 |
美商23與我有限公司 |
抗il1rap抗體及其使用方法
|
JPWO2020045545A1
(ja)
|
2018-08-29 |
2021-08-12 |
中外製薬株式会社 |
抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
|
BR112021003416A2
(pt)
|
2018-08-30 |
2021-05-18 |
TCR2 Therapeutics Inc. |
composições e métodos para reprogramação de tcr usando proteínas de fusão
|
SG11202101552SA
(en)
|
2018-08-31 |
2021-03-30 |
Alector Llc |
Anti-cd33 antibodies and methods of use thereof
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US20220364055A1
(en)
|
2018-08-31 |
2022-11-17 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
GB201814281D0
(en)
|
2018-09-03 |
2018-10-17 |
Femtogenix Ltd |
Cytotoxic agents
|
GB2576914A
(en)
|
2018-09-06 |
2020-03-11 |
Kymab Ltd |
Antigen-binding molecules comprising unpaired variable domains produced in mammals
|
WO2020053325A1
(en)
|
2018-09-12 |
2020-03-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a covalently bound antigen as well as methods of making and uses thereof
|
US20220098613A1
(en)
|
2018-09-12 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
EP3850012A4
(en)
|
2018-09-12 |
2022-06-15 |
Eucure (Beijing) Biopharma Co., Ltd |
ANTI-TNFRSF9 ANTIBODIES AND THEIR USES
|
WO2020061060A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
CA3112578A1
(en)
|
2018-09-19 |
2020-03-26 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant cd80 fusion proteins and related constructs
|
EP4249917A3
(en)
|
2018-09-21 |
2023-11-08 |
F. Hoffmann-La Roche AG |
Diagnostic methods for triple-negative breast cancer
|
EP3856778A1
(en)
|
2018-09-24 |
2021-08-04 |
The Medical College of Wisconsin, Inc. |
System and method for the development of cd30 bispecific antibodies for immunotherapy of cd30+ malignancies
|
CN113365697A
(zh)
|
2018-09-25 |
2021-09-07 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
CN113286817A
(zh)
|
2018-09-25 |
2021-08-20 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
AU2019347751A1
(en)
|
2018-09-27 |
2021-04-29 |
Xilio Development, Inc. |
Masked cytokine polypeptides
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
CN112654641A
(zh)
|
2018-10-01 |
2021-04-13 |
豪夫迈·罗氏有限公司 |
具有与cd40的三价结合的双特异性抗原结合分子
|
MX2021003548A
(es)
|
2018-10-01 |
2021-05-27 |
Hoffmann La Roche |
Moleculas de union a antigeno biespecificas que comprenden el clon 212 anti-fap.
|
SG11202103192RA
(en)
|
2018-10-03 |
2021-04-29 |
Xencor Inc |
Il-12 heterodimeric fc-fusion proteins
|
MA53812A
(fr)
|
2018-10-04 |
2021-08-11 |
Genmab Holding B V |
Compositions pharmaceutiques comprenant des anticorps anti-cd37 bispécifiques
|
US20200109200A1
(en)
|
2018-10-09 |
2020-04-09 |
Genentech, Inc. |
Methods and systems for determining synapse formation
|
MX2021004147A
(es)
|
2018-10-09 |
2021-09-08 |
Sanofi Sa |
Proteínas de unión triespecíficas anti-cd38, anti-cd28 y anti-cd3 y métodos de uso para tratar una infección viral.
|
WO2020076977A2
(en)
|
2018-10-11 |
2020-04-16 |
Inhibrx, Inc. |
Dll3 single domain antibodies and therapeutic compositions thereof
|
TW202028246A
(zh)
|
2018-10-11 |
2020-08-01 |
美商英伊布里克斯公司 |
B7h3單域抗體及其治療性組合物
|
AU2019356573A1
(en)
|
2018-10-11 |
2021-05-27 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
EP3863721A1
(en)
|
2018-10-11 |
2021-08-18 |
Inhibrx, Inc. |
5t4 single domain antibodies and therapeutic compositions thereof
|
US11377477B2
(en)
|
2018-10-12 |
2022-07-05 |
Xencor, Inc. |
PD-1 targeted IL-15/IL-15RALPHA fc fusion proteins and uses in combination therapies thereof
|
EP3867646A1
(en)
|
2018-10-18 |
2021-08-25 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
WO2020086758A1
(en)
|
2018-10-23 |
2020-04-30 |
Dragonfly Therapeutics, Inc. |
Heterodimeric fc-fused proteins
|
CN113056287A
(zh)
|
2018-10-24 |
2021-06-29 |
豪夫迈·罗氏有限公司 |
缀合的化学降解诱导剂及使用方法
|
JP2022512798A
(ja)
|
2018-10-25 |
2022-02-07 |
エフ.ホフマン-ラ ロシュ アーゲー |
抗体FcRn結合の改変
|
GB201817354D0
(en)
|
2018-10-25 |
2018-12-12 |
Hummingbird Bioscience Pte Ltd |
Engineered FC
|
WO2020084034A1
(en)
|
2018-10-26 |
2020-04-30 |
F. Hoffmann-La Roche Ag |
Multispecific antibody screening method using recombinase mediated cassette exchange
|
WO2020092455A2
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Car t cell transcriptional atlas
|
BR112021008105A2
(pt)
|
2018-10-29 |
2021-08-03 |
Biogen Ma Inc. |
variantes de fc5 humanizadas e estabilizadas para intensificação de transporte através de barreira hematoencefálica
|
CR20210200A
(es)
|
2018-10-29 |
2021-05-25 |
Hoffmann La Roche |
Formulación de anticuerpos
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
EP3877407A1
(en)
|
2018-11-05 |
2021-09-15 |
F. Hoffmann-La Roche AG |
Methods of producing two chain proteins in prokaryotic host cells
|
KR20210124959A
(ko)
|
2018-11-06 |
2021-10-15 |
젠맵 에이/에스 |
항체 제제
|
TW202031683A
(zh)
|
2018-11-09 |
2020-09-01 |
新加坡商優其洛伊生物私人有限公司 |
介白素2受體β(IL2Rβ)/共同γ鏈抗體
|
TW202039557A
(zh)
|
2018-11-09 |
2020-11-01 |
新加坡商優其洛伊生物私人有限公司 |
介白素2受體β(IL2Rβ)/共同γ鏈抗體
|
SG11202104864QA
(en)
|
2018-11-13 |
2021-06-29 |
Compass Therapeutics Llc |
Multispecific binding constructs against checkpoint molecules and uses thereof
|
CN113227142B
(zh)
|
2018-11-19 |
2022-11-29 |
百奥赛图(北京)医药科技股份有限公司 |
抗pd-1抗体及其用途
|
CN113395979A
(zh)
|
2018-11-20 |
2021-09-14 |
詹森生物科技公司 |
用抗il-23特异性抗体治疗银屑病的安全且有效的方法
|
WO2020104496A1
(en)
|
2018-11-20 |
2020-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Bispecific antibody targeting transferrin receptor 1 and soluble antigen
|
CA3120868A1
(en)
|
2018-11-30 |
2020-06-04 |
Alpine Immune Sciences, Inc. |
Cd86 variant immunomodulatory proteins and uses thereof
|
CN113490499A
(zh)
|
2018-12-04 |
2021-10-08 |
大日本住友制药肿瘤公司 |
用作治疗癌症的活性剂的cdk9抑制剂及其多晶型物
|
CA3121699A1
(en)
|
2018-12-05 |
2020-06-11 |
Morphosys Ag |
Multispecific antigen-binding molecules
|
WO2020117257A1
(en)
|
2018-12-06 |
2020-06-11 |
Genentech, Inc. |
Combination therapy of diffuse large b-cell lymphoma comprising an anti-cd79b immunoconjugates, an alkylating agent and an anti-cd20 antibody
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020123275A1
(en)
|
2018-12-10 |
2020-06-18 |
Genentech, Inc. |
Photocrosslinking peptides for site specific conjugation to fc-containing proteins
|
AR117327A1
(es)
|
2018-12-20 |
2021-07-28 |
23Andme Inc |
Anticuerpos anti-cd96 y métodos de uso de estos
|
MX2021007392A
(es)
|
2018-12-20 |
2021-08-24 |
Novartis Ag |
Regimen de dosificacion y combinacion farmaceutica que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
AR117453A1
(es)
|
2018-12-20 |
2021-08-04 |
Genentech Inc |
Fc de anticuerpos modificados y métodos para utilizarlas
|
TW202038959A
(zh)
|
2018-12-20 |
2020-11-01 |
瑞士商諾華公司 |
Mdm2抑制劑之新型給藥方案
|
EP3897853A1
(en)
|
2018-12-20 |
2021-10-27 |
Xencor, Inc. |
Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and nkg2d antigen binding domains
|
CA3121804A1
(en)
|
2018-12-21 |
2020-06-25 |
Genentech, Inc. |
Methods of producing polypeptides using a cell line resistant to apoptosis
|
CR20210325A
(es)
|
2018-12-21 |
2021-07-20 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3
|
WO2020128049A1
(en)
|
2018-12-21 |
2020-06-25 |
Kymab Limited |
Fixaxfx bispecific antibody with common light chain
|
CA3120474A1
(en)
|
2018-12-21 |
2020-06-25 |
23Andme, Inc. |
Anti-il-36 antibodies and methods of use thereof
|
CN113286821A
(zh)
|
2018-12-21 |
2021-08-20 |
豪夫迈·罗氏有限公司 |
靶向肿瘤的激动性cd28抗原结合分子
|
JP2022513495A
(ja)
|
2018-12-21 |
2022-02-08 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
腫瘍標的化スーパーアゴニストcd28抗原結合分子
|
WO2020136564A1
(en)
|
2018-12-24 |
2020-07-02 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
EP3674316A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Multispecific binding proteins with mutant fab domains
|
AU2019412561A1
(en)
|
2018-12-24 |
2021-08-12 |
Sanofi |
Multispecific binding proteins with mutant Fab domains
|
EP3674319A1
(en)
|
2018-12-24 |
2020-07-01 |
Sanofi |
Pseudofab-based multispecific binding proteins
|
CN111378045B
(zh)
|
2018-12-28 |
2022-08-02 |
长春金赛药业有限责任公司 |
二价双特异性抗体及其制备方法、编码基因、宿主细胞、组合物
|
CN113412123A
(zh)
|
2018-12-28 |
2021-09-17 |
豪夫迈·罗氏有限公司 |
用于免疫应答增强的患者的治疗性用途的肽-mhc-i-抗体融合蛋白
|
CN111378044B
(zh)
|
2018-12-28 |
2022-07-15 |
长春金赛药业有限责任公司 |
抗体融合蛋白、制备方法及其应用
|
EP3903102B1
(en)
|
2018-12-30 |
2023-04-12 |
F. Hoffmann-La Roche AG |
Ph-gradient spr-based binding assay
|
KR20210113261A
(ko)
|
2019-01-04 |
2021-09-15 |
리졸브 테라퓨틱스, 엘엘씨 |
뉴클레아제 융합 단백질을 사용한 쇼그렌병의 치료
|
TW202043256A
(zh)
|
2019-01-10 |
2020-12-01 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
AU2020208397A1
(en)
|
2019-01-16 |
2021-08-12 |
Compass Therapeutics Llc |
Formulations of antibodies that bind human CD137 and uses thereof
|
MX2021008652A
(es)
|
2019-01-18 |
2021-10-26 |
Janssen Biotech Inc |
Receptores de antígenos quiméricos de gprc5d y células que los expresan.
|
MX2021008561A
(es)
|
2019-01-23 |
2021-08-19 |
Genentech Inc |
Metodos de produccion de proteinas multimericas en celulas huesped eucariotas.
|
CN113329770A
(zh)
|
2019-01-24 |
2021-08-31 |
中外制药株式会社 |
新型癌抗原及所述抗原的抗体
|
TWI829857B
(zh)
|
2019-01-29 |
2024-01-21 |
美商英塞特公司 |
作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
|
KR20210121137A
(ko)
|
2019-01-29 |
2021-10-07 |
샤이어-엔피에스 파마슈티칼즈, 인크. |
부갑상선 호르몬 변이체
|
GB201901197D0
(en)
|
2019-01-29 |
2019-03-20 |
Femtogenix Ltd |
G-A Crosslinking cytotoxic agents
|
US10871640B2
(en)
|
2019-02-15 |
2020-12-22 |
Perkinelmer Cellular Technologies Germany Gmbh |
Methods and systems for automated imaging of three-dimensional objects
|
KR20210129672A
(ko)
|
2019-02-15 |
2021-10-28 |
노파르티스 아게 |
치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
|
JP2022520811A
(ja)
|
2019-02-15 |
2022-04-01 |
ノバルティス アーゲー |
3-(1-オキソ-5-(ピペリジン-4-イル)イソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
KR20210133234A
(ko)
|
2019-02-18 |
2021-11-05 |
바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 |
인간화 면역글로불린 유전자좌를 갖는 유전적으로 변형된 비-인간 동물
|
US20210171596A1
(en)
|
2019-02-21 |
2021-06-10 |
Gregory Moore |
Untargeted and targeted il-10 fc-fusion proteins
|
GB2599228B
(en)
|
2019-02-21 |
2024-02-07 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to T cell related cancer cells and uses thereof
|
WO2020169698A1
(en)
|
2019-02-21 |
2020-08-27 |
F. Hoffmann-La Roche Ag |
Sensitization of cancer cells to tnf by bet inhibition
|
CA3130508A1
(en)
|
2019-02-21 |
2020-08-27 |
Marengo Therapeutics, Inc. |
Antibody molecules that bind to nkp30 and uses thereof
|
SG11202109056TA
(en)
|
2019-02-21 |
2021-09-29 |
Marengo Therapeutics Inc |
Multifunctional molecules that bind to calreticulin and uses thereof
|
CA3131014A1
(en)
|
2019-02-21 |
2020-08-27 |
Andreas Loew |
Anti-tcr antibody molecules and uses thereof
|
WO2020172598A1
(en)
|
2019-02-21 |
2020-08-27 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
|
WO2020172553A1
(en)
|
2019-02-22 |
2020-08-27 |
Novartis Ag |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
CN112703013B
(zh)
*
|
2019-02-22 |
2022-09-30 |
武汉友芝友生物制药股份有限公司 |
Cd3抗原结合片段及其应用
|
US20220152150A1
(en)
|
2019-02-25 |
2022-05-19 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
KR20210134725A
(ko)
|
2019-03-01 |
2021-11-10 |
젠코어 인코포레이티드 |
Enpp3과 cd3에 결합하는 이종이량체 항체
|
US20220235144A1
(en)
|
2019-03-04 |
2022-07-28 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-sirp-alpha antibodies
|
CA3132651A1
(en)
|
2019-03-05 |
2020-09-10 |
Takeda Pharmaceutical Limited Company |
Conditionally activated binding proteins containing fc regions and moieties targeting tumor antigens
|
EP3934762A1
(en)
|
2019-03-05 |
2022-01-12 |
Takeda Pharmaceutical Company Limited |
Constrained conditionally activated binding proteins
|
KR20210138588A
(ko)
|
2019-03-08 |
2021-11-19 |
제넨테크, 인크. |
세포외 소포 상에서 막 관련 단백질을 검출하고 정량하기 위한 방법
|
TW202100556A
(zh)
*
|
2019-03-14 |
2021-01-01 |
美商建南德克公司 |
使用her2 t細胞依賴性雙特異性抗體之治療
|
MX2021011196A
(es)
|
2019-03-15 |
2021-10-22 |
Cartesian Therapeutics Inc |
Receptores de antigenos quimericos anti-antigeno de maduracion de celulas b (anti-bcma).
|
US20220153875A1
(en)
|
2019-03-19 |
2022-05-19 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule containing antigen-binding domain of which binding activity to antigen is changed depending on mta, and library for obtaining said antigen-binding domain
|
WO2020191326A1
(en)
|
2019-03-20 |
2020-09-24 |
Sumitomo Dainippon Pharma Oncology, Inc. |
Treatment of acute myeloid leukemia (aml) with venetoclax failure
|
EP3941580A1
(en)
|
2019-03-22 |
2022-01-26 |
Reflexion Pharmaceuticals, Inc. |
D-peptidic compounds for vegf
|
US20230051872A1
(en)
|
2019-03-22 |
2023-02-16 |
Reflexion Pharmaceuticals, Inc. |
Multivalent D-Peptidic Compounds for Target Proteins
|
MA55519A
(fr)
|
2019-03-29 |
2022-02-09 |
Atarga Llc |
Anticorps anti-fgf23
|
JP7249432B2
(ja)
|
2019-03-29 |
2023-03-30 |
エフ. ホフマン-ラ ロシュ アーゲー |
多価分子の機能分析のための、sprをベースとする結合アッセイ
|
EP3947440A1
(en)
|
2019-03-29 |
2022-02-09 |
F. Hoffmann-La Roche AG |
Method for generating avid-binding multispecific antibodies
|
CA3136488A1
(en)
|
2019-04-08 |
2020-10-15 |
Biogen Ma Inc. |
Anti-integrin antibodies and uses thereof
|
US11613576B2
(en)
|
2019-04-09 |
2023-03-28 |
Sanofi |
Trispecific binding proteins, methods, and uses thereof
|
CN113677403A
(zh)
|
2019-04-12 |
2021-11-19 |
豪夫迈·罗氏有限公司 |
包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
|
JP2022527565A
(ja)
|
2019-04-12 |
2022-06-02 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
CEA CD3二重特異性抗体及びWntシグナル伝達阻害剤を使用するがんの治療
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CA3136816A1
(en)
|
2019-04-17 |
2020-10-22 |
Alpine Immune Sciences, Inc. |
Methods and uses of variant icos ligand (icosl) fusion proteins
|
EP3956664A1
(en)
|
2019-04-18 |
2022-02-23 |
Genentech, Inc. |
Antibody potency assay
|
WO2020214995A1
(en)
|
2019-04-19 |
2020-10-22 |
Genentech, Inc. |
Anti-mertk antibodies and their methods of use
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
MX2021012872A
(es)
|
2019-04-25 |
2021-11-17 |
Hoffmann La Roche |
Polipeptidos multiespecificos terapeuticos activados mediante intercambio de cadenas polipeptidicas.
|
EP3959244A1
(en)
|
2019-04-25 |
2022-03-02 |
F. Hoffmann-La Roche AG |
Generation of antibody-derived polypeptides by polypeptide chain exchange
|
AU2020263910A1
(en)
|
2019-04-25 |
2021-10-21 |
F. Hoffmann-La Roche Ag |
Activatable therapeutic multispecific polypeptides with extended half-life
|
CN113795514A
(zh)
|
2019-05-09 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
制备抗体的方法
|
EP3969907A1
(en)
|
2019-05-13 |
2022-03-23 |
F. Hoffmann-La Roche AG |
Interference-suppressed pharmacokinetic immunoassay
|
CA3137512A1
(en)
|
2019-05-14 |
2020-11-19 |
Werewolf Therapeutics, Inc. |
Separation moieties and methods and use thereof
|
AU2020275415A1
(en)
|
2019-05-14 |
2021-11-25 |
Genentech, Inc. |
Methods of using anti-CD79B immunoconjugates to treat follicular lymphoma
|
US20220213194A1
(en)
|
2019-05-15 |
2022-07-07 |
Neotx Therapeutics Ltd. |
Cancer treatment
|
WO2020232295A1
(en)
|
2019-05-16 |
2020-11-19 |
Procisedx Inc. |
An assay method for the detection of vcam-1 and alpha-2-macroglobulin in blood
|
JP2022532381A
(ja)
|
2019-05-16 |
2022-07-14 |
プロサイセデクス インコーポレイティド |
Vcam-1及びカルプロテクチンのための分析検出方法
|
EP3969119A1
(en)
|
2019-05-17 |
2022-03-23 |
Xencor, Inc. |
Il-7-fc-fusi0n proteins
|
CA3140142A1
(en)
|
2019-05-21 |
2020-11-26 |
Novartis Ag |
Trispecific binding molecules against bcma and uses thereof
|
EP3972993A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Variant cd58 domains and uses thereof
|
EP3972998A1
(en)
|
2019-05-21 |
2022-03-30 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
US11780911B2
(en)
|
2019-05-23 |
2023-10-10 |
Janssen Biotech, Inc. |
Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
|
JP2022534227A
(ja)
|
2019-05-23 |
2022-07-28 |
プロサイセデクス インコーポレイティド |
ヒト血清アルブミン、ビタミンd、c反応性タンパク質、及び抗トランスグルタミナーゼ自己抗体の検出のためのアッセイ方法
|
CN114174344A
(zh)
|
2019-05-30 |
2022-03-11 |
美国安进公司 |
工程改造铰链区以驱动抗体二聚化
|
BR112021024003A2
(pt)
|
2019-05-31 |
2022-04-19 |
Alx Oncology Inc |
Métodos de tratamento de câncer com fusão sirp alfa-fc em combinação com um inibidor de checkpoint imunológico
|
JP2022535534A
(ja)
|
2019-06-03 |
2022-08-09 |
ヤンセン バイオテツク,インコーポレーテツド |
活動性強直性脊椎炎を治療するための抗tnf抗体、組成物、及び方法
|
BR112021023735A2
(pt)
|
2019-06-05 |
2022-01-04 |
Chugai Pharmaceutical Co Ltd |
Molécula de ligação de sítio de clivagem de anti-corpo
|
AR119264A1
(es)
|
2019-06-05 |
2021-12-09 |
Genentech Inc |
Método para reutilización de cromatografía
|
EP3980779A1
(en)
|
2019-06-06 |
2022-04-13 |
ProciseDx Inc. |
Detection of hemoglobin a1c (hba1c) in blood
|
SG11202112010RA
(en)
|
2019-06-07 |
2021-12-30 |
Argenx Bvba |
PHARMACEUTICAL FORMULATIONS OF FcRn INHIBITORS SUITABLE FOR SUBCUTANEOUS ADMINISTRATION
|
EP3981429A4
(en)
|
2019-06-10 |
2023-07-26 |
Chugai Seiyaku Kabushiki Kaisha |
ANTI-T-CELL ANTIGEN-BINDING MOLECULE FOR USE IN COMBINATION WITH A CYTOKINE INHIBITOR
|
KR20220031616A
(ko)
|
2019-06-11 |
2022-03-11 |
알렉터 엘엘씨 |
치료요법에 사용하기 위한 항-소르틸린 항체
|
AR119746A1
(es)
|
2019-06-14 |
2022-01-05 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
MX2021015536A
(es)
|
2019-06-19 |
2022-02-10 |
Hoffmann La Roche |
Metodo para la generacion de una celula que expresa proteina mediante integracion dirigida usando acido ribonucleico mensajero (arnm) de cre.
|
KR20220010549A
(ko)
|
2019-06-19 |
2022-01-25 |
에프. 호프만-라 로슈 아게 |
정의된 조직에서 다중 발현 카세트의 표적화된 통합에 의해 다가 이중특이성 항체 발현 세포를 생성하는 방법
|
KR20220024636A
(ko)
|
2019-06-19 |
2022-03-03 |
에프. 호프만-라 로슈 아게 |
정의된 조직의 다수 발현 카세트들의 표적화 통합에 의한 다가, 다중특이성 항체 발현 세포의 생성 방법
|
CA3140318A1
(en)
|
2019-06-19 |
2020-12-24 |
Johannes Auer |
Method for the generation of a bivalent, bispecific antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
EP3986925A1
(en)
|
2019-06-19 |
2022-04-27 |
F. Hoffmann-La Roche AG |
Method for the generation of a trivalent antibody expressing cell by targeted integration of multiple expression cassettes in a defined organization
|
CN112111012B
(zh)
|
2019-06-20 |
2023-07-04 |
成都恩沐生物科技有限公司 |
共价多特异性抗体
|
CA3144324A1
(en)
|
2019-06-24 |
2020-12-30 |
Novartis Ag |
Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
|
JP2022540764A
(ja)
|
2019-06-25 |
2022-09-20 |
プロサイセデクス インコーポレイティド |
抗TNFα生物製剤および抗薬剤抗体の検出
|
AU2020304813A1
(en)
|
2019-06-26 |
2022-01-06 |
F. Hoffmann-La Roche Ag |
Fusion of an antibody binding CEA and 4-1BBL
|
BR112021026286A2
(pt)
|
2019-06-26 |
2022-03-03 |
Hoffmann La Roche |
Método para aumentar o título de polipeptídeo heterólogo e/ou reduzir a produção de lactato de uma célula de mamífero recombinante e métodos para produzir um polipeptídeo heterólogo e uma célula de mamífero recombinante
|
EP3990492A1
(en)
|
2019-06-27 |
2022-05-04 |
F. Hoffmann-La Roche AG |
Novel icos antibodies and tumor-targeted antigen binding molecules comprising them
|
WO2020264384A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
WO2020264300A1
(en)
|
2019-06-28 |
2020-12-30 |
Genentech, Inc. |
Composition and methods for stabilizing liquid protein formulations
|
MX2021015433A
(es)
|
2019-07-02 |
2022-06-08 |
Hutchinson Fred Cancer Res |
Vectores ad35 recombinantes y mejoras de la terapia génica relacionadas.
|
WO2021001289A1
(en)
|
2019-07-02 |
2021-01-07 |
F. Hoffmann-La Roche Ag |
Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
|
MX2022000111A
(es)
|
2019-07-10 |
2022-02-10 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union a claudina-6 y usos de las mismas.
|
JP2022541742A
(ja)
|
2019-07-11 |
2022-09-27 |
カール メディカル リミテッド |
ヘテロダイマーおよびその使用方法
|
AR119382A1
(es)
|
2019-07-12 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos de pre-direccionamiento y métodos de uso
|
AR119393A1
(es)
|
2019-07-15 |
2021-12-15 |
Hoffmann La Roche |
Anticuerpos que se unen a nkg2d
|
JP2022541459A
(ja)
|
2019-07-16 |
2022-09-26 |
サノフイ |
アルツハイマー病の処置のための中和抗アミロイドベータ抗体
|
AU2020315878A1
(en)
|
2019-07-19 |
2022-03-03 |
Oncoresponse, Inc. |
Immunomodulatory antibodies and methods of use thereof
|
JP2022542240A
(ja)
|
2019-07-26 |
2022-09-30 |
ジェネンテック, インコーポレイテッド |
IL-22 Fc融合タンパク質による移植片対宿主病(GVHD)の予防又は治療のための投薬
|
CA3145278A1
(en)
|
2019-07-26 |
2021-02-04 |
Vanderbilt University |
Human monoclonal antibodies to enterovirus d68
|
US20230374130A1
(en)
|
2019-07-30 |
2023-11-23 |
Qlsf Biotherapeutics, Inc. |
Bispecific anti lrrc15 and cd3epsilon antibodies
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
KR20220058540A
(ko)
|
2019-07-31 |
2022-05-09 |
알렉터 엘엘씨 |
항-ms4a4a 항체 및 이의 사용 방법
|
SG11202112491WA
(en)
|
2019-07-31 |
2021-12-30 |
Hoffmann La Roche |
Antibodies binding to gprc5d
|
KR20220044527A
(ko)
|
2019-08-01 |
2022-04-08 |
인사이트 코포레이션 |
Ido 억제제의 투여 요법
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
WO2021026387A2
(en)
|
2019-08-06 |
2021-02-11 |
Xencor, Inc. |
HETERODIMERIC IgG-LIKE BISPECIFIC ANTIBODIES
|
CN114641490B
(zh)
|
2019-08-06 |
2023-06-06 |
新旭生技股份有限公司 |
结合至病理性tau种类的抗体及其用途
|
EP4010371A1
(en)
|
2019-08-08 |
2022-06-15 |
Regeneron Pharmaceuticals, Inc. |
Novel antigen binding molecule formats
|
CN114867751A
(zh)
|
2019-08-12 |
2022-08-05 |
阿帕特夫研究和发展有限公司 |
4-1bb和ox40结合蛋白及相关组合物和方法、抗-4-1bb抗体、抗-ox40抗体
|
TW202120551A
(zh)
|
2019-08-12 |
2021-06-01 |
美商普瑞諾生物科技公司 |
藉由adcc靶向cd39表現細胞促進及增強t細胞介導免疫反應之方法及組合物
|
WO2021028752A1
(en)
|
2019-08-15 |
2021-02-18 |
Janssen Biotech, Inc. |
Anti-tfn antibodies for treating type i diabetes
|
KR20220062494A
(ko)
|
2019-08-15 |
2022-05-17 |
얀센 바이오테크 인코포레이티드 |
개선된 단일 사슬 가변 단편을 위한 재료 및 방법
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
EP4021579A1
(en)
|
2019-08-30 |
2022-07-06 |
Qilu Puget Sound Biotherapeutics Corporation |
Anti-cd20 antibodies, anti-cd37 antibodies, and mixtures thereof
|
GB201913079D0
(en)
|
2019-09-11 |
2019-10-23 |
Hummingbird Bioscience Holdings Pte Ltd |
Treatment and prevention of cancer using her3 antigen-binding molecules
|
TW202118512A
(zh)
|
2019-09-12 |
2021-05-16 |
美商建南德克公司 |
治療狼瘡性腎炎之組成物及方法
|
BR112022002351A2
(pt)
|
2019-09-16 |
2022-07-19 |
Surface Oncology Inc |
Composições e métodos de anticorpo anti-cd39
|
BR112022004972A2
(pt)
|
2019-09-18 |
2022-06-28 |
Genentech Inc |
Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
|
RU2753282C2
(ru)
|
2019-09-19 |
2021-08-12 |
Закрытое Акционерное Общество "Биокад" |
ИММУНОЦИТОКИН, ВКЛЮЧАЮЩИЙ ГЕТЕРОДИМЕРНЫЙ БЕЛКОВЫЙ КОМПЛЕКС НА ОСНОВЕ IL-15/IL-15Rα, И ЕГО ПРИМЕНЕНИЕ
|
US20220348687A1
(en)
|
2019-09-20 |
2022-11-03 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
US20220372147A1
(en)
|
2019-09-25 |
2022-11-24 |
Universität Stuttgart |
Binding modules comprising modified ehd2 domains
|
EP4034559A1
(en)
|
2019-09-25 |
2022-08-03 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
EP4034245A1
(en)
|
2019-09-25 |
2022-08-03 |
Universität Stuttgart |
Trivalent binding molecules
|
EP4036116A4
(en)
|
2019-09-27 |
2024-01-24 |
Nanjing Genscript Biotech Co Ltd |
ANTI-VHH DOMAIN ANTIBODIES AND USE THEREOF
|
EP4036114A4
(en)
|
2019-09-29 |
2023-11-08 |
Jacobio Pharmaceuticals Co., Ltd. |
LIFE-SPECIFIC BINDING MOLECULE AND USE THEREOF
|
CN115916233A
(zh)
|
2019-10-03 |
2023-04-04 |
Xencor股份有限公司 |
靶向IL-12异源二聚体Fc融合蛋白
|
TW202128757A
(zh)
|
2019-10-11 |
2021-08-01 |
美商建南德克公司 |
具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
|
EP4045917A1
(en)
*
|
2019-10-14 |
2022-08-24 |
Pierce Biotechnology, Inc. |
Peptide purification formulations and methods
|
TW202122114A
(zh)
|
2019-10-18 |
2021-06-16 |
美商建南德克公司 |
使用抗CD79b 免疫偶聯物治療彌漫性大B 細胞淋巴瘤的方法
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
CN114786679A
(zh)
|
2019-10-21 |
2022-07-22 |
诺华股份有限公司 |
具有维奈托克和tim-3抑制剂的组合疗法
|
WO2021084104A1
(en)
|
2019-10-30 |
2021-05-06 |
Bioinvent International Ab |
Tetravalent antibody molecules
|
JP2022553830A
(ja)
|
2019-11-05 |
2022-12-26 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
N末端scFv多重特異性結合分子
|
KR20220093323A
(ko)
|
2019-11-05 |
2022-07-05 |
에프. 호프만-라 로슈 아게 |
HLA-A2/WT1 x CD3 이중특이적 항체 및 레날리도미드를 이용한 암의 치료
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
WO2021097223A2
(en)
|
2019-11-15 |
2021-05-20 |
Genzyme Corporation |
Biparatopic cd73 antibodies
|
AU2020384917A1
(en)
|
2019-11-15 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Prevention of visible particle formation in aqueous protein solutions
|
IL293046A
(en)
|
2019-11-18 |
2022-07-01 |
Janssen Biotech Inc |
Anti-cd79 chimeric antigen receptors, car-t cells and uses thereof
|
US20230047631A1
(en)
|
2019-11-19 |
2023-02-16 |
Amgen Inc. |
Novel multispecific antibody format
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
BR112022010096A2
(pt)
|
2019-12-06 |
2022-09-06 |
CSL Behring Lengnau AG |
Composições estáveis de multímeros fc
|
EP4073119A1
(en)
|
2019-12-12 |
2022-10-19 |
Alector LLC |
Methods of use of anti-cd33 antibodies
|
AU2020403145A1
(en)
|
2019-12-13 |
2022-07-07 |
Genentech, Inc. |
Anti-Ly6G6D antibodies and methods of use
|
US11702474B2
(en)
|
2019-12-17 |
2023-07-18 |
Pfizer Inc. |
Antibodies specific for CD47, PD-L1, and uses thereof
|
TW202136287A
(zh)
|
2019-12-17 |
2021-10-01 |
法商Ose免疫治療公司 |
包含il-7變體之雙官能分子
|
JP7296467B2
(ja)
|
2019-12-18 |
2023-06-22 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Hla-a2/mage-a4に結合する抗体
|
CN114867532A
(zh)
|
2019-12-18 |
2022-08-05 |
豪夫迈·罗氏有限公司 |
双特异性抗ccl2抗体
|
WO2021123173A1
(en)
|
2019-12-20 |
2021-06-24 |
F. Hoffmann-La Roche Ag |
Il-37 fusion proteins and uses thereof
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
CN115023444A
(zh)
|
2019-12-20 |
2022-09-06 |
再生元制药公司 |
新型il2激动剂及其使用方法
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
WO2021123902A1
(en)
|
2019-12-20 |
2021-06-24 |
Novartis Ag |
Combination of anti tim-3 antibody mbg453 and anti tgf-beta antibody nis793, with or without decitabine or the anti pd-1 antibody spartalizumab, for treating myelofibrosis and myelodysplastic syndrome
|
MX2022007746A
(es)
|
2019-12-23 |
2022-10-07 |
Genentech Inc |
Anticuerpos especificos de apolipoproteina l1 y metodos de uso.
|
AU2020415451A1
(en)
|
2019-12-23 |
2022-07-21 |
Soteria Biotherapeutics, Inc. |
Chemically induced association and dissociation of therapeutic Fc compositions and chemically induced dimerization of T cell engager with human serum albumin
|
CR20220357A
(es)
|
2019-12-27 |
2022-08-24 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti antígeno-4 asociado al linfocito t citotóxico (ctla-4) y uso del mismo
|
CN114930170A
(zh)
|
2020-01-02 |
2022-08-19 |
豪夫迈·罗氏有限公司 |
用于测定脑中的治疗性抗体量的方法
|
WO2021138498A1
(en)
|
2020-01-03 |
2021-07-08 |
Incyte Corporation |
Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
|
TW202135824A
(zh)
|
2020-01-03 |
2021-10-01 |
美商英塞特公司 |
包含a2a/a2b及pd-1/pd-l1抑制劑之組合療法
|
IL294436A
(en)
|
2020-01-03 |
2022-09-01 |
Incyte Corp |
Anti-cd73 antibodies and their uses
|
WO2021138407A2
(en)
|
2020-01-03 |
2021-07-08 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to cd33 and uses thereof
|
KR20220122628A
(ko)
|
2020-01-06 |
2022-09-02 |
백시넥스 인코포레이티드 |
항-ccr8 항체 및 이의 용도
|
TW202140552A
(zh)
|
2020-01-08 |
2021-11-01 |
比利時商阿根思公司 |
用於治療天皰瘡病症的方法
|
CA3164979A1
(en)
|
2020-01-09 |
2021-07-15 |
Jiangsu Hengrui Medicine Co., Ltd. |
New polypeptide complex
|
IL292780A
(en)
|
2020-01-09 |
2022-07-01 |
Hoffmann La Roche |
A new 4-1bbl trimer containing antigen-binding molecules
|
CN110818795B
(zh)
|
2020-01-10 |
2020-04-24 |
上海复宏汉霖生物技术股份有限公司 |
抗tigit抗体和使用方法
|
US20230076768A1
(en)
|
2020-01-14 |
2023-03-09 |
Synthekine, Inc. |
IL2 Orthologs and Methods of Use
|
JP2023510382A
(ja)
|
2020-01-15 |
2023-03-13 |
エフ. ホフマン-ラ ロシュ アーゲー |
組換えタンパク質製造プロセスから不純物を減少させる方法
|
EP4090365A1
(en)
|
2020-01-15 |
2022-11-23 |
Immatics Biotechnologies GmbH |
Antigen binding proteins specifically binding prame
|
US20210222244A1
(en)
|
2020-01-17 |
2021-07-22 |
Becton, Dickinson And Company |
Methods and compositions for single cell secretomics
|
IL293752A
(en)
|
2020-01-17 |
2022-08-01 |
Novartis Ag |
A combination containing a tim-3 inhibitor and a substance that causes hypomethylation for use in the treatment of myeloplastic syndrome or chronic myelomonocytic leukemia
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
BR112022014667A2
(pt)
|
2020-01-29 |
2022-09-20 |
Inhibrx Inc |
Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
|
US20230348624A1
(en)
|
2020-01-30 |
2023-11-02 |
Umoja Biopharma, Inc. |
Bispecific transduction enhancer
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
WO2021155916A1
(en)
|
2020-02-04 |
2021-08-12 |
BioNTech SE |
Treatment involving antigen vaccination and binding agents binding to pd-l1 and cd137
|
US20210277092A1
(en)
|
2020-02-11 |
2021-09-09 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
|
TW202144395A
(zh)
|
2020-02-12 |
2021-12-01 |
日商中外製藥股份有限公司 |
用於癌症之治療的抗cd137抗原結合分子
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
CN115768463A
(zh)
|
2020-02-21 |
2023-03-07 |
哈普恩治疗公司 |
Flt3结合蛋白及使用方法
|
US20230256017A1
(en)
|
2020-02-27 |
2023-08-17 |
Jennifer Brogdon |
Methods of making chimeric antigen receptor-expressing cells
|
CA3173737A1
(en)
|
2020-02-27 |
2021-09-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
CA3169910A1
(en)
|
2020-02-28 |
2021-09-02 |
Shanghai Henlius Biotech, Inc. |
Anti-cd137 constructs, multispecific antibody and uses thereof
|
JP2023516945A
(ja)
|
2020-02-28 |
2023-04-21 |
上海復宏漢霖生物技術股▲フン▼有限公司 |
抗cd137コンストラクト及びその使用
|
CN111269326A
(zh)
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
EP3875478A1
(en)
|
2020-03-05 |
2021-09-08 |
Canvax Biotech, S.L. |
Novel non-immunogenic chimeric antigen receptors and uses thereof
|
EP4114860A1
(en)
|
2020-03-06 |
2023-01-11 |
Go Therapeutics, Inc. |
Anti-glyco-cd44 antibodies and their uses
|
US20210275666A1
(en)
|
2020-03-06 |
2021-09-09 |
Incyte Corporation |
Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
NPM1c陽性がんの免疫療法のための組成物および方法
|
CR20220461A
(es)
|
2020-03-13 |
2022-10-21 |
Genentech Inc |
Anticuerpos anti-interleucina-33 y usos de estos
|
IL302349A
(en)
|
2020-03-13 |
2023-06-01 |
Janssen Biotech Inc |
Materials and methods for binding SIGLEC-3/CD33
|
BR112022015572A2
(pt)
|
2020-03-18 |
2022-09-27 |
Genmab As |
Anticorpo, composição, composição farmacêutica, anticorpo para uso como um medicamento, métodos para tratar uma doença e para produzir um anticorpo, ácido nucléico, um ou mais ácidos nucléicos, célula, e, kit de partes
|
KR20220156575A
(ko)
|
2020-03-19 |
2022-11-25 |
제넨테크, 인크. |
동종형 선택적 항-tgf-베타 항체 및 이용 방법
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
CA3169967A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Tie2-binding agents and methods of use
|
US11345741B2
(en)
|
2020-03-26 |
2022-05-31 |
Vanderbilt University |
Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
|
WO2021195385A1
(en)
|
2020-03-26 |
2021-09-30 |
Vanderbilt University |
HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-GoV-2)
|
CN115315512A
(zh)
|
2020-03-26 |
2022-11-08 |
基因泰克公司 |
具有降低的宿主细胞蛋白质的经修饰的哺乳动物细胞
|
WO2021195513A1
(en)
|
2020-03-27 |
2021-09-30 |
Novartis Ag |
Bispecific combination therapy for treating proliferative diseases and autoimmune disorders
|
TW202204407A
(zh)
|
2020-03-30 |
2022-02-01 |
國立大學法人三重大學 |
雙特異性抗體
|
AU2021250381A1
(en)
|
2020-03-31 |
2022-10-06 |
Chugai Seiyaku Kabushiki Kaisha |
Method for producing multispecific antigen-binding molecules
|
AR121706A1
(es)
|
2020-04-01 |
2022-06-29 |
Hoffmann La Roche |
Moléculas de unión a antígeno biespecíficas dirigidas a ox40 y fap
|
US20230152280A1
(en)
|
2020-04-02 |
2023-05-18 |
Chugai Seiyaku Kabushiki Kaisha |
Analysis method for impurity molecules in composition containing multi-specific antigen-binding molecules
|
CN115698717A
(zh)
|
2020-04-03 |
2023-02-03 |
基因泰克公司 |
癌症的治疗和诊断方法
|
WO2021207669A1
(en)
|
2020-04-10 |
2021-10-14 |
Cytomx Therapeutics, Inc. |
Activatable cytokine constructs and related compositions and methods
|
WO2021207662A1
(en)
|
2020-04-10 |
2021-10-14 |
Genentech, Inc. |
Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
|
CA3180222A1
(en)
|
2020-04-15 |
2021-10-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
CN115485028A
(zh)
|
2020-04-15 |
2022-12-16 |
豪夫迈·罗氏有限公司 |
免疫缀合物
|
GB202005879D0
(en)
|
2020-04-22 |
2020-06-03 |
Petmedix Ltd |
Heterodimeric proteins
|
IL297495A
(en)
|
2020-04-22 |
2022-12-01 |
Dragonfly Therapeutics Inc |
Dosing regimen, formulation and manufacturing process for fc fusion heterodimeric proteins
|
PE20230078A1
(es)
|
2020-04-24 |
2023-01-11 |
Hoffmann La Roche |
Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados
|
JP2023523011A
(ja)
|
2020-04-24 |
2023-06-01 |
マレンゴ・セラピューティクス,インコーポレーテッド |
T細胞関連のがん細胞に結合する多機能性分子およびその使用
|
WO2021217051A1
(en)
|
2020-04-24 |
2021-10-28 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates
|
WO2021222935A2
(en)
|
2020-04-28 |
2021-11-04 |
The Rockefeller University |
Neutralizing anti-sars-cov-2 antibodies and methods of use thereof
|
WO2021222167A1
(en)
|
2020-04-28 |
2021-11-04 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
MX2022013453A
(es)
|
2020-04-29 |
2022-11-16 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
|
CA3214992A1
(en)
|
2020-04-29 |
2021-11-04 |
Teneobio, Inc. |
Multispecific heavy chain antibodies with modified heavy chain constant regions
|
WO2021222552A1
(en)
|
2020-04-30 |
2021-11-04 |
Celgene Corporation |
Methods of treating cytokine-related adverse events
|
WO2021222533A1
(en)
|
2020-04-30 |
2021-11-04 |
Procisedx Inc. |
Methods of detecting antibodies to sars-cov-2
|
CN116096758A
(zh)
|
2020-05-01 |
2023-05-09 |
诺华股份有限公司 |
工程化免疫球蛋白
|
EP4146283A1
(en)
|
2020-05-03 |
2023-03-15 |
Levena (Suzhou) Biopharma Co., Ltd. |
Antibody-drug conjugates (adcs) comprising an anti-trop-2 antibody, compositions comprising such adcs, as well as methods of making and using the same
|
IL297980A
(en)
|
2020-05-08 |
2023-01-01 |
Alpine Immune Sciences Inc |
Immunomodulatory proteins that inhibit april and baff and methods of using them
|
IL298038A
(en)
|
2020-05-11 |
2023-01-01 |
Hoffmann La Roche |
Combined treatment with modified pbmcs and an immune couple
|
US11673930B2
(en)
|
2020-05-12 |
2023-06-13 |
Regeneran Pharmaceuticals, Inc. |
IL10 agonists and methods of use thereof
|
KR20230022411A
(ko)
|
2020-05-12 |
2023-02-15 |
라이엘 이뮤노파마, 인크. |
키메라 항원 수용체 스페이서
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
WO2021231969A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind msln and cd3
|
JP2023520249A
(ja)
|
2020-05-15 |
2023-05-16 |
エフ. ホフマン-ラ ロシュ アーゲー |
非経口タンパク質溶液中の可視粒子形成の防止方法
|
WO2021229103A2
(en)
|
2020-05-15 |
2021-11-18 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2021236658A1
(en)
|
2020-05-19 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
CN115605185A
(zh)
|
2020-05-19 |
2023-01-13 |
豪夫迈·罗氏有限公司(Ch) |
螯合剂用于防止胃肠外蛋白质溶液中形成可见颗粒的用途
|
CN111849910B
(zh)
|
2020-05-27 |
2021-06-15 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
MX2022014938A
(es)
|
2020-05-27 |
2023-03-06 |
Janssen Biotech Inc |
Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
|
EP4157461A1
(en)
|
2020-05-29 |
2023-04-05 |
23Andme, Inc. |
Anti-cd200r1 antibodies and methods of use thereof
|
WO2021246720A1
(ko)
|
2020-06-01 |
2021-12-09 |
머스트바이오 주식회사 |
이중특이 항체 또는 그의 항원-결합 단편 및 이를 제조하는 방법
|
CR20220659A
(es)
|
2020-06-08 |
2023-08-21 |
Hoffmann La Roche |
Anticuerpos anti-hbv y metodos de uso
|
KR20220166837A
(ko)
|
2020-06-11 |
2022-12-19 |
난징 바이오흐엥 바이오테크 씨오., 엘티디 |
Nk억제 분자를 발현하는 조작된 면역 세포 및 그 용도
|
WO2021252920A1
(en)
|
2020-06-11 |
2021-12-16 |
Novartis Ag |
Zbtb32 inhibitors and uses thereof
|
CN115698719A
(zh)
|
2020-06-12 |
2023-02-03 |
基因泰克公司 |
用于癌症免疫疗法的方法和组合物
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
EP4168446A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3 and folr1
|
WO2021255137A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Protease-activated t cell bispecific antibodies
|
KR20230025783A
(ko)
|
2020-06-19 |
2023-02-23 |
에프. 호프만-라 로슈 아게 |
면역 활성화 Fc 도메인 결합 분자
|
TWI811703B
(zh)
|
2020-06-19 |
2023-08-11 |
瑞士商赫孚孟拉羅股份公司 |
與cd3及cd19結合之抗體
|
EP4168456A1
(en)
|
2020-06-19 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Antibodies binding to cd3
|
PE20230435A1
(es)
|
2020-06-19 |
2023-03-08 |
Chugai Pharmaceutical Co Ltd |
Moleculas de union al antigeno anti-celulas t para usarse en combinacion con un inhibidor de angiogenesis
|
WO2021255146A1
(en)
|
2020-06-19 |
2021-12-23 |
F. Hoffmann-La Roche Ag |
Antibodies binding to cd3 and cea
|
JP2023531222A
(ja)
|
2020-06-22 |
2023-07-21 |
アルミラル・ソシエダッド・アノニマ |
抗il-36抗体およびその使用方法
|
MX2022015795A
(es)
|
2020-06-23 |
2023-01-24 |
Hoffmann La Roche |
Moleculas agonistas de union al antigeno cd28 que se dirigen a her2.
|
JP2023531676A
(ja)
|
2020-06-23 |
2023-07-25 |
ノバルティス アーゲー |
3-(1-オキソイソインドリン-2-イル)ピぺリジン-2,6-ジオン誘導体を含む投与レジメン
|
CA3184747A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
WO2021260064A1
(en)
|
2020-06-25 |
2021-12-30 |
F. Hoffmann-La Roche Ag |
Anti-cd3/anti-cd28 bispecific antigen binding molecules
|
CA3165342A1
(en)
|
2020-06-29 |
2022-01-06 |
James Arthur Posada |
Treatment of sjogren's syndrome with nuclease fusion proteins
|
JP2023532764A
(ja)
|
2020-07-07 |
2023-07-31 |
エフ. ホフマン-ラ ロシュ アーゲー |
治療用タンパク質製剤の安定剤としての代替界面活性剤
|
IL298921A
(en)
|
2020-07-10 |
2023-02-01 |
Hoffmann La Roche |
Antibodies that bind to cancer cells and direct radionuclides to said cells
|
AU2021307614A1
(en)
|
2020-07-15 |
2023-01-19 |
Bioheng Therapeutics Limited |
Engineered immune cell for allotransplantation
|
EP4182025A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
US20230303682A1
(en)
|
2020-07-17 |
2023-09-28 |
Genentech, Inc. |
Anti-Notch2 Antibodies and Methods of Use
|
WO2022016119A1
(en)
|
2020-07-17 |
2022-01-20 |
Simurx, Inc. |
Chimeric myd88 receptors for redirecting immunosuppressive signaling and related compositions and methods
|
TW202216215A
(zh)
|
2020-07-21 |
2022-05-01 |
美商建南德克公司 |
Brm降解之抗體結合化學誘導物及其方法
|
WO2022018178A1
(en)
|
2020-07-24 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Method for the expression of an antibody-multimer-fusion
|
WO2022026592A2
(en)
|
2020-07-28 |
2022-02-03 |
Celltas Bio, Inc. |
Antibody molecules to coronavirus and uses thereof
|
GB2597532A
(en)
|
2020-07-28 |
2022-02-02 |
Femtogenix Ltd |
Cytotoxic compounds
|
EP4188439A2
(en)
|
2020-07-29 |
2023-06-07 |
Janssen Biotech, Inc. |
Proteins comprising hla-g antigen binding domains and their uses
|
CN114057890A
(zh)
|
2020-07-31 |
2022-02-18 |
南京北恒生物科技有限公司 |
新型共刺激结构域及其用途
|
CA3190649A1
(en)
|
2020-07-31 |
2022-02-03 |
Chugai Seiyaku Kabushiki Kaisha |
Pharmaceutical composition comprising cell expressing chimeric receptor
|
JP2023536164A
(ja)
|
2020-08-03 |
2023-08-23 |
ノバルティス アーゲー |
ヘテロアリール置換3-(1-オキソイソインドリン-2-イル)ピペリジン-2,6-ジオン誘導体及びその使用
|
AU2021320233A1
(en)
|
2020-08-05 |
2023-03-23 |
Synthekine, Inc. |
IL10Ra binding molecules and methods of use
|
WO2022032006A2
(en)
|
2020-08-05 |
2022-02-10 |
Synthekine, Inc. |
Il2rb binding molecules and methods of use
|
EP4192877A1
(en)
|
2020-08-05 |
2023-06-14 |
Synthekine, Inc. |
Il2rb/il2rg synthetic cytokines
|
MX2023001490A
(es)
|
2020-08-05 |
2023-04-27 |
Synthekine Inc |
Moleculas de union a il27r\03b1 y metodos de uso.
|
CA3187061A1
(en)
|
2020-08-06 |
2022-02-10 |
Karsten Beckmann |
Binding agents for coronavirus s protein
|
CN112063588A
(zh)
|
2020-08-13 |
2020-12-11 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
CA3192204A1
(en)
|
2020-08-19 |
2022-02-24 |
Xencor, Inc. |
Anti-cd28 and/or anti-b7h3 compositions
|
JP2023538118A
(ja)
|
2020-08-21 |
2023-09-06 |
ノバルティス アーゲー |
Car発現細胞のインビボ生成のための組成物及び方法
|
CN116761818A
(zh)
|
2020-08-26 |
2023-09-15 |
马伦戈治疗公司 |
检测trbc1或trbc2的方法
|
GB2616128A
(en)
|
2020-08-26 |
2023-08-30 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKp30 and uses thereof
|
CA3190755A1
(en)
|
2020-08-26 |
2022-03-03 |
Andreas Loew |
Multifunctional molecules that bind to calreticulin and uses thereof
|
WO2022044248A1
(ja)
|
2020-08-28 |
2022-03-03 |
中外製薬株式会社 |
ヘテロ二量体Fcポリペプチド
|
TW202227625A
(zh)
|
2020-08-28 |
2022-07-16 |
美商建南德克公司 |
宿主細胞蛋白質之CRISPR/Cas9多重剔除
|
WO2022043557A1
(en)
|
2020-08-31 |
2022-03-03 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204020A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
JP2023542049A
(ja)
|
2020-09-01 |
2023-10-04 |
武田薬品工業株式会社 |
インターロイキン-2ムテイン及びその使用
|
WO2022049061A1
(en)
|
2020-09-01 |
2022-03-10 |
Merck Patent Gmbh |
Nkp30 binders
|
JP2023541858A
(ja)
|
2020-09-10 |
2023-10-04 |
ジェンマブ エー/エス |
慢性リンパ球性白血病を治療するためのcd3及びcd20に対する二重特異性抗体
|
CN114163532A
(zh)
|
2020-09-10 |
2022-03-11 |
南京北恒生物科技有限公司 |
包含新型共刺激结构域的嵌合抗原受体及其用途
|
BR112023004321A2
(pt)
|
2020-09-10 |
2023-04-04 |
Genmab As |
Método para tratar linfoma de célula b grande difusa em um sujeito humano
|
KR20230066386A
(ko)
|
2020-09-11 |
2023-05-15 |
리제너론 파마슈티칼스 인코포레이티드 |
항원 특이적 항체의 확인 및 제조
|
AU2021342284A1
(en)
|
2020-09-14 |
2023-04-20 |
Sutro Biopharma, Inc. |
Method for large scale production of antibodies using a cell-free protein synthesis system
|
AU2021342566A1
(en)
|
2020-09-21 |
2023-03-02 |
Genentech, Inc. |
Purification of multispecific antibodies
|
BR112023005399A2
(pt)
|
2020-09-24 |
2023-04-25 |
Hoffmann La Roche |
Anticorpo biespecífico, uso de um anticorpo biespecífico, métodos para tratamento de uma doença em um indivíduo e para prevenir ou mitigar um efeito adverso, inibidor de tirosina quinase, uso de um inibidor de tirosina quinase e invenção
|
CA3195257A1
(en)
|
2020-09-24 |
2022-03-31 |
F. Hoffmann-La Roche Ag |
Mammalian cell lines with gene knockout
|
AU2021353368A1
(en)
|
2020-09-29 |
2023-05-25 |
Innovent Biologics (Singapore) Pte. Ltd. |
Anti-cd3 antibody and uses thereof
|
CA3193952A1
(en)
|
2020-10-05 |
2022-04-14 |
Bernard Martin Fine |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
IL300314A
(en)
|
2020-10-08 |
2023-04-01 |
Affimed Gmbh |
Coupling materials with triple specificity
|
EP4228693A1
(en)
|
2020-10-13 |
2023-08-23 |
Janssen Biotech, Inc. |
Bioengineered t cell mediated immunity, materials and other methods for modulating cluster of differentiation iv &/or viii
|
US20220135684A1
(en)
|
2020-10-14 |
2022-05-05 |
Xencor, Inc. |
Bispecific antibodies that bind pd-l1 and cd28
|
US11440952B2
(en)
|
2020-10-16 |
2022-09-13 |
Invisishield Technologies Ltd. |
Compositions for preventing or treating viral and other microbial infections
|
CN116670169A
(zh)
|
2020-10-16 |
2023-08-29 |
魁尔斯弗生物治疗股份有限公司 |
与pd-l1结合的多特异性结合化合物
|
JP2023545566A
(ja)
|
2020-10-20 |
2023-10-30 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1軸結合アンタゴニストとlrrk2阻害剤との併用療法
|
AR123855A1
(es)
|
2020-10-20 |
2023-01-18 |
Genentech Inc |
Anticuerpos anti-mertk conjugados con peg y métodos de uso
|
WO2022084915A1
(en)
|
2020-10-22 |
2022-04-28 |
Janssen Biotech, Inc. |
Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
|
WO2022090439A1
(en)
|
2020-10-30 |
2022-05-05 |
F. Hoffmann-La Roche Ag |
TREATMENT OF CANCER USING A CEA CD3 BISPECIFIC ANTIBODY AND A TGFβ SIGNALING INHIBITOR
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
EP4237451A1
(en)
|
2020-11-02 |
2023-09-06 |
Hummingbird Bioscience Pte. Ltd. |
Bcma/taci antigen-binding molecules
|
CN114525259A
(zh)
|
2020-11-03 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
CN112300282A
(zh)
|
2020-11-03 |
2021-02-02 |
南京北恒生物科技有限公司 |
靶向cd7的人源化抗体及其用途
|
US11919945B2
(en)
|
2020-11-04 |
2024-03-05 |
The Rockefeller University |
Neutralizing anti-SARS-CoV-2 antibodies
|
WO2022097090A1
(en)
|
2020-11-05 |
2022-05-12 |
Novartis Ag |
Dosing regimen for combination therapies with multispecific antibodies targeting b-cell maturation antigen and gamma secretase inhibitors
|
JP2023547499A
(ja)
|
2020-11-06 |
2023-11-10 |
ノバルティス アーゲー |
抗体Fc変異体
|
MX2023005234A
(es)
|
2020-11-06 |
2023-05-18 |
Novartis Ag |
Terapia de combinacion de agente anti-cd19 y agente de direccionamiento a celulas b para el tratamiento de neoplasias malignas de celulas b.
|
WO2022099090A1
(en)
|
2020-11-06 |
2022-05-12 |
Xencor, Inc. |
Heterodimeric antibodies that bind tgfbrii
|
WO2022095970A1
(zh)
|
2020-11-06 |
2022-05-12 |
百奥泰生物制药股份有限公司 |
双特异抗体及其应用
|
EP4240491A1
(en)
|
2020-11-06 |
2023-09-13 |
Novartis AG |
Cd19 binding molecules and uses thereof
|
KR20230107235A
(ko)
|
2020-11-10 |
2023-07-14 |
에프. 호프만-라 로슈 아게 |
T 세포 관여제 관련 부정적인 효과의 예방 또는 완화
|
US20240010748A1
(en)
|
2020-11-10 |
2024-01-11 |
Shanghai Qilu Pharmaceutical Research And Development Centre Ltd. |
Bispecific antibody for claudin 18a2 and cd3 and application of bispecific antibody
|
US20240033358A1
(en)
|
2020-11-13 |
2024-02-01 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
EP4244254A1
(en)
|
2020-11-16 |
2023-09-20 |
F. Hoffmann-La Roche AG |
Combination therapy with fap-targeted cd40 agonists
|
AU2021376837A1
(en)
|
2020-11-16 |
2023-06-15 |
F. Hoffmann-La Roche Ag |
Fab high mannose glycoforms
|
CN114524876A
(zh)
|
2020-11-23 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向nkg2a的抗体及其用途
|
US20220241411A1
(en)
|
2020-11-30 |
2022-08-04 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
WO2022115120A1
(en)
|
2020-11-30 |
2022-06-02 |
Incyte Corporation |
Combination therapy with an anti-cd19 antibody and parsaclisib
|
AU2021390501A1
(en)
|
2020-12-01 |
2023-06-29 |
Aptevo Research And Development Llc |
Heterodimeric psma and cd3-binding bispecific antibodies
|
US20240101681A1
(en)
|
2020-12-02 |
2024-03-28 |
Alector Llc |
Methods of use of anti-sortilin antibodies
|
PE20232045A1
(es)
|
2020-12-04 |
2023-12-27 |
Hoffmann La Roche |
Polipeptidos de interleucina-2 mutante dependientes del ph
|
CN116802211A
(zh)
|
2020-12-07 |
2023-09-22 |
Ucb生物制药有限责任公司 |
针对白介素-22的抗体
|
US20240067758A1
(en)
|
2020-12-07 |
2024-02-29 |
UCB Biopharma SRL |
Multi-specific antibodies and antibody combinations
|
AU2021399841A1
(en)
|
2020-12-17 |
2023-07-06 |
F. Hoffmann-La Roche Ag |
Anti-hla-g antibodies and use thereof
|
JP2023554097A
(ja)
|
2020-12-17 |
2023-12-26 |
オーエスイー・イミュノセラピューティクス |
二機能性抗pd1/il-7分子
|
JP2023553692A
(ja)
|
2020-12-18 |
2023-12-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
標的治療のための前駆体タンパク質及びキット
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
AU2021410655A1
(en)
|
2020-12-23 |
2023-06-29 |
Regeneron Pharmaceuticals, Inc. |
Nucleic acids encoding anchor modified antibodies and uses thereof
|
US20220227867A1
(en)
|
2020-12-24 |
2022-07-21 |
Xencor, Inc. |
ICOS TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND ICOS ANTIGEN BINDING DOMAINS
|
WO2022147092A1
(en)
|
2020-12-29 |
2022-07-07 |
Incyte Corporation |
Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies
|
JP2024503826A
(ja)
|
2021-01-06 |
2024-01-29 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd1-lag3二重特異性抗体及びcd20 t細胞二重特異性抗体を用いる併用療法
|
EP4274616A2
(en)
|
2021-01-11 |
2023-11-15 |
Synthekine, Inc. |
Compositions and methods related to receptor pairing
|
WO2022148853A1
(en)
|
2021-01-11 |
2022-07-14 |
F. Hoffmann-La Roche Ag |
Immunoconjugates
|
EP4257610A1
(en)
|
2021-01-12 |
2023-10-11 |
Bioheng Therapeutics Limited |
Ror1-targeting antibody and use thereof
|
CA3206466A1
(en)
|
2021-01-12 |
2022-07-21 |
Christian Klein |
Split antibodies which bind to cancer cells and target radionuclides to said cells
|
EP4279510A1
(en)
|
2021-01-12 |
2023-11-22 |
SG Medical Inc. |
Novel antibody to cd55 and uses thereof
|
US20240076346A1
(en)
*
|
2021-01-13 |
2024-03-07 |
Kahr Medical Ltd. |
Type i membrane proteins heterodimers and methods of use thereof
|
WO2022152701A1
(en)
|
2021-01-13 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Combination therapy
|
JP2024505636A
(ja)
|
2021-01-15 |
2024-02-07 |
ザ ロックフェラー ユニバーシティー |
抗sars-cov-2中和抗体
|
JP2024503724A
(ja)
|
2021-01-20 |
2024-01-26 |
オンコレスポンス,インク. |
免疫調節抗体およびその使用
|
EP4281484A1
(en)
|
2021-01-22 |
2023-11-29 |
Bionecure Therapeutics, Inc. |
Anti-her-2/trop-2 constructs and uses thereof
|
WO2022162587A1
(en)
|
2021-01-27 |
2022-08-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
EP4284510A1
(en)
|
2021-01-29 |
2023-12-06 |
Novartis AG |
Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス, インコーポレイテッド |
結合剤およびそれを使用する方法
|
JP2024509695A
(ja)
|
2021-02-03 |
2024-03-05 |
ジェネンテック, インコーポレイテッド |
多重特異性結合タンパク質分解プラットフォームおよび使用方法
|
CN114853900A
(zh)
|
2021-02-03 |
2022-08-05 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
WO2022170063A1
(en)
|
2021-02-05 |
2022-08-11 |
Salubris Biotherapeutics, Inc. |
Il-15 fusion proteins and methods of making and using same
|
AU2022224508A1
(en)
|
2021-02-16 |
2023-10-05 |
Janssen Biotech, Inc. |
Materials and methods for enhanced linker targeting
|
JP2024512240A
(ja)
|
2021-02-18 |
2024-03-19 |
エフ. ホフマン-ラ ロシュ アーゲー |
複雑な多段階の抗体相互作用を解明するための方法
|
KR20220118961A
(ko)
|
2021-02-19 |
2022-08-26 |
(주)샤페론 |
Cd47에 대한 단일 도메인 항체 및 이의 용도
|
EP4296283A1
(en)
|
2021-02-19 |
2023-12-27 |
SHAPERON Inc. |
Single domain antibody against pd-l1 and use thereof
|
US20230022654A1
(en)
|
2021-02-25 |
2023-01-26 |
Lyell Immunopharma, Inc. |
Ror1 targeting chimeric antigen receptor
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
JP2024509169A
(ja)
|
2021-03-03 |
2024-02-29 |
ソレント・セラピューティクス・インコーポレイテッド |
抗bcma抗体を含む抗体-薬物コンジュゲート
|
JP2024512324A
(ja)
|
2021-03-05 |
2024-03-19 |
ジーオー セラピューティクス,インコーポレイテッド |
抗グリコcd44抗体およびその使用
|
KR20230156051A
(ko)
|
2021-03-09 |
2023-11-13 |
에프. 호프만-라 로슈 아게 |
Pd-1-표적화 il-2 변이체 면역접합체 및 fap/4-1bb 결합 분자의 병용 요법
|
IL305736A
(en)
|
2021-03-09 |
2023-11-01 |
Xencor Inc |
Heterodimeric antibodies that bind CD3 and CLDN6
|
JP2024512382A
(ja)
|
2021-03-09 |
2024-03-19 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
Pd-1標的化il-2バリアント免疫コンジュゲートと抗tyrp1/抗cd3二重特異性抗体の併用療法
|
TW202246357A
(zh)
|
2021-03-09 |
2022-12-01 |
加拿大商康爾義明生物製藥公司 |
雙功能同源二聚體抗PD-1及IL-15/IL-15Rα融合蛋白及其用途
|
EP4305065A1
(en)
|
2021-03-10 |
2024-01-17 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
EP4305062A1
(en)
|
2021-03-12 |
2024-01-17 |
Janssen Biotech, Inc. |
Method of treating psoriatic arthritis patients with inadequate response to tnf therapy with anti-il23 specific antibody
|
WO2022192647A1
(en)
|
2021-03-12 |
2022-09-15 |
Genentech, Inc. |
Anti-klk7 antibodies, anti-klk5 antibodies, multispecific anti-klk5/klk7 antibodies, and methods of use
|
IL305802A
(en)
|
2021-03-12 |
2023-11-01 |
Janssen Biotech Inc |
A safe and effective method for the treatment of rheumatoid arthritis with a specific anti-IL23 antibody
|
WO2022198192A1
(en)
|
2021-03-15 |
2022-09-22 |
Genentech, Inc. |
Compositions and methods of treating lupus nephritis
|
JP2024511387A
(ja)
|
2021-03-16 |
2024-03-13 |
シートムエックス セラピューティクス,インコーポレイテッド |
マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
|
JP2024512002A
(ja)
|
2021-03-18 |
2024-03-18 |
アレクトル エルエルシー |
抗tmem106b抗体、及び、その使用方法
|
WO2022197877A1
(en)
|
2021-03-19 |
2022-09-22 |
Genentech, Inc. |
Methods and compositions for time delayed bio-orthogonal release of cytotoxic agents
|
JP2024511137A
(ja)
|
2021-03-22 |
2024-03-12 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
JP2024512574A
(ja)
|
2021-03-22 |
2024-03-19 |
ノビミューン エスアー |
Cd47およびpd-l1を標的とする二重特異性抗体ならびにその使用方法
|
WO2022204274A1
(en)
|
2021-03-23 |
2022-09-29 |
Alector Llc |
Anti-tmem106b antibodies for treating and preventing coronavirus infections
|
CA3214259A1
(en)
|
2021-03-24 |
2022-09-29 |
Janssen Biotech, Inc. |
Antibody targeting cd22 and cd79b
|
JP2024510777A
(ja)
|
2021-03-24 |
2024-03-11 |
ヤンセン バイオテツク,インコーポレーテツド |
Cd3抗原結合ドメインを含むタンパク質及びその使用
|
KR20230162793A
(ko)
|
2021-03-26 |
2023-11-28 |
얀센 바이오테크 인코포레이티드 |
쌍 나선형 필라멘트 타우에 대한 인간화 항체 및 이의 용도
|
BR112023017510A2
(pt)
|
2021-03-29 |
2023-10-10 |
Daiichi Sankyo Co Ltd |
Molécula multiespecífica estável e uso da mesma
|
WO2022206872A1
(zh)
|
2021-03-31 |
2022-10-06 |
江苏恒瑞医药股份有限公司 |
截短的taci多肽及其融合蛋白和用途
|
AR125236A1
(es)
|
2021-03-31 |
2023-06-28 |
Hoffmann La Roche |
Purificación de anticuerpos por cromatografía de modo mixto
|
TW202304994A
(zh)
|
2021-04-02 |
2023-02-01 |
美商泰尼歐生物公司 |
促效性抗il-2r抗體及使用方法
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
JP2024513474A
(ja)
|
2021-04-09 |
2024-03-25 |
エフ. ホフマン-ラ ロシュ アーゲー |
異種ポリペプチドを発現する細胞クローンを選択するための方法
|
EP4320155A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
New scaffold for bifunctional molecules with improved properties
|
EP4320156A1
(en)
|
2021-04-09 |
2024-02-14 |
Ose Immunotherapeutics |
Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains
|
EP4319820A1
(en)
|
2021-04-10 |
2024-02-14 |
Profoundbio Us Co. |
Folr1 binding agents, conjugates thereof and methods of using the same
|
AU2022258552A1
(en)
|
2021-04-12 |
2023-10-19 |
Acm Biolabs Pte Ltd |
Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
|
EP4322938A1
(en)
|
2021-04-14 |
2024-02-21 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
New method to improve nk cells cytotoxicity
|
WO2022219076A1
(en)
|
2021-04-14 |
2022-10-20 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to improve the anti-tumoral activity of macrophages
|
AR125344A1
(es)
|
2021-04-15 |
2023-07-05 |
Chugai Pharmaceutical Co Ltd |
Anticuerpo anti-c1s
|
EP4326855A1
(en)
|
2021-04-19 |
2024-02-28 |
Genentech, Inc. |
Modified mammalian cells
|
WO2022225329A1
(ko)
|
2021-04-20 |
2022-10-27 |
고려대학교 산학협력단 |
향상된 암세포 사멸효능을 갖는 비대칭 항체
|
CA3217520A1
(en)
|
2021-04-22 |
2022-10-27 |
Guangdong Fapon Biopharma Inc. |
Bispecific multifunctional fusion polypeptide
|
WO2022226317A1
(en)
|
2021-04-23 |
2022-10-27 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
AR125468A1
(es)
|
2021-04-27 |
2023-07-19 |
Novartis Ag |
Sistema de producción de vectores virales
|
IL307821A
(en)
|
2021-04-30 |
2023-12-01 |
Hoffmann La Roche |
Dosage for treatment with BISPIFIC ANTI-CD20/ANTI-CD3 antibody
|
CN117321078A
(zh)
|
2021-04-30 |
2023-12-29 |
豪夫迈·罗氏有限公司 |
针对用抗cd20/抗cd3双特异性抗体和抗cd79b抗体药物缀合物进行组合治疗的给药
|
AR125732A1
(es)
|
2021-05-03 |
2023-08-09 |
UCB Biopharma SRL |
Anticuerpos anti-trem1
|
CN117597365A
(zh)
|
2021-05-04 |
2024-02-23 |
再生元制药公司 |
多特异性fgf21受体激动剂及其应用
|
TW202307007A
(zh)
|
2021-05-04 |
2023-02-16 |
美商再生元醫藥公司 |
多特異性fgf21受體促效劑及其等用途
|
AU2022269828A1
(en)
|
2021-05-05 |
2023-11-23 |
Immatics Biotechnologies Gmbh |
Bma031 antigen binding polypeptides
|
TW202309071A
(zh)
|
2021-05-05 |
2023-03-01 |
德商英麥提克生物技術股份有限公司 |
特異性結合prame之抗原結合蛋白
|
WO2022235867A2
(en)
|
2021-05-06 |
2022-11-10 |
The Rockefeller University |
Neutralizing anti-sars- cov-2 antibodies and methods of use thereof
|
IL308336A
(en)
|
2021-05-07 |
2024-01-01 |
Alpine Immune Sciences Inc |
Methods of dosing and treatment with TACI-FC modulatory fusion protein
|
CN117396509A
(zh)
|
2021-05-07 |
2024-01-12 |
健玛保 |
包含结合b7h4和cd3的双特异性抗体的药物组合物
|
EP4334348A1
(en)
|
2021-05-07 |
2024-03-13 |
Surface Oncology, LLC |
Anti-il-27 antibodies and uses thereof
|
WO2022238481A1
(en)
|
2021-05-11 |
2022-11-17 |
Modiquest B.V. |
Antibodies
|
WO2022241446A1
(en)
|
2021-05-12 |
2022-11-17 |
Genentech, Inc. |
Methods of using anti-cd79b immunoconjugates to treat diffuse large b-cell lymphoma
|
TW202306990A
(zh)
|
2021-05-12 |
2023-02-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
特異性結合rankl和ngf的抗原結合分子及其醫藥用途
|
CA3219388A1
(en)
|
2021-05-14 |
2022-11-17 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule
|
AU2022273303A1
(en)
|
2021-05-14 |
2023-11-02 |
Genentech, Inc. |
Agonists of trem2
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
WO2022243261A1
(en)
|
2021-05-19 |
2022-11-24 |
F. Hoffmann-La Roche Ag |
Agonistic cd40 antigen binding molecules targeting cea
|
WO2022246259A1
(en)
|
2021-05-21 |
2022-11-24 |
Genentech, Inc. |
Modified cells for the production of a recombinant product of interest
|
CN113278071B
(zh)
|
2021-05-27 |
2021-12-21 |
江苏荃信生物医药股份有限公司 |
抗人干扰素α受体1单克隆抗体及其应用
|
AR126009A1
(es)
|
2021-06-02 |
2023-08-30 |
Hoffmann La Roche |
Moléculas agonistas de unión al antígeno cd28 que se dirigen a epcam
|
WO2022255440A1
(en)
|
2021-06-04 |
2022-12-08 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-ddr2 antibodies and uses thereof
|
KR20240019109A
(ko)
|
2021-06-09 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
암의 치료에 이용하기 위한 특정 braf 억제제(패러독스 브레이크) 및 pd-1 축 결합 길항제의 조합물
|
WO2022263357A1
(en)
|
2021-06-14 |
2022-12-22 |
Argenx Iip Bv |
Anti-il-9 antibodies and methods of use thereof
|
WO2022262959A1
(en)
|
2021-06-15 |
2022-12-22 |
Astellas Pharma Europe Bv |
Bispecific binding agents binding to cldn18.2 and cd3
|
WO2022266219A1
(en)
|
2021-06-15 |
2022-12-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind claudin18.2 and cd3
|
EP4355783A1
(en)
|
2021-06-16 |
2024-04-24 |
Alector LLC |
Monovalent anti-mertk antibodies and methods of use thereof
|
CN117642426A
(zh)
|
2021-06-16 |
2024-03-01 |
艾莱克特有限责任公司 |
双特异性抗MerTK和抗PDL1抗体及其使用方法
|
WO2022263638A1
(en)
|
2021-06-17 |
2022-12-22 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2022263501A1
(en)
|
2021-06-18 |
2022-12-22 |
F. Hoffmann-La Roche Ag |
Bispecific anti-ccl2 antibodies
|
CA3219360A1
(en)
|
2021-06-22 |
2022-12-29 |
Novartis Ag |
Bispecific antibodies for use in treatment of hidradenitis suppurativa
|
CN117545776A
(zh)
|
2021-06-22 |
2024-02-09 |
默克专利股份公司 |
基于vhh的nkp30粘结剂
|
CA3220353A1
(en)
|
2021-06-25 |
2022-12-29 |
Chugai Seiyaku Kabushiki Kaisha |
Use of anti-ctla-4 antibody
|
CN117616123A
(zh)
|
2021-06-25 |
2024-02-27 |
中外制药株式会社 |
抗ctla-4抗体
|
WO2023274183A1
(zh)
|
2021-06-29 |
2023-01-05 |
江苏先声药业有限公司 |
Cd16抗体及其应用
|
KR20240028452A
(ko)
|
2021-07-02 |
2024-03-05 |
제넨테크, 인크. |
암을 치료하기 위한 방법 및 조성물
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023283345A1
(en)
|
2021-07-07 |
2023-01-12 |
Incyte Corporation |
Anti-b7-h4 antibodies and uses thereof
|
WO2023287663A1
(en)
|
2021-07-13 |
2023-01-19 |
Genentech, Inc. |
Multi-variate model for predicting cytokine release syndrome
|
US20230049152A1
(en)
|
2021-07-14 |
2023-02-16 |
Genentech, Inc. |
Anti-c-c motif chemokine receptor 8 (ccr8) antibodies and methods of use
|
AU2022309554A1
(en)
|
2021-07-14 |
2024-02-22 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Antigen-binding molecule specifically binding to hgfr and egfr, and pharmaceutical use thereof
|
CA3226924A1
(en)
|
2021-07-19 |
2023-01-26 |
Regeneron Pharmaceuticals, Inc. |
Il12 receptor agonists and methods of use thereof
|
WO2023004386A1
(en)
|
2021-07-22 |
2023-01-26 |
Genentech, Inc. |
Brain targeting compositions and methods of use thereof
|
CA3219606A1
(en)
|
2021-07-22 |
2023-01-26 |
F. Hoffmann-La Roche Ag |
Heterodimeric fc domain antibodies
|
CA3227537A1
(en)
|
2021-07-27 |
2023-02-02 |
Morphosys Ag |
Combinations of antigen binding molecules
|
US20230146665A1
(en)
|
2021-07-27 |
2023-05-11 |
Xencor, Inc. |
Il-18-fc fusion proteins
|
AU2022317820A1
(en)
|
2021-07-28 |
2023-12-14 |
F. Hoffmann-La Roche Ag |
Methods and compositions for treating cancer
|
AU2022320793A1
(en)
|
2021-07-28 |
2024-02-01 |
Genentech, Inc. |
Il15/il15r alpha heterodimeric fc-fusion proteins for the treatment of blood cancers
|
WO2023007023A1
(en)
|
2021-07-30 |
2023-02-02 |
Affimed Gmbh |
Duplexbodies
|
CN117897404A
(zh)
|
2021-08-02 |
2024-04-16 |
信达生物制药(苏州)有限公司 |
抗CD79b×CD3双特异性抗体及其用途
|
WO2023012147A1
(en)
|
2021-08-03 |
2023-02-09 |
F. Hoffmann-La Roche Ag |
Bispecific antibodies and methods of use
|
CA3228178A1
(en)
|
2021-08-05 |
2023-02-09 |
Go Therapeutics, Inc. |
Anti-glyco-muc4 antibodies and their uses
|
CN115702931A
(zh)
|
2021-08-06 |
2023-02-17 |
百奥泰生物制药股份有限公司 |
抗pd-l1/cd47双特异抗体在治疗疾病中的应用
|
WO2023019239A1
(en)
|
2021-08-13 |
2023-02-16 |
Genentech, Inc. |
Dosing for anti-tryptase antibodies
|
US20230110958A1
(en)
|
2021-08-16 |
2023-04-13 |
Regeneron Pharmaceuticals, Inc. |
Il27 receptor agonists and methods of use thereof
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
AR126838A1
(es)
|
2021-08-20 |
2023-11-22 |
Novartis Ag |
Métodos para preparar células que expresan receptores de antígeno quiméricos
|
CA3229448A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023028612A2
(en)
|
2021-08-27 |
2023-03-02 |
Board Of Regents, The University Of Texas System |
Anti-tslpr (crlf2) antibodies
|
AU2022332303A1
(en)
|
2021-08-27 |
2024-02-01 |
Genentech, Inc. |
Methods of treating tau pathologies
|
WO2023034750A1
(en)
|
2021-08-30 |
2023-03-09 |
Genentech, Inc. |
Anti-polyubiquitin multispecific antibodies
|
CN113683694B
(zh)
|
2021-09-03 |
2022-05-13 |
江苏荃信生物医药股份有限公司 |
一种抗人tslp单克隆抗体及其应用
|
TW202328191A
(zh)
|
2021-09-03 |
2023-07-16 |
英商癌症研究科技有限公司 |
使用her3抗原結合分子的癌症之治療及預防
|
CN113603775B
(zh)
|
2021-09-03 |
2022-05-20 |
江苏荃信生物医药股份有限公司 |
抗人白介素-33单克隆抗体及其应用
|
AU2022339667A1
(en)
|
2021-09-03 |
2024-04-11 |
Go Therapeutics, Inc. |
Anti-glyco-cmet antibodies and their uses
|
WO2023034571A1
(en)
|
2021-09-03 |
2023-03-09 |
Go Therapeutics, Inc. |
Anti-glyco-lamp1 antibodies and their uses
|
EP4148067A1
(en)
|
2021-09-08 |
2023-03-15 |
F. Hoffmann-La Roche AG |
Method for the expression of an antibody-multimer-fusion
|
CA3229822A1
(en)
|
2021-09-13 |
2023-03-16 |
Patrick John DOONAN |
Cd33 x v?2 multispecific antibodies for the treatment of cancer
|
WO2023041745A1
(en)
|
2021-09-16 |
2023-03-23 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using vista antigen-binding molecules
|
WO2023044483A2
(en)
|
2021-09-20 |
2023-03-23 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023046071A1
(zh)
|
2021-09-23 |
2023-03-30 |
江苏恒瑞医药股份有限公司 |
抗klb抗体及用途
|
WO2023046322A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceutica Nv |
Proteins comprising cd20 binding domains, and uses thereof
|
WO2023049922A1
(en)
|
2021-09-27 |
2023-03-30 |
Xencor, Inc. |
B-cell maturation antigen (bcma) binding domain compositions
|
WO2023046979A1
(en)
|
2021-09-27 |
2023-03-30 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using vista antigen-binding molecules
|
TW202323304A
(zh)
|
2021-09-30 |
2023-06-16 |
大陸商江蘇恆瑞醫藥股份有限公司 |
抗il23抗體融合蛋白及用途
|
TW202334187A
(zh)
|
2021-10-08 |
2023-09-01 |
美商Cytomx生物製藥公司 |
可活化細胞激素構築體及相關組成物與方法
|
AU2022361691A1
(en)
|
2021-10-08 |
2024-03-28 |
Genmab A/S |
Antibodies binding to cd30 and cd3
|
TW202333781A
(zh)
|
2021-10-08 |
2023-09-01 |
日商中外製藥股份有限公司 |
抗hla-dq2﹒5抗體製劑
|
CA3233707A1
(en)
|
2021-10-08 |
2023-04-13 |
Alexey Yevgenyevich Berezhnoy |
Activatable cytokine constructs and combination methods
|
WO2023062050A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
New interleukin-7 immunoconjugates
|
WO2023062048A1
(en)
|
2021-10-14 |
2023-04-20 |
F. Hoffmann-La Roche Ag |
Alternative pd1-il7v immunoconjugates for the treatment of cancer
|
TW202323281A
(zh)
|
2021-10-14 |
2023-06-16 |
美商泰尼歐生物公司 |
間皮素結合蛋白及其用途
|
CA3234162A1
(en)
|
2021-10-15 |
2023-04-20 |
Michele Fiscella |
Antibodies and methods of using thereof
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023072159A1
(en)
|
2021-10-27 |
2023-05-04 |
Virtuoso Binco, Inc. |
Multispecific antibodies for treating cd47-associated diseases
|
WO2023073599A1
(en)
|
2021-10-28 |
2023-05-04 |
Novartis Ag |
Engineered fc variants
|
WO2023073615A1
(en)
|
2021-10-29 |
2023-05-04 |
Janssen Biotech, Inc. |
Methods of treating crohn's disease with anti-il23 specific antibody
|
TW202325742A
(zh)
|
2021-11-01 |
2023-07-01 |
瑞士商赫孚孟拉羅股份公司 |
使用 HLA-A2/WT1 x CD3 雙特異性抗體及 4-1BB (CD137) 促效劑治療癌症
|
WO2023081898A1
(en)
|
2021-11-08 |
2023-05-11 |
Alector Llc |
Soluble cd33 as a biomarker for anti-cd33 efficacy
|
WO2023086807A1
(en)
|
2021-11-10 |
2023-05-19 |
Genentech, Inc. |
Anti-interleukin-33 antibodies and uses thereof
|
TW202334223A
(zh)
|
2021-11-11 |
2023-09-01 |
美商再生元醫藥公司 |
Cd20-pd1結合分子及其使用方法
|
US20230151095A1
(en)
|
2021-11-12 |
2023-05-18 |
Xencor, Inc. |
Bispecific antibodies that bind to b7h3 and nkg2d
|
US20230151087A1
(en)
|
2021-11-15 |
2023-05-18 |
Janssen Biotech, Inc. |
Methods of Treating Crohn's Disease with Anti-IL23 Specific Antibody
|
WO2023088889A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
CD137 ligands
|
WO2023088876A1
(en)
|
2021-11-16 |
2023-05-25 |
Apogenix Ag |
Multi-specific immune modulators
|
WO2023092004A1
(en)
|
2021-11-17 |
2023-05-25 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of tau-related disorders
|
WO2023089587A1
(en)
|
2021-11-22 |
2023-05-25 |
Janssen Biotech, Inc. |
Compositions comprising enhanced multispecific binding agents for an immune response
|
US20230159633A1
(en)
|
2021-11-23 |
2023-05-25 |
Janssen Biotech, Inc. |
Method of Treating Ulcerative Colitis with Anti-IL23 Specific Antibody
|
WO2023094282A1
(en)
|
2021-11-25 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Quantification of low amounts of antibody sideproducts
|
WO2023094569A1
(en)
|
2021-11-26 |
2023-06-01 |
F. Hoffmann-La Roche Ag |
Combination therapy of anti-tyrp1/anti-cd3 bispecific antibodies and tyrp1-specific antibodies
|
TW202330623A
(zh)
|
2021-12-08 |
2023-08-01 |
美商英塞特公司 |
抗突變鈣網伴護蛋(calr))抗體及其用途
|
AR127887A1
(es)
|
2021-12-10 |
2024-03-06 |
Hoffmann La Roche |
Anticuerpos que se unen a cd3 y plap
|
WO2023114658A1
(en)
|
2021-12-13 |
2023-06-22 |
Kenjockety Biotechnology, Inc. |
Anti-abcb1 antibodies
|
TW202339797A
(zh)
|
2021-12-14 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
使用hla-a2mage-a4xcd3雙特異性抗體及4-1bb(cd137)促效劑治療癌症
|
TW202340248A
(zh)
|
2021-12-20 |
2023-10-16 |
瑞士商赫孚孟拉羅股份公司 |
促效性ltbr抗體及包含其之雙特異性抗體
|
WO2023117325A1
(en)
|
2021-12-21 |
2023-06-29 |
F. Hoffmann-La Roche Ag |
Method for the determination of hydrolytic activity
|
TW202334231A
(zh)
|
2021-12-22 |
2023-09-01 |
德商莫菲西斯公司 |
抗cd19抗體療法的治療範例
|
WO2023129974A1
(en)
|
2021-12-29 |
2023-07-06 |
Bristol-Myers Squibb Company |
Generation of landing pad cell lines
|
WO2023141445A1
(en)
|
2022-01-19 |
2023-07-27 |
Genentech, Inc. |
Anti-notch2 antibodies and conjugates and methods of use
|
WO2023147329A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation and methods thereof
|
WO2023147328A1
(en)
|
2022-01-26 |
2023-08-03 |
Genentech, Inc. |
Antibody-conjugated chemical inducers of degradation with hydolysable maleimide linkers and methods thereof
|
WO2023147331A1
(en)
|
2022-01-26 |
2023-08-03 |
Mabswitch Inc. |
Bispecific molecule with tunable affinity to a targetted antigen
|
WO2023147399A1
(en)
|
2022-01-27 |
2023-08-03 |
The Rockefeller University |
Broadly neutralizing anti-sars-cov-2 antibodies targeting the n-terminal domain of the spike protein and methods of use thereof
|
TW202342548A
(zh)
|
2022-02-07 |
2023-11-01 |
美商威特拉公司 |
抗獨特型(anti-idiotype)抗體分子及其用途
|
WO2023154953A1
(en)
|
2022-02-14 |
2023-08-17 |
Ngm Biopharmaceuticals, Inc. |
Gdf15 polypeptides for treating and preventing autoimmune diseases
|
WO2023159220A1
(en)
|
2022-02-18 |
2023-08-24 |
Kenjockety Biotechnology, Inc. |
Anti-cd47 antibodies
|
WO2023156614A1
(en)
|
2022-02-21 |
2023-08-24 |
argenx BV |
Methods for treating myositis using fcrn antagonists
|
WO2023164510A1
(en)
|
2022-02-23 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-psma antibodies
|
WO2023164640A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-trop2 antibodies
|
WO2023164627A1
(en)
|
2022-02-24 |
2023-08-31 |
Xencor, Inc. |
Anti-cd28 x anti-msln antibodies
|
WO2023161457A1
(en)
|
2022-02-27 |
2023-08-31 |
Evobright Gmbh |
Bispecific antibodies against cd277 and a tumor-antigen
|
US20230365641A1
(en)
|
2022-02-28 |
2023-11-16 |
Xilio Development, Inc. |
Targeted cytokines and methods of use thereof
|
WO2023164286A1
(en)
|
2022-02-28 |
2023-08-31 |
Xilio Development, Inc. |
Engineered cd122 compositions and methods thereof
|
US20240117030A1
(en)
|
2022-03-03 |
2024-04-11 |
Pfizer Inc. |
Multispecific antibodies and uses thereof
|
WO2023172883A1
(en)
|
2022-03-07 |
2023-09-14 |
Alpine Immune Sciences, Inc. |
Immunomodulatory proteins of variant cd80 polypeptides, cell therapies thereof and related methods and uses
|
WO2023173026A1
(en)
|
2022-03-10 |
2023-09-14 |
Sorrento Therapeutics, Inc. |
Antibody-drug conjugates and uses thereof
|
TW202346594A
(zh)
*
|
2022-03-11 |
2023-12-01 |
中國大陸商科望(上海)生物醫藥科技有限公司 |
經修飾之抗體及其用途
|
TW202346355A
(zh)
|
2022-03-11 |
2023-12-01 |
比利時商健生藥品公司 |
多特異性抗體及其用途(二)
|
WO2023170291A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
WO2023170295A1
(en)
|
2022-03-11 |
2023-09-14 |
Janssen Pharmaceutica Nv |
Multispecific antibodies and uses thereof
|
WO2023174521A1
(en)
|
2022-03-15 |
2023-09-21 |
Genmab A/S |
Binding agents binding to epcam and cd137
|
WO2023178357A1
(en)
|
2022-03-18 |
2023-09-21 |
Evolveimmune Therapeutics, Inc. |
Bispecific antibody fusion molecules and methods of use thereof
|
US20230414750A1
(en)
|
2022-03-23 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
|
WO2023186756A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Interferon gamma variants and antigen binding molecules comprising these
|
WO2023186760A1
(en)
|
2022-03-28 |
2023-10-05 |
F. Hoffmann-La Roche Ag |
Improved folr1 protease-activatable t cell bispecific antibodies
|
WO2023187707A1
(en)
|
2022-03-30 |
2023-10-05 |
Janssen Biotech, Inc. |
Method of treating mild to moderate psoriasis with il-23 specific antibody
|
US20230364020A1
(en)
|
2022-04-01 |
2023-11-16 |
Genentech, Inc. |
Hydroxypropyl methyl cellulose derivatives to stabilize polypeptides
|
WO2023191816A1
(en)
|
2022-04-01 |
2023-10-05 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2023192973A1
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Activatable multispecific molecules and methods of use thereof
|
GB202204813D0
(en)
|
2022-04-01 |
2022-05-18 |
Bradcode Ltd |
Human monoclonal antibodies and methods of use thereof
|
WO2023192606A2
(en)
|
2022-04-01 |
2023-10-05 |
Cytomx Therapeutics, Inc. |
Cd3-binding proteins and methods of use thereof
|
US20240025968A1
(en)
|
2022-04-07 |
2024-01-25 |
Xencor, Inc. |
LAG-3 TARGETED HETERODIMERIC FUSION PROTEINS CONTAINING IL-15/IL-15RA Fc-FUSION PROTEINS AND LAG-3 ANTIGEN BINDING DOMAINS
|
WO2023193239A1
(en)
|
2022-04-08 |
2023-10-12 |
Peter Peizhi Luo |
Anti-cd28 antibodies and methods of use thereof
|
WO2023201299A1
(en)
|
2022-04-13 |
2023-10-19 |
Genentech, Inc. |
Pharmaceutical compositions of therapeutic proteins and methods of use
|
US20230383012A1
(en)
|
2022-04-13 |
2023-11-30 |
Xencor, Inc. |
Antibodies that bind pd-l1, pd-l2, and/or cd28
|
WO2023198727A1
(en)
|
2022-04-13 |
2023-10-19 |
F. Hoffmann-La Roche Ag |
Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
|
WO2023202967A1
(en)
|
2022-04-19 |
2023-10-26 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
TW202400658A
(zh)
|
2022-04-26 |
2024-01-01 |
瑞士商諾華公司 |
靶向il—13和il—18的多特異性抗體
|
WO2023209124A1
(en)
|
2022-04-29 |
2023-11-02 |
Immatics Biotechnologies Gmbh |
Mammalian display platform for multispecific antigen binding proteins
|
KR20230156844A
(ko)
|
2022-05-02 |
2023-11-14 |
노보 노르디스크 에이/에스 |
고농도 조성물 및 피하 투여에 적합한 신규한 항-angptl3 항체
|
WO2023215737A1
(en)
|
2022-05-03 |
2023-11-09 |
Genentech, Inc. |
Anti-ly6e antibodies, immunoconjugates, and uses thereof
|
WO2023215498A2
(en)
|
2022-05-05 |
2023-11-09 |
Modernatx, Inc. |
Compositions and methods for cd28 antagonism
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
US20240059799A1
(en)
|
2022-05-11 |
2024-02-22 |
Pfizer Inc. |
Anti-tl1a antibodies and methods of use thereof
|
WO2023220647A1
(en)
|
2022-05-11 |
2023-11-16 |
Regeneron Pharmaceuticals, Inc. |
Multispecific binding molecule proproteins and uses thereof
|
WO2023220695A2
(en)
|
2022-05-13 |
2023-11-16 |
Voyager Therapeutics, Inc. |
Compositions and methods for the treatment of her2 positive cancer
|
WO2023218431A1
(en)
|
2022-05-13 |
2023-11-16 |
BioNTech SE |
Rna compositions targeting hiv
|
WO2023223265A1
(en)
|
2022-05-18 |
2023-11-23 |
Janssen Biotech, Inc. |
Method for evaluating and treating psoriatic arthritis with il23 antibody
|
US20230382969A1
(en)
|
2022-05-27 |
2023-11-30 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
US20230416412A1
(en)
|
2022-05-31 |
2023-12-28 |
Hoffmann-La Roche Inc. |
Prevention or mitigation of t-cell engaging agent-related adverse effects
|
WO2023232961A1
(en)
|
2022-06-03 |
2023-12-07 |
F. Hoffmann-La Roche Ag |
Improved production cells
|
US20230391844A1
(en)
|
2022-06-04 |
2023-12-07 |
Regeneron Pharmaceuticals, Inc. |
Interleukin-2 proproteins and uses thereof
|
US20240018201A1
(en)
|
2022-06-08 |
2024-01-18 |
Sanofi |
Methods for purification of multi-specific antibodies
|
WO2023242372A1
(en)
|
2022-06-15 |
2023-12-21 |
argenx BV |
Fcrn/hsa binding molecules and methods of use
|
WO2023245105A1
(en)
|
2022-06-17 |
2023-12-21 |
Genentech, Inc. |
Use of kosmotropes to enhance yield of an affinity chromatography purification step
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024013727A1
(en)
|
2022-07-15 |
2024-01-18 |
Janssen Biotech, Inc. |
Material and methods for improved bioengineered pairing of antigen-binding variable regions
|
WO2024015960A1
(en)
|
2022-07-15 |
2024-01-18 |
Xilio Development, Inc. |
Engineered cleavable fc domain as carriers and methods of use thereof
|
WO2024013315A1
(en)
|
2022-07-15 |
2024-01-18 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
WO2024020432A1
(en)
|
2022-07-19 |
2024-01-25 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024020564A1
(en)
|
2022-07-22 |
2024-01-25 |
Genentech, Inc. |
Anti-steap1 antigen-binding molecules and uses thereof
|
WO2024020579A1
(en)
|
2022-07-22 |
2024-01-25 |
Bristol-Myers Squibb Company |
Antibodies binding to human pad4 and uses thereof
|
WO2024026358A1
(en)
|
2022-07-27 |
2024-02-01 |
Teneobio, Inc. |
Mesothelin binding proteins and uses thereof
|
WO2024023271A1
(en)
|
2022-07-27 |
2024-02-01 |
Ablynx Nv |
Polypeptides binding to a specific epitope of the neonatal fc receptor
|
WO2024023750A1
(en)
|
2022-07-28 |
2024-02-01 |
Astrazeneca Uk Limited |
Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
|
WO2024026471A1
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Cd98hc antigen-binding domains and uses therefor
|
WO2024026472A2
(en)
|
2022-07-29 |
2024-02-01 |
Alector Llc |
Transferrin receptor antigen-binding domains and uses therefor
|
WO2024030850A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030845A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030858A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable substrates and methods of use thereof
|
WO2024030847A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024030843A1
(en)
|
2022-08-01 |
2024-02-08 |
Cytomx Therapeutics, Inc. |
Protease-cleavable moieties and methods of use thereof
|
WO2024028386A1
(en)
|
2022-08-02 |
2024-02-08 |
Ose Immunotherapeutics |
Multifunctional molecule directed against cd28
|
US20240052047A1
(en)
|
2022-08-03 |
2024-02-15 |
Pfizer Inc. |
Anti- il27r antibodies and methods of use thereof
|
WO2024030976A2
(en)
|
2022-08-03 |
2024-02-08 |
Voyager Therapeutics, Inc. |
Compositions and methods for crossing the blood brain barrier
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024036139A2
(en)
|
2022-08-09 |
2024-02-15 |
Qlsf Biotherapeutics, Inc. |
Antibodies binding to clec12a
|
US20240067691A1
(en)
|
2022-08-18 |
2024-02-29 |
Regeneron Pharmaceuticals, Inc. |
Interferon receptor agonists and uses thereof
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
US20240092859A1
(en)
|
2022-08-18 |
2024-03-21 |
Immunocore Ltd |
T cell receptors and fusion proteins thereof
|
WO2024040247A1
(en)
|
2022-08-18 |
2024-02-22 |
Regeneron Pharmaceuticals, Inc. |
Interferon proproteins and uses thereof
|
CN115353552B
(zh)
*
|
2022-08-19 |
2023-07-18 |
山东大学 |
一种降低蛋白质变性温度的方法及其突变体与应用
|
WO2024049949A1
(en)
|
2022-09-01 |
2024-03-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
WO2024052922A1
(en)
|
2022-09-11 |
2024-03-14 |
Yeda Research And Development Co. Ltd. |
Anti-klk4 antibodies and uses thereof
|
WO2024056861A1
(en)
|
2022-09-15 |
2024-03-21 |
Avidicure Ip B.V. |
Multispecific antigen binding proteins for stimulating nk cells and use thereof
|
WO2024059739A1
(en)
|
2022-09-15 |
2024-03-21 |
Voyager Therapeutics, Inc. |
Tau binding compounds
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024062073A1
(en)
|
2022-09-22 |
2024-03-28 |
Hummingbird Bioscience Pte. Ltd. |
Treatment and prevention of cancer using vista antigen-binding molecules
|
US20240101718A1
(en)
|
2022-09-28 |
2024-03-28 |
Incyte Corporation |
Anti-pd-1/lag-3 bispecific antibodies and uses thereof
|
WO2024068572A1
(en)
|
2022-09-28 |
2024-04-04 |
F. Hoffmann-La Roche Ag |
Improved protease-activatable t cell bispecific antibodies
|
WO2024068996A1
(en)
|
2022-09-30 |
2024-04-04 |
Centre Hospitalier Universitaire Vaudois (C.H.U.V.) |
Anti-sars-cov-2 antibodies and use thereof in the treatment of sars-cov-2 infection
|
WO2024077018A2
(en)
|
2022-10-04 |
2024-04-11 |
Alpine Immune Sciences, Inc. |
Methods and uses of taci-fc fusion immunomodulatory protein
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024077239A1
(en)
|
2022-10-07 |
2024-04-11 |
Genentech, Inc. |
Methods of treating cancer with anti-c-c motif chemokine receptor 8 (ccr8) antibodies
|